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Abstract
Mesenchymal stem cells (MSC) have been used clinically to treat a range of conditions, and 
have been shown to enhance skin wound healing in vivo. There is evidence suggesting that 
the beneficial effects of MSC transplantation may be mediated more through their paracrine 
activity than through their differentiation into mature cell types. 
This  thesis  has sought  to  examine the effects  of MSC secreted factors  on dermal 
fibroblasts, keratinocytes, and endothelial cells, using an in vitro wound healing model. The 
results  presented  demonstrate  that  mesenchymal  stem  cell-conditioned  culture  medium 
(MSC-CM)  enhances  wound  closure  by  dermal  fibroblasts  and  keratinocytes  through 
increased skin cell migration. MSC-CM was similarly shown to enhance wound closure by 
endothelial cells. The contents of MSC-CM were analysed by immunological techniques and 
mass  spectrometry  to  reveal  targets  for  further  investigation.  These  included  cytokines, 
notably interleukin-6 (IL-6),  interleukin-8 (IL-8) and transforming growth factor-beta one 
(TGF-β1); and extracellular matrix (ECM) components, notably collagen type I, fibronectin 
and decorin. Examining these factors individually or in combination with each other or MSC-
CM  demonstrated  differential  and  interdependent  effects.  Fibronectin  was  generally 
stimulatory  to  wound  closure,  whilst  decorin  was  inhibitory.  The  cytokines  studied  had 
variable effects,  e.g.  TGF-β1 was stimulatory to fibroblast migration in combination with 
collagen type I,  elicited no effect  in  combination with fibronectin,  and was inhibitory to 
keratinocyte migration in both conditions.
This study has thereby progressed our understanding of how MSC secreted factors 
influence  skin  wound  healing  and suggests  that  further  investigation  of  MSC activity  is 
needed in order to inform the eventual clinical use of MSC to treat severe or chronic skin 
wounds. With further work, MSC-related therapy, using MSC transplantation or the delivery 
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of  MSC  secreted  products,  might  provide  a  preferable  alternative  to  current  treatment 
strategies for these wounds, either in terms of patient benefit or clinical cost reduction.
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Chapter 1
Introduction
1
1.1 Skin structure and function.
The  largest  organ  of  the  vertebrate  body,  skin  is  comprised  of  three  layers,  the 
epidermis,  dermis  and hypodermis,  or subcutaneous layer  (Stevens & Lowe 1997, 
Metcalfe & Ferguson 2007) (Figure 1.1). These layers contribute individually and in 
combination  to  skin  function  and  maintenance.  Skin  provides  barrier  protection 
against  chemicals,  micro-organisms,  and  ultra-violet  (UV)  light  (MacNeil  2007, 
Metcalfe & Ferguson 2007, Stevens & Lowe 1997), as well as protecting the body 
from mechanical damage (Metcalfe & Ferguson 2007), and also contributes to the 
maintenance  of  homeostasis  by  transducing  external  stimuli  and  effecting 
thermoregulatory actions via sweat glands, follicles and vasculature (Stevens & Lowe 
1997). 
Epidermis: The outermost of the three layers, the epidermis, is responsible for barrier 
function (Metcalfe & Ferguson 2007) and contributes to homeostasis. The epidermis 
is mostly cellular, composed mainly of keratinocytes (Hoath & Leahy 2003, Metcalfe 
& Ferguson 2007, Stevens & Lowe 1997) and organised into two principal strata: A 
basal layer, from which all keratinocytes of the epidermis are derived, and the stratum 
corneum, a layer of keratinizing cornifying cells which are displaced outwards and 
shed desquamously once terminally differentiated (Stevens & Lowe 1997). As well as 
keratinocytes  the  epidermis  contains  melanocytes  and  Langerhans  cells  (Hoath  & 
Leahy 2003, Stevens & Lowe 1997), both interacting with local keratinocytes to form 
functional epidermal units (Hoath & Leahy 2003). The ratio of both melanocytes and 
Langerhans cells to nucleated keratinocytes is maintained at a markedly constant level 
(1:36 ratio of melanocytes: keratinocytes and 1:53 Langerhans cells: keratinocytes) 
(Hoath  &  Leahy  2003).   Melanocytes  are  dendritic  cells  responsible  for  skin 
2
pigmentation and protection from damage from UV radiation (Stevens & Lowe 1997), 
by interacting with adjacent keratinocytes to comprise epidermal melanin units of one 
melanocyte and ≈36 viable keratinocytes (Hoath & Leahy 2003). Langerhans cells are 
responsible for the immune surveillance of the other cells of the epidermis (Hoath & 
Leahy 2003). The extracellular matrix of the epidermis consists of small amounts of 
intercellular proteoglycans, and constitutes a vastly smaller portion of the epidermis 
than the cellular components.  Between the epidermis and underlying dermis is the 
dermal-epidermal  junction,  or  basement  membrane  zone,  responsible  for  the 
mechanical support of the epidermis and the adherence between the two layers, as 
well  as  maintaining  the  compartmentalisation  of  the  skin  strata  ).  The  basement 
membrane zone is comprised of the plasma membrane of the basal keratinocytes, and 
the Lamina Lucida and Lamina Densa, and is permeated by anchoring fibrils secreted 
by epidermal keratinocytes either terminating in the Lamina Densa, or extending into 
the dermis (Stevens & Lowe 1997). 
Dermis and hypodermis: The dermis is the thickest layer of the skin, and makes up 
the bulk of its mass. It is much less cellular than the epidermis, consisting mainly of 
extracellular  matrix  components;  collagen  and  elastic  fibres  embedded  in 
proteoglycans and glycoproteins (Metcalfe & Ferguson 2007). Eighty five percent to 
ninety percent of the collagen present in the dermis is type I collagen, with type III 
(8%-11%), type V (2%-4%), and very small amounts of type VI, type XII, type XIII 
and type XIV making up the rest. The major proteoglycan (PG) component of the 
dermal extracellular matrix is decorin, a Small Leucine Rich Proteoglycan (SLRP). 
Another SLRP, biglycan, is also present in smaller amounts. In addition, a network of 
elastic  fibres  within  the  dermis  contributes  to  skin  resilience  and  elasticity.  The 
cellular component of the dermis is comprised mostly of fibroblasts (Sorrell & Caplan 
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2004). These cells are responsible for the formation of the extracellular matrix which 
comprises the larger portion of the skin, and the regulation of the skin physiology 
through  communication  with  other  cell  types.  Fibroblasts  also  differentiate  in 
response to injury, adopting a migratory phonotype (myofibroblast). Myofibroblasts 
contribute to the closure of cutaneous wounds by contracting the wound area. As well 
as the fibroblast population the dermis is inhabited by neural and vascular cells that 
make up the nervous and circulatory system supporting the skin. Fibroblasts can be 
divided spatially and physiologically into three distinct subpopulations. Two of these 
form the papillary and reticular layers of the dermis,  whilst the third is associated 
specifically with hair follicles embedded within the dermal papillary region (Sorrell & 
Caplan,  2004).  The  papillary  dermis  is  that  portion  of  the  dermal  layer  directly 
adjacent to the basement membrane (Figure 1.2), and is involved in the sustenance of 
the epidermis,  containing the neural and vascular components required to maintain 
viable  keratinocytes.  These  components  are  extended  towards  the  basement 
membrane  zone  within  the  dermal  papillae  -  folds  in  the  papillary  surface  that 
increase  the  surface  area  available  for  delivery  of  soluble  molecules  into  the 
epidermis.  The extracellular  matrix  of papillary dermal  tissue is  made up of thin, 
poorly  organised  bundles  of  primarily  type  I  and  type  III  collagens,  and  large 
quantities of the proteoglycan, decorin. A vascular plexus, the rete subpapillaire, lies 
between the papillary dermis and the reticular dermis. The extracellular matrix of the 
reticular layer is made up of thicker and more organised collagen bundles than the 
papillary dermis, and has a higher proportion of type III to type I collagen (Sorrell & 
Caplan,  2004).  This  reticular  layer  extends  from  below  the  rete  subpapillaire  to 
another vascular plexus, the rete cutaneum, which marks the lower limit of the dermis 
and lies adjacent to the hypodermal layer (Sorrell & Caplan 2004). The hypodermis, 
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or subcutis, is made up of adipose tissue and loose connective tissues, and contains 
the major nerves and blood vessels from which the overlying layers are supplied. The 
hypodermis is permeated by fibrous bands growing out from the dermis, dividing the 
hypodermal layer into lobules and anchoring the skin by extending into the underlying 
periosteum or facia.
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Figure 1.1. The structure of human skin. The horizontal organisation of the 
dermal, epidermal, and subcutaneous layers comprising human skin, as well as 
major skin appendages (adapted from MacNeil, 2007).
Figure 1.2. The Papillary and Reticular dermis. The organisation of the dermal 
lamina, divided by the rete subpapillaire, and also dermal papillae extending into 
the epidermis. Bar = 45µm. (Image taken from Sorrell and Caplan, 2004).
1.2 Skin damage and repair.
Skin damage  can  occur  as  a  result  of  burns,  cuts/incisions,  abrasions,  ulcers,  and 
various  other  causes,  to  varying  degrees  of  severity.  Any breach  in  the  skin  can 
compromise its barrier function and expose the body’s tissues to microbial infections 
and mechanical damage, and affect the maintenance of homeostasis if left unrepaired. 
The process of tissue regeneration and repair is generally considered in terms of three 
overlapping phases; inflammation, proliferation, and remodelling (Figure 1.3). These 
processes all require complex interactions between the dermal and epidermal cells, the 
extracellular  matrix  components  and the  nervous  and vascular  components  of  the 
damaged and surrounding skin (Yamada and Clark, 1996, Harding et al, 2002). 
Inflammation; Immediately  following  a  common  or  minor  skin  injury,  thrombus 
formation maintains haemostasis and triggers an inflammatory response by releasing 
vasodilators  from  platelets  within  the  clot,  and  triggering  complement  activation 
(Metcalfe  & Ferguson 2007). Recruited on initiation of an inflammatory response, 
neutrophils are the initial immune entity responsible for removal of foreign material 
and potential pathogens from the wound site, by phagocytosis and the secretion of 
extracellular  enzymes,  until  macrophages  replace  them in  this  role  (Cooper  et  al 
1994).  Macrophages  also  initiate  progression  to  the  next  phase  of  repair,  the 
proliferation stage, by secreting the various growth factors and cytokines that recruit 
keratinocytes and fibroblasts to the wound site.
Proliferation: Keratinocytes migrate into the wound area from the basal population 
around the wound edge before contact inhibition triggers their resumption of a basal 
phenotype,  and  subsequent  differentiation  into  stratified  squamous  keratinizing 
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epidermis,  reepithelialising  the  wound  and  restoring  the  barrier  function  of  the 
damaged skin. Fibroblasts are of major significance in cutaneous wound healing as 
they contribute to wound contraction, secrete new extracellular matrix materials and 
produce  matrix  metalloproteinases,  enzymes  required  to  remodel  the  extracellular 
matrix.  Initially  migrating  to  the  site  along with sprouting  vasculature,  fibroblasts 
differentiate into specialised myofibroblast cells (Sorrell & Caplan 2004). These cells 
respond to macrophage derived factors to provide a provisional wound matrix made 
up of  fibronectin  and hyaluronan,  and provide  the  motive  force  required  for  skin 
wound contraction.  These myofibroblasts die off by apoptosis and are replaced by a 
second wave of fibroblasts from the surrounding dermis. 
Remodelling: Fibroblasts produce new extracellular matrix material, and also matrix 
metalloproteinases,  a  group  of  zinc  dependant  endopeptidases  that  cleave  the 
extracellular  matrix  material  around  the  margins  of  the  wound  site.  Remodelling 
follows  wound  closure,  and  can  take  place  over  months  or  years  as  matrix 
metalloproteinases cleave old collagen and new collagen is formed (Harding  et al, 
2002) (Bayat et al, 2003) ). The formation of an acellular collagenous scar, combined 
with wound contraction and re-epithelialisation leads to the complete closure of the 
wound (Sorrell & Caplan 2004). 
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Figure 1.3. Phases of wound healing. Numerous processes contribute to cutaneous 
wound healing including the actions of both circulatory and local cells. These can 
be broadly divided into three overlapping phases as represented above: 
Inflammation in blue, Proliferation in green and Remodelling in yellow (image 
taken from Harding et al 2002).
Scarring: Scarring  can  manifest  as  multiple  varieties  including  normal  fine  lines, 
widespread scars, contracting scars, and atrophic, hypertrophic or keloid scar types 
(Figure 1.4) (Bayat  et al, 2003). Often the balance between new and old collagen 
determines the final characteristics of the scar. Wide spread scars are flat pale scars 
occurring when fine lines become stretched or widened, often occurring after knee or 
shoulder  surgery.  The  abdominal  striae  seen  after  pregnancy  are  a  variant  of 
widespread scar in which there is damage to the dermal and hypodermal layers, but 
without breach in the epidermis. Atrophic scars are flat and depressed, often small and 
rounded, usually occurring due to acne or chickenpox. Hypertrophic and keloid scars 
are characterised by being raised above the surrounding skin. Hypertrophic scars are 
associated  with  burns  on  the  trunk  and  extremities  and  are  often  red,  itchy  and 
inflamed, and sometimes even painful. Keloid scars are invasive, spreading beyond 
the original wound into surrounding skin. Keloid scars do not spontaneously regress 
and have a 50%-80% chance of recurrence after excision. These tend to occur in the 
ear lobe following piercing,  the deltoid after vaccination and on the sternum after 
acne, chickenpox, or trauma/surgery. Predisposing factors to the occurrence of keloid 
scars include age, with 10-30 year-olds being predominantly afflicted, and race, with 
dark  skinned  populations  being  more  prone.  Puberty  and  pregnancy  are  also 
associated with increased incidence of keloid scarring. Interestingly, keloid scars are a 
uniquely human condition (Bayat, et al, 2003). Scar contractures can occur when a 
scar  is  formed  perpendicular  to  skin  creases  or  joints  (Figure  1.5).  Contracture 
generally takes place before the scar has matured, and is common following severe 
burns across joints. These scars can be hypertrophic, and are often disabling and/or 
dysfunctional.
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Figure 1.4. Scar types. Examples of abnormal scarring: (a) Atrophic, (b) Keloid, 
and (c) Hypertrophic scars (images taken from www.dermis.net).
Figure 1.5. Scar contracture. An example of scar contracture across the forearm 
and wrist following a burn injury (image taken from Bayat et al, 2003).
Foetal  wound healing: During the first  third of  the gestational  period,  damage to 
foetal skin results in scarless healing and the complete regeneration of functional skin, 
indistinguishable  from  that  present  prior  to  being  damaged,  including  regularly 
distributed appendages and appropriate vasculature (reviewed in Metcalfe & Ferguson 
2007,  Ferguson  and  O’Kane,  2004).  Studies  have  shown  this  process  of  tissue 
regeneration to be dependant upon the degree of differentiation of the skin tissues and 
the magnitude of the inflammatory response. The correct deposition of collagens and 
hyaluronan  is  essential  to  the  absence  of  scarring  in  foetal  wound  repair  and  is 
regulated  by  the  cytokine  environment  of  the  wound  site  (Whitby  &  Ferguson 
1991a,b, Lindblad, 1998). The lack of fibrin clots and platelet degranulation, and the 
significantly  reduced  inflammatory  responses  that  characterise  foetal  regeneration 
result in a growth factor profile markedly different from that found in adult wound 
repair,  featuring  reduced  levels  of  growth  factors  released  by  platelets  and 
inflammatory  cells,  such as  TGF-  β1,  TGF-β2 and platelet  derived  growth factor 
(PDGF), and elevated TGF- β3. Exogenous addition of TGF-β3 or the neutralisation 
of  TGF-β1,  TGF-β2,  PDGF  etc  have  been  shown  experimentally  to  reduce  or 
eliminate scarring in adult rodents (Shah et al, 1994, Shah et al, 1995).
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Factors influencing wound healing.
Growth factors/cytokines
Cell signalling molecules such as cytokines and growth factors are essential mediators 
of wound healing,  necessary for the initiation of each phase of the wound healing 
response  and  its  orderly  resolution  as  one  phase  progresses  to  the  next.  These 
signalling molecules recruit circulating cells such as neutrophils to the wound site, 
coordinate the proliferation of cells needed for effective reepithelialisation and neo-
angiogenesis,  and  stimulate  the  synthesis  of  both  the  matrix  metalloproteinases 
(MMPs) and also new extracellular matrix components required for the remodelling 
of repaired tissue.
Platelet-derived  growth  factor  (PDGF).  Released  by  platelets  and  secreted  by 
activated macrophages, PDGF is an essential mediator the early phases of the wound 
healing response acting as a chemoattractant for neutrophils and monocytes (Werner 
and Grose, 2003). PDGF also influences the later stages of wound healing, recruiting 
fibroblasts  to  the  wound site  and stimulating  the  production  of  new extracellular 
matrix  proteins,  as  well  as  promoting  myofibroblast  differentiation  leading  to  the 
contraction of the wound area (Heldin and Westermark, 1999). Additionally PDGF 
has a role in the inhibition of apoptosis required for effective progression through the 
sequential phases of wound healing (Ching et al., 2011, Greenhalgh, 1998).
Fibroblast growth factors (FGF). FGF is expressed strongly in the central area of skin 
wounds, decreasing towards the periphery and almost absent in uninjured skin (Gu et  
al., 2000). FGFs have a broad pectrum of effects (Werner and Grose, 2003, Ching et  
al.,  2011), stimulating both the proliferation and migration of numerous cell  types 
involved in wound healing and angiogenesis including keratinocytes, fibroblasts and 
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endothelial  cells  (Werner  and Grose 2003,  Nissen  et  al., 1996,  Montesano  et  al., 
1986). Additionally, members of the FGF protein family have been demonstrated to 
contribute to the macrophage activation and the production of new ECM (Ching  et  
al., 2011, Greenhalgh, 1996). Keratinocyte growth factors (KGF) are members of the 
FGF  family  that  promote  reepithelialisation  by  stimulating  the  migration  and 
proliferation of keratinocytes, as well as stimulation of the formation of granulation 
tissue and the deposition of collagen within the wound (Soler  et al., 1999, Ching et  
al., 2011, Xia et al., 1999). KGF also plays a role in protecting cells from the harmful 
effects of oxidative stress. In the earliest stages of wound healing, the disruption of 
normal blood supply through damage to blood vessels and vasoconstriction results in 
localised hypoxia and an increase in reactive oxygen species (ROS) within the wound 
environment (Gorlach  et al., 2000, Schremi  et al., 2010). In normal wound healing 
this increase results in the release of enzymes capable of detoxifying ROS, mediated 
by the actions  of  appropriate  cytokines.  Keratinocyte  growth factor  stimulates  the 
expression of the intracellular enzyme peroxiredoxin-6, protecting keratinocytes from 
ROS-induced  oxidative  damage  (Kumin  et  al., 2007).  The  impairment  of  this 
protective response is associated with chronic wounds, with the resulting imbalance of 
oxidants and antioxidants causing the healing process to stall in a persistent state of 
inflammation (Soneja et al., 2005, Schafer and Werner, 2008).
Epidermal  growth  factors  (EGF)  EGFs  are  another  family  of  mitogenic  factors 
involved in wound healing. Expressed by macrophages, epidermal keratinocytes and 
hair follicle epithelial cells (Rappolee et al., 1988, Cribbs et al., 2002), EGF stimulate 
the  proliferation  of  epithelial  and  endothelial  cells  as  well  as  accelerating 
reepithelialisation and increasing the tensile strength of healed dermis (Alemdaroglu 
et al., 2006, Alemdaroglu et al., 2008, Brown et al., 1989).
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Vascular  endothelial  growth  factor  (VEGF).  VEGF  are  cytokine  mediators  of 
angiogenesis that stimulate the proliferation and migration of endothelial cells (Nissen 
et al., 1998, Papapetropoulos  et al., 2009), as well as promoting reepithelialisation 
and collagen deposition with in the wound (Bao  et al., 2009). There is evidence to 
suggest that the application of exogenous VEGF through a variety of means results in 
the acceleration or enhancement of wound healing (Romano  et al., 2002, Dedato  et  
al., 2002, Galeano et al., 2003, Muhlhauser et al., 1995).
Insulin like growth factor (IGF). IGF has well characterised systemic anabolic effects 
and  contributes  to  wound  healing  by  promoting  the  migration  of  fibroblasts  and 
keratinocytes as well as inhibiting apoptosis and stimulating the deposition of new 
ECM (Martin 1997, Steenfos 1994, Dasu  et al., 2003, Spies  et al., 2001). IGF also 
mediates the production of pro and anti-inflammatory cytokines (Ching et al., 2011).
Transforming Growth Factor-Beta (TGF-β).  The mammalian TGF-β family consists 
of three structurally and functionally similar isoforms: TGF-β1, TGF-β2 and TGF-β3, 
and  affects  every  phase  of  the  wound  healing  process.  TGF-β  stimulates  the 
deposition  of  collagen  and  other  matrix  components  by  fibroblasts,  inhibits 
collagenase, enhances angiogenesis, and is chemotactic for fibroblasts, monocytes and 
macrophages.  TGF-β induces  alpha-smooth  muscle  actin  expression in  fibroblasts, 
providing the  motive  force  for  contraction  of  the wound margins  (Barnard  et  al., 
1990, Sporn and Roberts 1992, Desmouliere  et al., 1993). Additionally TGF-β, and 
specifically the relative expression of the different isoforms, is strongly implicated in 
the process of scar formation (Shah et al., 1994, Shah et al., 1995).
Additional factors. Further growth factors have been experimentally implicated in the 
process of cutaneous wound healing. Exogenous nerve growth factor (NGF) has been 
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shown to accelerate  the healing of chronic wounds in  both mice (Li  et  al., 1980, 
Matsuda et al., 1998) and humans (Bernabei et al., 1999). Hepatocyte growth factor 
(HGF)  stimulates  migration,  proliferation  (Matsumoto  et  al., 1991),  and  matrix 
metalloproteinase (Dunsmore  et al., 1996) production by keratinocytes,  as well  as 
neo-angiogenesis (Bussolino et al., 1992), and so has been suggested to play a role in 
cutaneous wound repair  (Werner and Grose 2002). BMP-6 may play a role in the 
reepithelialisation  of  cutaneous  wounds.  BMP-6  is  highly  expressed  in  the 
keratinocytes at the leading edge of the wound margin as well as in granulation tissue 
fibroblasts,  before  accumulating  throughout  the  supra-basal  layers  of  the  newly 
formed epidermis upon completion of wound closure (Kaiser et al., 1998). BMP-6 has 
also been shown to induce keratinocyte differentiation in vitro (D’Souza et al., 2001, 
McDonnell et al., 2001).
Extracellular matrix components
The  behaviour  of  cells  both  in  vitro and  in  vivo is  influenced  by the  nature  and 
composition  of  the  local  extracellular  matrix  (ECM).  Specifically  relevant  to  the 
investigations presented within this thesis are three ECM proteins: Type I collagen, 
fibronectin and decorin.
Collagen I.   Collagens are the most  abundant fibrous proteins in ECM. The most 
common of these, and the most common protein found in the human body (Di Lullo 
et al., 2002), Type I collagen is a heterotrimeric ECM protein comprised of three 
alpha chains (two α1 chains and one α2) in a triple helix conformation (Gordon and 
Hahn  2010).  The  polypeptide  precursors  to  these  chains  are  synthesised  by 
fibroblasts,  as  well  as  osteoblasts  and  odontoblasts,  and  trimerise  within  the 
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endoplasmic reticulum before being secreted into the extracellular space.  Within the 
extracellular space multiple triple helices associate in a ‘quarter-stagger’ pattern to 
form thick bundles or fibrils which become the major component of the ECM found 
in skin, tendon, vascular ligature, organs, and the organic portion of bone. (Ghosh 
2002, Myllyharju and Kivirikko 2001, Byers 2000).
Fibronectin.  Usually existing as a dimer of two subunits of approximately 250 kDa, 
fibronectin  mediates  a  wide  variety  of  cellular  interactions  with  the  extracellular 
matrix  (ECM) and  plays  important  roles  in  cell  adhesion,  migration,  growth  and 
differentiation (Pankov and Yamada 2002). Each of the two subunits is made up of 
three  different  repeating  domains  that  between  them  comprise  90%  of  the  gene 
sequence (Patel et al., 1987).  Multiple forms of the protein can arise from alternative 
splicing  of  pre-mRNA  (French-Constant  1995,  Kosmehl  et  al., 1996).  Of  these 
variants, the most significant sub-division is between the soluble fibronectin abundant 
within  plasma  and  other  bodily  fluids  and  the  insoluble  fibronectin  of  the  ECM 
(Pankov and Yamada 2002). Fibronectin is involved in a broad range of biological 
processes mediated by its ability to ligate numerous integrin receptors (Plow  et al., 
2000), binding to a number of biologically important molecules including heparin, 
collagen and ﬁbrin (Yamada and Clark 1996, Pankov and Yamada,  2002) and its 
aggregation into fibrils (Geiger et al., 2001).
Decorin.  Decorin is a small  proteoglycan comprised of a leucine-rich core protein 
(approximately 40 kDa) and associated dermatan sulphate/chondroitin sulphate side 
chains  (Heinegard  and  Oldberg,  1989).  Decorin  associates  with  other  protein 
components  of  the  ECM  including  fibronectin  and  collagen  types  I  and  II 
(Hardingham and Fosang, 1992), modulating the formation of collagen fibres (Scott 
and Haigh, 1988), and also sequesters TGF-β effectively neutralising the effects of the 
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growth factor (Markmann et al., 2000). As TGF-β stimulates the synthesis of decorin 
core protein and its glycosaminoglycan side chain, the resulting inhibition of growth 
factor function suggests a role for decorin in the negative feedback control of TGF-β 
(Ruoslahti and Yamaguchi 1991).
Cytoskeletal biology and cell migration
The directional  migration  of  cells  occurs  in  response  to  a  variety  of  extracellular 
stimuli  including  gradients  in  the  concentration  of  growth  factors  and  cytokines 
(chemokines), mechanical forces, and extracellular matrix composition. Driven by the 
polymerisation  of  actin  filaments,  protrusions  of  the cell  membrane  extend in the 
direction of migration and are subsequently stabilised by adhesions linking the actin 
cytoskeleton  of  the  cell  to  the  underlying  ECM.  The  contraction  of  actomyosin 
generates  a  mechanical  force  upon  the  cell  whilst  simultaneously  stimulating  the 
disassembly of adhesions towards the rear of the cell, resulting in a forward motion 
(Kaverina and Straube, 2011).
Cytoskeletal components.  The cytoskeleton of eukaryotic cells,  required to provide 
structure and shape to the cell membrane as well as the apparatus for cell migration 
and  division,  is  mainly  comprised  of  three  types  of  structural  filaments.  Actin 
filaments,  the finest  of the cytoskeletal  structures,  are made up of  actin  polymers 
organised into polarised molecules possessing fast-growing ‘barbed-ends’ and slow-
growing ‘pointed-ends’.  (Fuchs  and Cleveland,  1998)  The  difference  between  the 
rates of growth between these ends generates a motive force utilising energy provided 
by ATP hydrolysis,  transporting the filament  in  the direction  of the ‘barbed-end’. 
Intermediate filaments are a larger component of the cellular cytoskeleton involved in 
the maintenance of the three dimensional shape and support of the cell membrane as 
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well as anchoring various organelles within the cytoplasm. These can be made up of a 
variety of protein components, such as vimentin, common to mesenchymal lineage 
cells, keratins that make up intermediate filaments in the cytoplasm of epithelial cells, 
or lamins that provide structure within the nucleus. Microtubules, polymers of dimeric 
α  and β  tubulin,  are  the  largest  filaments  in  the  cytoskeleton.  These  hollow tube 
structures are highly polarised, similar to actin filaments, with a stable (-) end capped 
by a  third  tubulin  isotype  (γ-tubulin)  and dynamic  (+)  end  capable  of  GTP/GDP 
dependent growth and shrinkage in response to the local concentrations of soluble α 
and β tubulin (Kaverina and Straube, 2011, Fuchs and Cleveland, 1998).
Cytoskeletal  changes  in  migrating  cells.  The  polymerisation  of  actin  filaments 
towards  the  leading edge of  a  migrating  cell  results  in  the  extensions  of  the  cell 
membrane termed lamellipodia (broad ‘sheet-like’ protusions) or filopodia (narrow 
‘spike-like’ protrusions) (Pollard and Borisy, 2003). Cells express a range of surface 
adhesion receptors, of which the best characterised are the integrin family receptors. 
Integrin  extracellular  domains  bind  to  specific  sequence  motifs  present  in  ECM 
proteins  such  as  fibronectin  and  collagen.  The  binding  of  integrins  to  these 
extracellular ligands induces a conformational change that results in their attachment 
to the actin cytoskeleton (Puklin-Faucher and Sheetz, 2009, Vicente-Manzanares  et  
al., 2009, Hynes 2002).
The initial adhesions formed between the cellular cytoskeleton at the leading edge of 
lamellipodia and the ECM are small and relatively short lived ‘nascent’ adhesions that 
will persist for approximately a minute before either breaking down or maturing to 
form larger points of adhesion termed ‘focal complexes’. These focal complexes exist 
further  away from the leading edge of the protruding membrane than the nascent 
adhesions, and will persist for longer before potentially maturing further into larger 
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focal adhesions. The focal adhesions associate with the ends of large actin bundles 
extending towards the centre and rear of the cytoplasmic body of the cell. As traction 
forces  move  the  cell  forwards,  the  rearmost  focal  adhesions  are  disassembled 
(Zimerman et al., 2004, Parsons et al., 2010).
 The breakdown of adhesions between the cytoskeleton and the ECM occurs both 
towards the rear of the cell and at those areas of lamellipodia undergoing retraction, in 
a tension-dependent manner, from the periphery of the adhesion inwards towards the 
centre resulting in the eventual dispersal of the  adhesion structures (Broussard et al., 
2008, Ballestrem et al., 2001).
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1.3 Chronic wounds and impaired repair.
Chronic  or  non-healing  wounds  occur  when  the  normal  processes  of  tissue 
regeneration fail to achieve closure re-epithelialisation of the damaged skin, instead 
appearing to become arrested in a state of prolonged inflammation. This can occur as 
a  result  of foreign bodies present in  the wound site,  ischemia,  infection,  or tissue 
maceration. Common chronic wounds include diabetic leg and foot ulcers, decubitus 
ulcers (pressure sores) and venous ulcers. Malnutrition, advanced age, impaired renal 
function and diabetes are all potential contributing factors to the development of a 
chronic  wound,  as  well  as  reduced  growth  factor  expression  and  imbalance  in 
proteinases and proteinase inhibitors (Harding et al, 2002). Effects of platelet derived 
growth  factor,  basic  fibroblast  growth  factor,  epidermal  growth  factor,  vascular 
endothelial growth factor and TGF-β have all been shown to be reduced in chronic 
ulcers , and it is thought that they may be trapped by extracellular matrix molecules or 
excessively  degraded  by  proteases  involved  in  matrix  remodelling.  Studies  have 
shown  reduced  levels  of  matrix  metalloproteinase  9  and  elevated  matrix 
metalloproteinase 2 in human diabetic chronic wound fluid compared to fluid from 
acute  wounds  ().  These  proteinase  enzymes  are  thought  to  contribute  to  the 
degradation of the growth factors involved in normal tissue regeneration and to cause 
excessive degradation of the extracellular matrix, resulting in non-closure. Vascular 
endothelial growth factor has been shown to exhibit increased levels of expression in 
chronic wounds, but suffer rapid degradation due to the increased proteolytic activity 
associated with the wound environment. This impairs angiogenesis and results in the 
absence of new capillaries, a characteristic feature of venous, diabetic, and decubitus 
ulcers (Lauer  et al, 2000). As the formation of new vasculature is essential for the 
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formation of granulation tissue, the breakdown of vascular endothelial growth factor 
due to increased protease activity may be a direct cause of the failure to heal chronic 
wounds. Age related senescence in dermal fibroblasts  might also contribute to the 
development of chronic wounds, by reducing the degree of the cellular response to 
growth factors (Agren et al, 1999, Hasan et al, 1997, Stanley et al, 1997). The effect 
of these wounds on the quality of life  for those afflicted can be severe and often 
debilitating, due to the intense pain resulting from the damage to tissues and nerve 
cells. Estimates suggest that up to 63% of chronic wound patients may suffer from 
depression as a result of their ailment. 
Infection  of  chronic  wounds: Infection  is  another  important  aspect  of  non-healing 
wounds. The compromised barrier  function of the damaged epidermis exposes the 
tissue to bacterial colonisation, and prior to debridement any necrotic material present 
provides an ideal growth medium for bacteria. Despite prevention strategies such as 
surgical  removal  of  necrotic  tissue  and  cleansing  the  wound  with  saline,  chronic 
wounds tend to become infected,  often through contact with surrounding skin,  the 
local  environment  and  healthcare  providers,  and  endogenous  patient  sources. 
Secondary  bacteraemia  and  septicaemia  are  potential  complications  of  these 
infections and are both associated with increased mortality of chronic wound patients. 
Organisms known to infect chronic wounds include Staphylococcus aureus (including 
MRSA),  Pseudomonas  species  such  as  Pseudomonas  aeruginosa,  β-haemolytic 
streptococci,  vancomycin-resistant  enterococci  as well  as Gram negative coliforms 
and anaerobes. Most chronic wound infections progress through three characteristic 
stages:  colonisation,  critical  colonisation,  and infection.  Colonisation is  thought  to 
begin  with  aerobic  species,  Staphylococci,  Pseudomonas  aeruginosa and  β-
haemolytic streptococci, with these species being predominant in wounds less than 
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one  month  old.  Over  time,  as  the  ulcer  fails  to  heal,  the  spectrum of  organisms 
broadens, and Gram negative species also become established. Critical colonisation 
follows, causing increased friability and drainage of the wound, and contributing to 
the  degradation  of  granulation  tissue,  hindering  tissue  regeneration.  Some  of  the 
organisms above may produce a biofilm on the wound bed, protecting themselves 
from immune detection and challenge. Once the host immune response is overcome 
full  infection  ensues,  leading  to  erythema,  increased  tissue  damage  and  further 
friability,  as  well  as  purulent  drainage,  these  signs  sometimes  spreading  beyond 
wound margins in deep infections. These deep infections can lead to increased wound 
size  and  secondary  ulceration,  and  in  sufficiently  severe  or  long  term ulcers  can 
extend to the bone, causing osteomyelitis.  This is particularly common in diabetic 
ulcer  patients.  Infections  of  this  nature  are treated  with both topical  and systemic 
antibiotics as necessary (Reviewed in Frank et al, 2005).
Pressure  ulcers: Pressure  ulcers  are  an  area  of  localised  damage  to  the  skin  and 
underlying  tissue,  caused  by  shear  forces,  pressure,  and  friction,  over  prolonged 
periods  of  time  resulting  in  ischemia  and  reperfusion.  This  leads  to  necrosis  of 
muscle, subcutaneous tissue and of the dermis and epidermis. Pressure ulcers are a 
significant  cause of  increased morbidity  and mortality  in  elderly patients,  and are 
commonly associated with spinal injuries as well as impaired sensation and mobility. 
The prevalence of pressure ulcers in hospitals is between 1% and 5%, rising to up to 
8% amongst patients confined to bed or a wheelchair  for just one week. Amongst 
spinal injury patients pressure ulcer incidence lies between 20% and 30%, and can be 
as high as 70% in elderly patients suffering orthopaedic problems. Pressure ulcers in 
elderly patients are associated with a five-fold increase in mortality. The annual cost 
to the NHS of treating these wounds has been estimated to be anywhere between 
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£180million and almost £2billion (Grey et al, 2006). Pressure ulcers occur most often 
upon areas of the body where prolonged pressure is common, and will usually centre 
over bony prominences, where the effects of the body’s weight, in terms of pressure, 
friction and shear force generated, are most profound (Figure 1.6) or over points of 
prolonged contact between a wheelchair and wheelchair user (Figure 1.7). It has been 
suggested that  pressure ulcers originate within the muscle  rather  than the skin,  as 
muscle is softer and more vulnerable to the ischemia and reperfusion related damage 
responsible for the tissue death that leads to ulcer formation. As muscle requires more 
oxygen than skin it seems likely that muscle would suffer greater damage from the 
occlusion of capillaries  caused by prolonged pressure (Consortium for spinal  cord 
medicine, 2007, Grey et al,  2006, Reddy et al,  2006).
Pressure  ulcer  grading: Pressure  ulcers  are  graded  from  I  to  IV  according  to 
presentation, giving an indication of the severity of the wound (Figure 1.8), although 
they do not  progress  sequentially  from grade I  to  IV,  nor  necessarily  heal  in  the 
reverse  order  (Consortium  for  spinal  cord  medicine,  2007,  Grey  et  al,  2006). 
Consequences of pressure ulcers include the prolongation of rehabilitation following 
injury,  severe  pain,  and impaired  psychological  and social  well  being,  as  well  as 
potentially giving rise to local and systemic infections, septicaemia, bacteraemia and 
osteomyelitis  (Grey  et  al,  2006).  In  severe  cases  these  infections  can  necessitate 
amputation  of  ulcerated  limbs,  leading  to  impaired  mobility,  with  social  and 
psychological implications and reduced quality of life for patients. 
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Figure 1.6. Areas of the body commonly associated with pressure ulcer 
incidence. Bony prominences and areas of prolonged contact in different positions 
contributing to pressure ulceration (Image taken from Grey et al 2006).
Figure 1.7. Areas commonly associated with pressure ulcer incidence in 
wheelchair users. Areas of prolonged contact between patient and wheelchair, 
contributing to pressure ulceration (Consortium for spinal cord medicine, Clinical 
Practical Guidelines, 2007).
I II
III I
V
Figure 1.8. Classification of pressure ulcers by grade.
I: Observable difference in intact skin, potentially including temperature, redness, 
pain, itching or tissue consistency.
II: Partial-thickness skin loss, involving epidermis, dermis or both, and presenting 
superficially as an abrasion or blister.
III: Full-thickness skin loss, and damage to or necrosis of underlying tissue, 
extending down to but not through the underlying facia.
IV: Extensive destruction, tissue necrosis, or damage to muscle, bone or supporting 
structures, with or without full-thickness skin loss. (Adapted from Consortium for 
spinal cord medicine, Clinical Practical Guidelines, 2007)
Treatment of pressure ulcers: Currently much of pressure ulcer care is focused on the 
prevention of ulcer formation. Recommended prevention strategies are based around 
regular  skin  inspections,  focused  on but  not  confined  to  the  areas  most  likely  to 
develop pressure ulcers,  (Ischii,  Sacrum,  Coccyx,  Trochanters,  Heels,  Etc)  and on 
management of pressure upon these areas. Regular turning of patients confined to bed 
is essential to relieve built up pressure, especially over bony prominences, and it is 
recommended  that  in  moving  patients  care  staff  endeavour  to  avoid  stretching or 
folding  skin,  or  inducing  shear  forces  whilst  moving  patients.  Pressure  reducing 
support surfaces are available to protect soft tissues from injury, and care should be 
taken whilst positioning immobile patients, avoiding loads upon the trochanter, and 
contact between knees and ankles if lying in the lateral position. In some cases, often 
with patients considered to be high risk, or when contact between commonly afflicted 
areas and support surfaces is unavoidable, Dynamic mattresses and overlays can be 
used to provided cyclical pressure relief. Moisture accumulation at the skin-support 
surface  interface  is  also  to  be  avoided.  Individually  prescribed  wheelchairs  with 
pressure reducing seating systems can reduce pressure ulcer incidence in wheelchair 
users.  Where  feasible  it  is  recommended  to  have an  ongoing exercise  regime for 
patients  to  maintain  skin  and  muscle  integrity  and  to  avoid  atrophy.  Appropriate 
nutrition  is  also  an  important  factor  in  pressure  ulcer  prevention,  and  aggressive 
nutritional  support  may  be  required  for  nutritionally  compromised  patients.  Once 
developed, the current methods for pressure ulcer treatment and care are somewhat 
limited. Regular wound cleansing is required, using saline and avoiding antiseptics. 
Care must be taken when cleaning and irrigating to avoid causing further trauma to 
the  wound site.  Surgical  debridement  of  eschar  and necrotic  or  devitalised  tissue 
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should be undertaken where appropriate to the ulcer’s progression and the patient’s 
condition/goals.  Appropriate  dressing  is  also  necessary  to  pressure  ulcer  care. 
Dressing should keep the wound bed continually moist and the surrounding intact skin 
dry.  Materials  that  macerate  surrounding tissue  should  be  avoided.  Ulcer  cavities 
should  be  filled  with  dressing  material  but  over  packing  is  to  be  avoided.  The 
placement of dressing materials should be monitored and dressings changes regularly. 
Grade III and IV pressure ulcers may benefit from electrical stimulation to promote 
wound closure (Reviewed in Consortium for spinal cord medicine, 2007, Reddy et al,  
2006,  Grey  et  al, 2006).  Postoperative  care  is  often  of  paramount  importance  to 
promote  wound  healing  and  prevent  recurrence,  and  should  include  continued 
pressure management, manually moving the patient’s lying or sitting position every 
two hours if immobile, and avoiding direct pressure to the wound site when possible 
and  monitoring  the  ulcer’s  progress  regularly.  Patients  lying  down  should  be 
progressively  mobilised  to  a  sitting  position,  where  possible,  over  4  to  8  weeks 
following surgery to prevent any re-injury of the wound site. Topical growth factors 
have shown some potential for the healing of chronic wounds. Platelet derived growth 
factor is currently licensed for use on non-infected diabetic foot ulcers, and has shown 
some value in  treating pressure ulcers,  as has fibroblast  growth factor.  There is  a 
strong  theoretical  basis  in  support  of  the  development  of  proteinase  inhibitors  as 
agents  to  treat  chronic  wounds  such  as  pressure  ulcers,  and  alternatives  such  as 
occlusive dressings and negative pressure therapy have potential applications in this 
area. To date, however, there does not appear to be sufficient evidence from clinical 
trials  supporting these methods to justify their use in the treatment of  pressure ulcers 
(Reviewed in Consortium for spinal cord medicine, 2007, Reddy et al, 2006, Grey et  
al, 2006).
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Spinal  injury  and pressure  ulcers: As previously mentioned spinal  injury patients 
show an increased incidence of pressure ulceration. (20% to 30% compared to 1% to 
5% in the general hospitalised population). Not only do spinal injuries often result in 
prolonged periods of immobility, wheelchair use or loss of sensation that contribute to 
pressure ulcer formation, but spinal injury can affect the physical properties of the 
skin, rendering it more prone to damage. Sufficiently severe spinal injury can impair 
the thermoregulatory processes necessary to maintain skin temperature, causing the 
skin  to  overheat.  Neurologically  impaired  skin  also  undergoes  distinct  metabolic 
changes  that  often  do  not  stabilize  for  years  following  injury.  Increased  collagen 
catabolism,  combined  with  decreased  activity  of  lysyl  hydroxylase,  an  enzyme 
involved in collagen biosynthesis, reduces the tensile strength of the skin, and renders 
it more fragile below the level of injury. Increased excretion of glycosaminoglycans 
reduces the elasticity of the skin, leaving it ill equipped to deal with the mechanical 
forces  of  pressure,  shear  and  friction  associated  with  immobility.  A  decrease  in 
adrenergic  receptors  in  neurologically  impaired  skin  leads  to  unusual  vascular 
reactions, and it has been reported that this can dramatically reduce the skin’s ability 
to  withstand  ischemia.  The  reduced  blood  supply  associated  with  spinal  injury 
contributes to this, leaving tissues at risk of severe hypoxia. Spinal injury also results 
in a reduced proportion of type I collagen, compared to type III. As type III collagen 
forms thinner,  weaker fibrils than type I,  this  contributes to the increased fragility 
seen in neurologically impaired skin, which leaves patients at significantly increased 
risk of pressure ulceration. It has also been shown that blood reflow rates immediately 
following occlusion are reduced in spinal injury sufferers compared with able bodied 
individuals. The muscular atrophy caused by paralysis originating from spinal injuries 
leads to the loss of muscle mass  in the affected areas.  This reduced muscle mass 
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results in less padding between prominences and support surfaces, further increasing 
the  risk  of  pressure  ulcer  development.  The  combination  periods  of  prolonged 
immobility,  sensory  impairment,  or  wheelchair  use,  and  the  physiological, 
mechanical, and biochemical factors outlined above goes a long way to explain the 
increased incidence of pressure ulcers associated with spinal injuries (Reviewed in 
Consortium for spinal cord medicine 2007).
33
1.4 Model systems for the investigation of chronic wounds and skin wound 
healing.
Systems used to investigate pressure ulcers, and skin damage or repair in general can 
be divided broadly into in vitro and in vivo models. 
In  vivo  models: The  majority  of  in  vivo studies  have  utilised  animal  models,  as 
pressure ulcers are too hazardous and expensive to induce in the clinical environment, 
thus  limiting  human  studies  to  patients  with  already  existing  ulcers.  Individual 
variations in the intrinsic (anaemia, lean body mass, neurological impairment etc) and 
extrinsic  factors  (shear,  friction,  immobility,  pressure)  as  well  as  co-morbid 
conditions between patients also limit the reliability of the results of human studies. 
Animal models have traditionally utilised rats, mice, and swine, as there skin types are 
considered similar to that of humans. The use of rats and mice in particular avoids the 
impediments and expenditure associated with bigger bodied animals in large scale 
experiment. Experimentally induced pressure ulcers have been used to determine the 
degree  of  external  pressure  that  will  consistently  lead  to  tissue  damage.  Animal 
studies have involved the application of standardised pressures or shear forces to soft 
tissue, followed by histological observation of the resulting breakdown. Work using 
pigs in the 1970s, for example, featured paraplegic and normal swine, and utilised 
light and electron microscopy of tissue biopsies. These studies showed pressure ulcers 
to be caused by two main factors, friction and ischemic pressure, and demonstrated 
that friction did not contribute to ischemia in pressure ulcer development (Dinsdale et  
al, 1973).  Both  rat  and swine models  have been used to  demonstrate  the  role  of 
myofibroblasts in cutaneous wound contraction (Salcido  et al,  2006). The Diabetes 
mouse has been used as a model for impaired dermal wound healing to investigate the 
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expression  of  matrix  metalloproteinases  (Wall  et  al,  2002).  In  addition,  other 
mammals  such  as  rabbits  and  greyhounds  have  also  been  used  as  models  for 
mammalian  wound  healing  (Salcido  et  al, 2006).  These  models  do  not  however 
accurately represent normal human skin conditions. Pigs skin is covered in hair much 
coarser  than  that  found  in  humans,  and  the  porcine  dermis  is  only  moderately 
vascularised compared to our own. Pigs also lack the epidermal stratum lucidum, a 
layer of flat keratinocytes immediately below the cornified surface cells in thick skin, 
and this may influence the regeneration of the outer layer.   Rat skin is much less 
cellular than human skin, and derives its circulation directly from large blood vessels 
such as the cutaneous arteries,  as opposed to human skin, which is sustained by a 
more complex system of smaller blood vessels, derived from the musculocutaneous 
arteries. The use of animal models in research as a whole has been in decline since the 
1970s as  a  combined  effect  of  the  animal  rights  movement,  increased  public  and 
scientific sympathy towards ethical issues, and the development of biotechnological 
alternatives that reduce the need for animal testing (Salcido et al, 2006).
In vitro models: In vitro models used in pressure ulcers tend to be tissue cultured skin 
substitutes, or donor skin tissue. Keratinocytes cultures, either primary keratinocytes 
or  cell  lines,  can  be  used  to  represent  the  epidermis,  ).  Fibroblasts  seeded  in 
extracellular  matrix  proteins,  such  as  collagen  gels  ),  or  de-epidermalised  human 
dermis (Haddow et al, 2001) have been used to represent the dermis. Organotypic co-
cultures,  incorporating  both  a  dermal  and  epidermal  equivalent  can  be  used  to 
represent whole or living skin (Marionnet et al, 2006). The growing of keratinocytes 
at an air-liquid interface leads to nearly complete differentiation and the formation of 
an organised stratified epidermal substitute similar to living skin (Marionnet  et al, 
2006). An example of a reconstructed human skin equivalent,  Episkin, consists of 
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primary human keratinocytes grown upon an acellular dermal substitute of type I and 
III collagens covered by a film of collagen type IV and is being investigated for its 
use in skin irritation studies. Models such as these contain primary cells, which are 
known  to  demonstrate  inter-individual  variations.  In  order  to  develop  more 
reproducible skin equivalents work has been done regarding the incorporation of cell 
lines  into living skin models  ).   Sterile  acellular  de-epidermalised   human dermis 
(DED) is used as a wound bed model and has been used in the study of the transfer of 
cultured cells from tissue engineered dressings to the model wound bed (Haddow et  
al, 2001). Although these models are used to represent human skin to a degree, they 
do  not  have  common  skin  appendages  such  as  follicles  or  sweat  glands,  do  not 
incorporate immune or circulatory responses, nor contain cells such as Langerhans 
cells, melanocytes, or macrophages and so do not exactly reproduce in vivo conditions 
(Metcalfe & Ferguson 2007).
2 dimensional (2D) models of cell migration (scratch assays)
In vivo,  most cell migration occurs in three dimensions (3D) or at least in a laminar 
manner. Whilst  assays are being developed for the assessment of cell migration in 3D 
conditions, the use of such model systems is made difficult and limited compared to 
2D cell migration assays by their relative degree of complexity in set up and analysis, 
high expense in time and resource, and by being markedly less well characterised and 
established within the current literature. Of the 2D cell migration assays in common 
use, the most widely utilised is the scratch assay (as described in the methods section 
of this thesis) (Ashby and Zilastra,  2012). The scratch assay is advantageous as a 
model system of cell migration mostly due to its simplicity and versatility, allowing 
migration to be assessed under a variety of culture conditions and in relatively high 
numbers  of  replicates  whilst  requiring  no  specialised  equipment  outside  of  that 
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commonly present within a culture laboratory (Nikolic  et al., 2006). In addition, the 
scratch  assay  has  value  as  an  established  model  of  re-epithelialisation  especially, 
where  the  migrating  keratinocytes  move  across  the  surface  of  an  ECM, much  as 
occurs in scratch assays involving a pre-prepared substrata of ECM molecules. The 
main  disadvantages  of  scratch  assays  arise  from the  difficulty  in  determining  the 
degree of damage to both the cells and the underlying matrix material done by the 
mechanical means of scratching, and the possible effects of this upon cell migration in 
to the scratch area. Additionally,  the high density of cells required for these assays 
may  result  in  the  modification  of  an  exogenous  substrate  of  interest  by  the  cell 
population as they migrate (Ashby and Zilastra, 2012).
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1.5 Cell therapies for skin wound healing.
Extensive wounds require barrier protection to prevent infection and desiccation, and 
the loss of full thickness skin over an area exceeding 4cm diameter will not heal well 
without a graft (Reviewed in MacNeil, 2007). As far back as 1871 the transplantation 
of either full thickness or split thickness skin from elsewhere on the patient’s body has 
been the standard surgical treatment for wounds of this severity; as the patient will re-
grow skin over the source site, provided sufficient epidermal cells remain within the 
dermal  surface.  In  many  wounds  however,  especially  severe  burns,  there  is  not 
enough  skin  available  on  the  patient’s  body  for  transplantation,  without  causing 
further damage. This has led to the development of engineered skin substitutes for use 
as biological  dressings. These dressings not only achieve the initial  closure of the 
wound but can also promote regeneration, and reduce healing time. Current strategies 
include the engineering of substitute dermis, epidermis or both, and often include an 
artificial  extracellular  matrix  (Metcalfe  & Ferguson 2007, Horch  et  al, 2005).  No 
substitute yet developed accurately replicates the full properties of uninjured skin, but 
the numerous criteria that an ideal skin substitute should fulfil are listed below: 
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Engineered skin substitutes should demonstrate:
 Absence of antigenicity
 Tissue compatible
 No local or systemic toxicity
 Impermeability to exogenous micro-organisms
 Transmission of water vapour similar to normal skin
 Rapid and sustained adherence to the wound bed
 Conformation to surface irregularities
 Elasticity to permit motion of underlying tissue
 Resistance to linear and shear stresses
 Sufficient tensile strength to resist fragmentation
 Inhibition of wound surface flora and bacteria
 Long shelf life, minimal storage requirements
 Low cost
 Minimised nursing care of wound
 Minimised patient discomfort
 Translucent properties to allow direct observation of healing
 Reduced healing time
 Non increased rate of infection
 Patient acceptance
(Ehrenreich and Ruszczak, 2006)
Generally, tissue engineered skin is created by expanding skin cells in the laboratory, 
at a rate far exceeding that which would occur in vivo. Utilising the rapid growth of 
cells in culture, enough skin to cover almost the entire surface area of the body can 
potentially be grown within three weeks (MacNeil 2007).
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Epidermal repair: Cultured keratinocytes are widely used to provide an engineered 
epidermis, to restore skin barrier function, and to promote regeneration. This can be 
achieved using a range of methods. Integrated sheets of autologous keratinocytes can 
be grown from a biopsy of patient’s cells, and enzymatically removed from culture for 
direct application to the wound site (Epicel, Genzyme Tissue Repair). Alternatively, a 
subconfluent  population  of  cells  can  be  delivered  to  the  patient  on  a  chemically 
defined carrier dressing (Myskin, CellTran). Keratinocytes in suspension can also be 
applied to the wound bed as a spray,  sometimes also containing fibrin (CellSpray, 
Clinical Cell Culture). Small sheets of keratinocytes can be cultured from patient’s 
hair follicles (Epidex, Modex Therapeutics) (Metcalfe & Ferguson 2007, Horch et al, 
2005) . As yet, there has been little direct comparison of the relative effectiveness of 
these methods. 
Dermal repair: Epidermal replacements will generally fail to take in the absence of a 
vascularised dermis, and in the case of chronic wounds the replacement of the dermal 
layer is important to promote healing. Allografts of human donor skin can be used as 
a  temporary  cover  for  full  thickness  wounds,  before  removing  the  non-immune 
compatible  epidermal  layer.  This  leaves  behind  a  donor  dermis  with  sufficient 
vasculature  to  support  subsequent  skin  grafts  or  engineered  epidermal  substitutes 
(Metcalfe  & Ferguson 2007).  Integra,  an  alternative  dermal  substitute,  consists  of 
bovine  collagen  and  shark  chondroitin  sulphate  and  a  silicone  membrane.  When 
grafted  onto  a  wound  bed,  this  forms  a  temporary  barrier,  and  stimulates 
vasculogenesis.  Once  vascularised,  the  silicone  membrane  can  be  removed  and  a 
subsequent graft,  either split thickness autologous skin or an engineered epidermal 
substitute can be applied (MacNeil 2007). Synthetic materials seeded with cultured or 
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donor fibroblasts (Dermagraft and Transcyte, Advanced Biohealing) have also been 
used to generate a vascularised dermis prior to epidermal replacements.
Whole  skin  repair: Problems  with  adherence  between  replacement  epidermis  and 
prepared dermal wound beds led to the development of composite skin replacement 
materials,  such as Apligraf,  Orcel  and Permaderm,  incorporating  both dermal  and 
epidermal components. Apligraf (Organogenesis) and OrCel (Ortec international) use 
allogeneic keratinocytes and fibroblasts in a bovine collagen matrix, and are suitable 
for  use  in  the  treatment  of  chronic  wounds.  Permaderm  utilises  autologous 
keratinocytes and fibroblasts in reconstructed skin with bovine collagen, and is used 
to treat burns patients (Metcalfe & Ferguson 2007). 
Issues  with  engineered  skin  substitutes: The  range  of  currently  available  skin 
substitutes still has certain aspects which require address or improvement. The use of 
animal  products  such  as  bovine  collagen,  animal  serums  and  enzymes  in  culture 
medium  has  potential  health  implications  for  patients,  centred  on  the  transfer  of 
viruses  or  prion disease proteins.  Work has been done to  develop xenobiotic  free 
protocols for tissue engineering and the bovine serums and collagens currently used 
are sourced from herds known to be free of bovine spongiform encephalitis (BSE) 
(Bullock  et al, 2006). Wound infection is a major cause of graft loss, and cultured 
skin is more susceptible to damage from bacterial infection than conventional grafts 
due to the fragility of the non-cornified epithelium and the incomplete development of 
the dermal-epidermal junction (Horch et al,  2005). Given the very high incidence of 
infection amongst chronic wounds this is potentially a very serious failing. Scarring at 
the margins of grafts is a problem common to conventional and tissue engineered skin 
grafts. As well as some degree of mechanical impairment, pronounced scarring is an 
aesthetic defect that may be of more concern to patients than physicians. The study of 
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foetal  scar  free regeneration  has  lead  to  the  experimental  manipulation  of  growth 
factors  in  adult  wounds,  resulting  in  the  reduction  and  prevention  of  scarring 
(reviewed in Ferguson and O’Kane, 2004). The timescale involved in skin culture is 
an area for potential improvement. Although cells grow much more rapidly in culture 
than they do in vivo, the time taken to grow autologous skin equivalents is still quite 
significant, around two to three weeks (Metcalfe & Ferguson 2007), especially when 
compared to the ability of allogeneic products to be produced and stored ready for use 
(Mansbridge 2006), or the immediate availability of patient’s skin for conventional 
grafting. Dermagraft for example can be cryopreserved for a shelf life of up to six 
months,  although this process may have an effect on the efficacy of the product.  
Immune  rejection  of  allogeneic  cells  also  limits  the  effectiveness  of  some 
engineered skin substitutes. Although there are reports of immunogenic tolerance to 
allogeneic fibroblasts permitting their survival for weeks and even months within a 
host  (Coulomb et  al.,  1998,  reviewed in  Shevchenko  et  al.,  2010),  there  are  also 
studies that suggest that these cells do not persist for longer than seven days in either 
human or porcine hosts (Price et al., 2004,  Kolokol’chikova et al., 2001), Similarly 
allogeneic  keratinocytes  are  reported  to  suffer  immune  rejection  within  weeks 
(Strande et al., 1997, Clark et al., 2007).
Failure  of  integration  is  a  common  problem  associated  artificial  skin 
substitutes. Vascularisation of grafts is essential if the replacement skin is to take and 
survive long term, successfully integrating with host tissues. Often the vascularisation 
of cultured skin grafts (in those that do allow angiogenesis to occur) is too slow or 
insufficient to allow the construct to take, resulting in cell death and ultimately the 
sloughing off of the skin graft. The recent observation of the origins of vascularisation 
occurring within the central area of the graft suggests that engineered skin substitutes 
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which incorporate prefabricated vessels may vascularise more rapidly, increasing the 
success rate of these grafts  (Metcalfe  & Ferguson 2007). Cultured skin substitutes 
generally consist of keratinocytes, fibroblasts, or co-cultures of both, and as such do 
not contain many of the appendages and functional structures found in skin. A lack of 
follicles  means that  the grafts  lack hair,  and combined with the absence of sweat 
glands may result in some impairment of thermoregulation over the graft area. The 
absence of dendritic cells and macrophages in engineered skin grafts leaves the graft 
area potentially devoid of immune surveillance,  although this is thought to benefit 
allografts  by  preventing  rejection.  Studies  have,  however,  experimented  with  the 
incorporation  of  these  structures,  as  well  as  melanocytes  for  pigmentation,  into 
engineered  skin tissue,  with some success.  In  a  case described by Zheng and co-
workers the injection of dermal cells  and epidermal aggregates  into the dermis  of 
nude mice resulted in normal hair morphogenesis, giving rise to hair follicles within 
8-12 days (Zheng et al, 2005). 
Commercial considerations: Commercially, those tissue engineered products licensed 
for clinical use have fallen short of promoters expectations (Ehrenreich & Ruszczak 
2006), receiving less of the market share than anticipated. This short fall is, in part, 
due to the extensive differences between the laboratory environment in which these 
products  are  developed,  and  the  requirements  for  high  quality  and  cost  effective 
manufacturing.  Allogeneic  cells  are  well  suited  to  commercial  scale  up,  whilst 
autologous cells  inherently are not,  and so it  is  the allogeneic products (Apligraf, 
Dermagraft  etc)  that  have  met  with  a  greater  degree  of  commercial  success.  For 
example, Dermagraft has been developed to incorporate several beneficial features for 
commercial production- through the design of an aseptic bioreactor suitable for use in 
automated systems, being capable of preservation by cryofreezing, and the  inclusion 
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of translucent and ink accepting surfaces allowing wound outlines to be traced upon 
the  packaged tissue  pocket,  dermagraft  was designed to  provide  optimal  end-user 
convenience (Mansbridge 2006).
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1.6 Mesenchymal Stem Cells
Background: Over  100  years  ago  Conheim,  a  German  pathologist,  proposed  that 
fibroblastic  cells  present with adult  bone marrow could contribute to the repair  of 
damaged peripheral tissues (Prokop, 1997). Subsequently in the 1970s Friedenstein 
and colleagues demonstrated the clonogenic potential of fibroblast-like cells isolated 
from  rodent  bone  marrow  (Friedenstein  et  al, 1970,  Friedenstein  et  al, 1976, 
Friedenstein,  1980).  Friedenstein’s  method  of  flushing  whole  bone  marrow  into 
plastic  culture  vessels  and  discarding  the  non  adherent  population  gave  rise  to  a 
heterogeneous population of plastic adherent fibroblastic colony forming cells, and 
has formed the basis for the isolation of MSC from bone and bone marrow to this day. 
Friedenstein also demonstrated that these cells possessed a capacity for self-renewal, 
as  well  as  the  potential  to  form  bone.  Since  Friedenstein’s  initial  experiments, 
numerous  groups  have  expanded  upon  these  findings,  demonstrating  that  an 
equivalent cell population was present in human bone marrow, and that cells isolated 
by methods similar to Friedenstein’s could be sub-passaged in vitro and differentiated 
into other cells of the mesenchymal  lineage such as osteoblasts,  chondrocytes  and 
adipocytes (reviewed in Caplan, 2007, Bianco et al, 2008).
Characteristics  and  definition  of  MSC: There  are  currently  no  single  markers  or 
receptors  considered  to  be  unique  to  MSC (Rastegar  et  al,  2010)  but  established 
criteria dictates that in order to be considered to be MSC, a population of cells must 
be  plastic  adherent,  capable  of  differentiation  into  osteoblasts,  chondrocytes  and 
adipocytes, and to express cluster of differentiation (CD) markers CD105, CD73 and 
CD90 whilst  not  expressing  CD34,  CD45,  or  CD14 (Dominici  et  al,  2006).  This 
profile is consistent between cell populations isolated from a range of tissues that are 
considered to be MSC, but the expression of other cell surface molecules can differ 
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quite markedly between MSC isolated from different sources (Table 1.1) (Cao et al, 
2005, Pittenger  et al, 1999, Jörn  et al, 2010, Schaffler  et al, 2007, De Ugarte  et al, 
2003, Zuk et al, 2002, Tondreau et al, 2005).
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Bone marrow-MSC Adipose tissue-MSC Peripheral blood-MSC
Positive CD13
CD44
CD73
CD90
CD105
CD166
STRO-1
CD9
CD13
CD29
CD44
CD54
CD73
CD90
CD105
CD106
CD146
CD166
HLA
STRO-1
CD44
CD54
CD90
CD105
CD166
Negative CD14
CD34
CD45
CD11B
CD14
CD19
CD31
CD34
CD45
CD79α
CD133
CD144
HLA-DR
CD14
CD34
CD45
CD31
Table 1.1. Differential expression of  cluster of differentiation (CD) markers 
between MSC isolated from different source tissues.
Sources of MSC: Whilst the majority of MSC used for experimental investigation are 
isolated  from bone  marrow,  and  these  are  generally  regarded  as  being  the  ‘gold 
standard’ (Hass  et al, 2011), MSC have been isolated from numerous other tissues 
including  adipose  tissue,  peripheral  and umbilical  cord  blood,  bone,  placenta  and 
amniotic membrane (Kern et al, 2006, Miao et al, 2006, Tsai et al, 2007). Whilst bone 
marrow derived MSC are often considered to be preferable, the process of harvesting 
bone marrow aspirate from patient donors is invasive, often painful and carries an 
associated  risk  of  infection  (Hass  et  al, 2011,  Malgieri  et  al,  2010).  Conversely, 
Adipose  tissue  suitable  for  the  isolation  of  MSC can  be  easily  obtained  through 
elective procedures such as liposuction or lipoplasty.  The low cost of isolation and 
ease  of  accessibility  of  adipose  derived  MSC  establishes  them  as  an  attractive 
alternative to bone marrow derived cells  (Romanov  et al, 2005),  especially as the 
capacity of adipose tissue derived MSC to differentiate along the mesodermal lineage 
is equal to that of bone marrow MSC (Baglioni et al, 2009).  Birth-associated tissues 
such as  umbilical  cord  and umbilical  cord  blood are  often  considered  as  medical 
waste in delivery rooms and can be collected and utilised in a non-invasive manner 
(Malgieri et al, 2010). Cells isolated from umbilical cord are also more primitive than 
bone marrow MSC (Lu et al, 2006, Can and Karahuseyinoglu 2007, Sarugaser et al, 
2005, Wu et al, 2007). Disadvantageously, the isolation of MSC form umbilical cord 
blood is markedly less regularly successful than from bone marrow (Kern et al, 2006).
MSC differentiation: As well as being isolated from numerous tissue sources, MSC 
have been successfully differentiated into numerous cell types from multiple lineages 
both in vitro and in vivo (Arthur et al, 2009, Deans et al, 2000, Bianco et al, 2000) 
(Figure 1.9), including the aforementioned cells  of mesodermal origin; osteoblasts, 
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chondrocytes and adipocytes, as well as skeletal and cardiac muscle, (Bianco  et al, 
2000, Tokcaer-Keskin  et al, 2009, Moscoso et al, 2005) and cells derived from both 
the ectodermal and endodermal lines, (Figure 1.10) e.g. astrocytes (Kopen et al, 1999) 
neurons (Sanchez-Ramos et al, 2000, Woodbury et al, 2000) and pancreatic islet cells 
(Chen  et  al, 2004).  Of  these  potential  MSC  progeny,  their  differentiation  into 
osteoblasts, chondrocytes and adipocytes are relatively well understood. MSC have 
been differentiated into osteoblasts  in vitro using a range of methods. Exposure to 
bone morphogenic proteins (BMP) such as BMP-2, BMP-4, BMP-6 ,  BMP-7 and 
BMP-9 have been shown to induce osteogenic  differentiation  of  MSC (Cei  et  al, 
2006, Chen et al, 2004, Fujii et al, 1999, Gu et al, 2004, Katagiri et al, 1994, Yeh et  
al, 2002,  Zachos et al, 2006, Zhu et al, 2006). BMP signal though serine/threonine 
kinase  receptors,  signalling  via  mitogen  associated  protein  kinase  (MAPK) 
components  to  trigger  the  transcription  of  genes  associated  with  osteoblasts  cells 
within the nucleus (Chen et al, 2004, Fujii et al, 1999). Transcription factors such as 
Runx2 (Arthur et al, 2009, Fujita et al, 2004) and oseterix (Tominaga et al, 2009) are 
also  known  to  promote  osteogenic  differentiation,  as  well  as  ex  vivo  culture  in 
osteogenic media supplemented with dexamethasone and ascorbate (Choi et al, 2010, 
Oreffo  et al, 1999). MSC differentiation into chondrocytes  can be induced by the 
aggregation of cells in culture into alginate beads or cell pellets, and by exposure to 
BMP and TGF-β (Shen  et  al,  2009, Mehlhorn  et  al,  2006).  MSC have also been 
shown to differentiate into chondrocytes when cultured in the presence of cartilage or 
nucleus  pulposus  tissues  (Rastegar  et  al,  2010).  The  differentiation  of  MSC into 
adipocytes is controlled by peroxisome proliferator-activated receptor γ (PPARγ), a 
nuclear receptor and transcription factor that regulates the expression of adipocytes 
associated genes (Michalik et al, 2006, Rosen and Spiegelman, 2000). In vitro, MSC 
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can  be  differentiated  into  adipocytes  by  culture  in  media  containing  insulin  and 
dexamethasone (Yin et al, 2010, Oishi et al, 2009). Numerous reports have suggested 
that MSC are capable of neural trans-differentiation, induced by a variety of methods, 
for  example  exposure  to  retinoic  acid  and  brain-derived  neurotrophic  factors 
(Sanchez-Ramos,  et al,  2000),  growth factors EGF and HGF (Bae  et al,  2011) or 
antioxidant compounds such as β-mercaptoethanol, dimethyl sulfoxide, and butylated 
hydroxyanisole (Woodbury  et al, 2000). Recently however, it has been shown that 
many of the markers used to demonstrate neural differentiation can be expressed in 
the undifferentiated MSC population (Montzka  et al, 2009). This considered along 
with the failure of some reports (e.g.  Sanchez-Ramos et al, 2000, Fu et al, 2008) to 
demonstrate  the  absence  of  neuronal  markers  in  the  MSC population  prior  to  the 
application  of  their  neural  differentiation  protocols,  and  the  variable  degrees  of 
success reported by some groups when attempting to differentiate MSC into neural 
cells  (Montzka  et  al,  2009),  should  inform  future  investigation  into  the  neural 
differentiation potential of MSC. This said, both human and rodent MSC have been 
successfully  and  robustly  differentiated  into  functional  neurons  that  effectively 
improve the symptoms of neurodegenerative disorders following transplantation into 
animal models (Dezawa et al, 2005).
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Figure 1.9. The differentiation potential of MSC. Mesenchymal stem cells have 
been shown to be capable of differentiation into cells of the mesenchymal lineage; 
osteoblasts, chondrocytes and adipocytes as well as other cell types such as neurons 
(Image adapted from Rastegar et al, 2010)
Figure 1.10. The Hierarchy of stem cells (Image taken from Salem and 
Thiemermann, 2010)
Clinical  applications  and  therapeutic  potential: MSC  have  shown  potential  as  a 
therapeutic agent for the treatment of a wide range of disorders, and have recently 
become the subject of numerous clinical trials (Table 1.2).  Following transplantation 
in humans, MSC have been reported to have therapeutic potential for the treatment of, 
for example; osteogenesis imperfecta (Horwitz et al, 2002), bone fracture (Bajada et  
al, 2007), traumatic brain injury  (Zhang  et al, 2008), stroke  (Honmou  et al, 2011, 
Bang et al, 2005), and myocardial infarction (Tendera et al, 2009, Hare et al, 2009). 
The  ability  of  MSC to  differentiate  into  osteoblasts  and  chondrocytes  has 
rendered  them  an  attractive  treatment  option  for  orthopaedic  complaints  such  as 
fracture non-union and critical sized bone defects, as well as for cartilage regeneration 
and the  treatment  of  osteogenesis  imperfecta  (Horwitz  et  al, 2002).  For  example, 
Bajada  et  al showed that  an  application  of  MSC delivered  with calcium sulphate 
resulted in enhanced repair of fracture non-union compared to calcium sulphate alone 
(Bajada et al, 2007) Similarly, reporting on a seven year pilot study, Marcacci and co-
workers showed that MSC in a bio-ceramic carrier significantly enhanced the healing 
of critical sized defects in long bones (Marcacci et al, 2007). These findings show that 
MSC represent  a  potential  alternative  to  autologous  bone  grafting,  which  despite 
being the standard treatment for such conditions is associated with significant donor 
site  morbidity  and limited  by the  availability  of  appropriate  donor  tissue  (Marsh, 
1998, Einhorn 1996). MSC have also been used in numerous cases to successfully 
regenerate  damaged  cartilage  in  both  injury  associated  defects  and  osteoarthritis 
(Wakitani  et  al, 2002, Wakitani  et al, 2004, Kuroda  et  al, 2007,  Wakitani  et al, 
2007).
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Clinical trial Disease Cell Source Location/Sponsor
Mesenchymal Stem Cells in Multiple 
Sclerosis
Multiple 
sclerosis
BM-derived 
autologous 
MSC
University of 
Cambridge, UK
Safety Study of Allogeneic Mesenchymal 
Precursor Cells (MPCs) in Subjects With  
recent Acute Myocardial Infarction 
Myocardial 
infarction
BM-derived
allogenic MSC
Angioblast Systems, 
U.S
Mesenchymal Stem Cells and Subclinical 
Rejection 
Organ 
Transplantation
BM-derived
allogenic MSC
Leiden Universitary 
Medical Center, 
Netherlands
Use of Autograft Mesenchymal Stem Cells 
Differentiated Into Progenitor of  
Hepatocytes for Treatment of Patients With 
End-Stage Liver Disease 
Cirrhosis, liver 
failure
Hepatocyte 
drived
autologous 
MSC
Shaheed Beheshti 
Medical University, 
Iran
A Phase II Dose-Escalation Study to Assess 
the Feasibility and Safety of 
Transendocardial Delivery of Three 
Different Doses of Allogeneic Mesenchymal 
Precursor Cells (MPCs) in Subjects With 
Heart Failure 
Heart failure BM-derived
allogenic MSC
Angioblast Systems, 
U.S
Mesenchymal Stem Cells Under 
Basiliximab/Low Dose RATG to Induce 
Renal Transplant Tolerance 
Kidney 
transplant
BM-derived
autologous 
MSC
Mario Negri Institute 
for Pharmacological 
Research, Italy
Safety and Efficacy Study of Adult Human 
Mesenchymal Stem Cells to Treat Acute 
GvHD.
Graft versus 
host disease
BM derived 
allogenic
MSC 
(Prochymal)
Osiris Therapeutics, 
U.S.
Autologous Implantation of Mesenchymal 
Stem Cells for the Treatment of Distal Tibial 
Fractures 
Tibial fracture BM-derived
autologous 
MSC
Hadassah Medical 
Organization, Israel
Prospective Randomized Study of 
Mesenchymal Stem Cell Therapy in Patients 
Undergoing Cardiac Surgery 
(PROMETHEUS) 
Left ventricular 
dysfunction
BM-derived
autologous 
MSC
National Heart, Lung, 
and Blood Institute, 
U.S.
Cord Blood Expansion on Mesenchymal 
Stem Cells 
Myelodysplastic 
syndrome; 
leukemia
CB-derived 
allogenic
MSC
U.T.M.D. Anderson 
Cancer Center, U.S
Mesenchymal Stem Cell Infusion as 
Prevention for Graft Rejection and Graft-
Versus-Host Disease
Hematological 
malignancies
BM-derived 
allogenic
MSC co- 
infusion with 
either HLA- 
mismatched 
PBSC or cord 
blood
University Hospital of 
Liege, Belgium
Clinical trial Disease Cell Source Location/Sponsor
Extended Evaluation of Prochymal Adult 
Human Stem Cells for Treatment-Resistant 
Moderate-to-Severe Crohn’s Disease 
Crohn’s 
disease
BM derived 
allogenic
MSC 
(Prochymal)
Osiris Therapeutics, 
U.S.
Efficacy and Safety of Adult Human 
Mesenchymal Stem Cells to Treat Patients 
Who Have Failed to Respond to Steroid 
Treatment for Acute Graft Versus Host 
Disease (GvHD) 
Graft-versus-
host disease
BM-derived
allogenic
MSC 
(Prochymal)
Osiris Therapeutics, 
U.S.
Prochymal (Human Adult Stem Cells) for 
the Treatment of Recently Diagnosed Type 
1 Diabetes Mellitus T1DM) 
Type 1 
diabetes 
mellitus
BM-derived 
allogenic
MSC 
(Prochymal)
Osiris Therapeutics, 
U.S.
Prochymal (Human Adult Stem Cells) for 
the Treatment of Moderate to Severe 
Chronic Obstructive Pulmonary Disease 
(COPD) 
Chronic 
obstructive 
pulmonary 
disease
BM-derived
allogenic 
MSC
(Prochymal)
Osiris Therapeutics, 
U.S.
Mesenchymal Stem Cell Transplantation in 
the Treatment of Chronic Allograft 
Nephropathy 
Chronic 
allograft 
nephropathy, 
kidney 
transplant
BM-derived 
MSC
Fuzhou General 
Hospital, China
Autologous Mesenchymal Stromal Cell 
Therapy in Heart Failure 
Congestive 
heart failure
BM-derived
autologous 
MSC
Rigshospitalet 
University Hospital, 
Copenhagen, 
Denmark
Marrow Mesenchymal Cell Therapy for 
Osteogenesis Imperfecta: A Pilot Study 
Osteogenesis 
imperfecta
BM-derived 
allogenic
MSC
St. Jude Children’s 
Research Hospital, 
Memphis
Abbreviations: BM, bone marrow; CB, cord blood; MSC, mesenchymal stromal cells.
Table 1.2. Clinical trials using mesenchymal stem cells. (adapted from Salem and 
Thiemermann, 2010)
Having  been  shown to  be  capable  of  differentiating  into  cardiomyocytes  in  vitro  
(Makino et al, 1999, Shiota et al, 2007), and following successful in vivo utilisation 
treating post-myocardial infarction rats (Miyahara  et al,  2006) and pigs (Schuleri  et  
al, 2008), MSC have been trialled clinically to treat damaged cardiac tissue following 
myocardial  infarction  with  contradictory  results;  reporting  upon  one  randomised 
multi-centre trial, Tendera and co-workers concluded that no significant improvement 
was observed in patients treated with MSC compared to the control group (Tendera et  
al, 2009), whereas Hare  et al  report a significant improvement in global symptom 
score and left ventricular ejection fraction in all MSC-treated compared to the placebo 
group patients (Hare et al, 2009).
Smaller initial trials have also produced promising results using MSC to treat 
traumatic brain injury (Zhang et al, 2008), Parkinson’s disease (Venkataramana et al, 
2009) and stroke (Honmou et al, 2011, Bang et al, 2005) and their findings reinforce 
the need for randomised, blinded and placebo controlled trials on a larger scale to 
rigorously investigate the efficacy of MSC treatments for these conditions.
Immunological activity of MSC: A large and increasing body of work demonstrates an 
immunoregulatory function for MSC in both in vitro and in vivo studies, suggesting 
that MSC can suppress immune function both locally by inhibiting the proliferation of 
immune cells in the immediate vicinity of the MSC, and systemically through their 
effects upon T cells and the generation of regulatory T cells (Ghannam et al, 2010). 
This immunosuppressive effect occurs as a response to an initial stimulation of MSC 
by immune cell secreted pro-inflammatory cytokines such as Interferon-gamma (IFN-
γ), Tumour necrosis factor-alpha (TNF-α), IL1-α, and IL1-β (Krampera  et al, 2006, 
Ren et al, 2008). In response to this initial stimulation, MSC secrete a range of soluble 
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factors  that,  in  combination,  inhibit  a  range  of  cellular  functions  involved  in  an 
effective immune response (Trento and Dazzi, 2010, Ghannam et al, 2010). (Figure 
1.11). 
The  immunoregulatory  properties  of  MSC  have  shown  potential  to  be 
exploited clinically, most notably in the prevention of graft versus host disease (Tisato 
et al, 2007) but also in the treatment of autoimmune diseases such as collagen induced 
arthritis  (Augello  et  al,  2007)  and  experimental  autoimmune  encephalomyelitis 
(Zappia et al, 2005, Gerdoni et al, 2007) and in systemic lupus erythematosus (Sun et  
al, 2009).  MSC immunoregulation  has  also  been  investigated  for  its  potential  to 
improve  engraftment  and survival  of  transplantations  of  skin  (Bartholomew  et  al, 
2001) and cardiac tissue (Casiraghi  et al, 2008), as well as hematopoietic stem cell 
transplants  (Koc  et  al, 2000).  Importantly,  clinical  trials  performed  to  date  have 
shown MSC transplantation to be safe for patients and not associated with any major 
side effects (Ghannam et al, 2010, Centeno et al, 2009, Tarte et al, 2009).
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Figure 1.11. Immunoregulatory action of MSC. Mesenchymal stem cells inhibit 
T cell proliferation and function and prevent the maturation of dendritic cells, whilst 
suppressing natural killer cell proliferation and function and inhibiting the migration 
of neutrophils into tissues. MSC may also inhibit B cell differentiation and 
proliferation and drive the generation of TREG  cells  (adapted from Ghannam et al, 
2010).
1.7 MSC and skin wound healing
As previously described, MSC have the potential to facilitate the repair of numerous 
damaged tissues. Amongst the many possible clinical applications for MSC, there is 
an emerging body of work that suggests that these cells may be able to enhance the 
rate of healing of wounded skin. Pre-clinical animal studies have shown that MSC 
transplantation enhances wound healing (Sasaki et al, 2008), and reports have shown 
that  increased  wound healing  also occurs  when MSC are applied  to  humans  with 
acute wounds (after treatment for skin cancer) or with lower extremity chronic skin 
wounds (Falanga et al, 2007, Vojtassák et al, 2006). The mechanisms responsible for 
the enhancement of skin wound healing by MSC are poorly understood but can be 
broadly divided into the cellular  engraftment  and differentiation of MSC into new 
skin tissue,  and the paracrine activity of MSC secreted trophic factors stimulating 
wound  healing  activity  of  the  endogenous  cell  population,  as  well  as  a  possible 
supportive  role  for  MSC,  stimulating  angiogenesis  and  promoting  wound  healing 
indirectly by facilitating the formation of new vasculature within the wound area.
MSC engraftment and differentiation into skin cells: Bone marrow derived MSC have 
been  previously  shown  to  accumulate  in  the  dermis  of  both  uninjured  skin  and 
cutaneous wounds (Fathke et al, 2006, Deng et al, 2005), supporting the possibility 
that they might facilitate skin wound healing by their engraftment into regenerated 
tissue. In an investigation carried out by Wu and co-workers, MSC used to treat full 
thickness in vivo wounds in mice have been shown to significantly enhance the rate of 
wound closure compared to dermal fibroblasts  or an acellular  carrier.  Histological 
examination of the wound showed a large number of MSC were present in the newly 
formed dermal tissue as well as the regenerated epidermis, with MSC present in the 
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epidermis expressing markers of differentiation into keratinocytes (Wu et al, 2007). 
Similarly,  Sasaki  and co-workers  showed that  MSC were capable  of  keratinocyte 
differentiation in vitro and, when applied in vivo to wounded mice, that MSC undergo 
differentiation into a range of cell types present in skin including keratinocytes, and 
again induced a significant enhancement to the rate of skin wound healing (Sasaki et  
al,  2008).  It  has been suggested that  the co-localisation  of MSC and keratinocyte 
markers observed might be due to the fusion of exogenous MSC with cells of the 
endogenous keratinocyte population (Wu et al, 2010), and this phenomena has been 
observed by  in vitro investigations (Baxter  et al, 2004), but in the afore mentioned 
studies,  fluorescence  in  situ  hybridisation  (FISH)  analysis  of  the  X  and  Y 
chromosomes of engrafted MSC indicates that this is not the case in vivo (Sasaki et al, 
2008, Wu et al, 2007, Wu et al, 2010).
Paracrine activity of MSC secreted factors: MSC are known to secrete a range of 
factors which are involved in one or more stages of normal cutaneous wound healing 
(Chen  et al, 2008). This, along with the relatively low degree of MSC engraftment 
observed  in  a  range  of  repaired  tissues  (Prockop,  2007)  suggests  that  MSC may 
contribute to wound healing by paracrine signalling,  enhancing the wound healing 
response of the endogenous cell population. This is supported by studies in which the 
growth  media  from MSC cultures  (MSC-CM) has  been  used  to  stimulate  wound 
healing-associated responses of skin cells (Chen et al, 2008, Jeon et al, 2010), and in 
which co-cultures of skin cells with MSC were divided by culture inserts, showing 
comparable results  (Smith  et al,  2010). Specifically,  MSC-CM has been shown to 
promote both proliferation and migration of human keratinocytes  in vitro as well as 
enhancing  in  vivo wound  healing  in  mice  (Chen  et  al,  2008)  and  the  survival, 
proliferation and migration of human dermal fibroblasts in vitro as well as increasing 
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the production of the ECM components collagen, fibronectin and elastin. Similarly,  
MSC were shown to enhance in vivo wound healing in rats (Jeon et al, 2010). MSC 
grown in co-culture with human dermal fibroblasts but divided by cell culture inserts 
have  also  been  shown  to  promote  their  proliferation  and  migration,  as  well  as 
enhancing the rate at which human dermal fibroblasts close wounds in an  in vitro 
model (Smith et al, 2010). 
Stimulation of angiogenesis by MSC: Mesenchymal stem cells may also contribute to 
cutaneous wound healing by stimulating angiogenesis. In vivo, the injection of MSC 
into wounded mice resulted in markedly accelerated formation of new vasculature 
within the wound sites compared to the injection of either fibroblasts or the vehicle 
medium alone. This enhancement may occur though paracrine mechanisms, as MSC 
have been shown to secrete  factors  known to be  pro-angiogenic  such as  vascular 
endothelial growth factor (VEGF) (Chen et al, 2008, Wu et al, 2007), and MSC-CM 
has  been shown to promote  the  formation  of  new vasculature  in  vitro, enhancing 
tubule  formation  by vascular  endothelial  cells,  and to  promote  the  recruitment  of 
endothelial  cells  to  wound sites  in  vivo.  However,  exogenous  MSC may  also  be 
involved in the formation of new vascular tissue in vivo. Bone marrow derived MSC 
have  been  shown  to  be  capable  of  differentiation  into  endothelial  cells  when 
introduced intravenously to an in vivo wound environment (Sasaki et al, 2008).
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1. 8 Experimental cell lines.
The  cell  lines  used  to  represent  the  cellular  components  of  skin  were:  L929 
Fibroblasts, HaCaT keratinocytes, and EaHy-926 endothelial cells. The advantages of 
using  these  cell  lines  instead  of  the  corresponding  primary  cells  include  their 
comparative consistency from culture to culture and across numerous passages when 
compared  to  the  inter-donor  variability  and  passage-induced  changes  common  to 
primary cells. This allows for a consistent model system with which to examine the 
potentially  variable  effects  of  different  MSC-CM  without  additional  confounding 
factors. It is also advantageous that these cell lines are highly proliferative, allowing 
for  the  high  numbers  of  cells  required  for  culture  experiments  dependent  upon 
confluent  monolayers  (i.e.  the  scratch  assays)  to  be regularly available.  However, 
these cells are limited in that they may differ in certain aspects of their behaviour to 
that  observed  in  primary  cells  either  in  culture  or  in vivo.  This  may manifest  as 
reduced  responsiveness  to  stimulatory  factors  such  as  those  secreted  by  MSCs 
(although as is apparent from data presented later in this thesis, it was evident that 
these cells do respond to MSC conditioned medium). In the case of L292 fibroblasts, 
which are of murine origin, there is also an issue of cross species differences as this 
thesis  has sought to examine the effects  of human MSC secreted factors on these 
cells,  as well as co-cultures of L929 cells with HaCaT cells. However, L929 cells 
have  been  shown  to  respond  to  growth  factors  and  cytokines,  including  human 
recombinant proteins, in a manner that is similar to human dermal fibroblasts. The 
limitations  associated  with  the  use  of  cell  lines,  combined  with  the  profound 
differences  between a culture system and the  in vivo  wound healing environment, 
limits  the  extent  to  which  this  model  system  accurately  represents  the  processes 
involved in the natural healing of a living wounded organism. Nonetheless, the model 
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does allow for a reductionist approach to be taken in a controlled test environment in 
which it is possible to examine individual aspects of the wound healing process in 
relative isolation.
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Table 1.3. Properties of cell lines.
1, 2  L929 Fibroblast 
cell line
3 HaCaT Keratinocyte 
cell line
4, 5 EaHy-926 
Endothelial cell line
Species Murine Human Human
Cell type Fibroblast Keratinocyte Endothelial
Tissue of origin Adipose/areolar Normal skin Umbilical vein/lung 
carcinoma cell hybrid
Morphology Fibroblastic, smaller 
than normal human 
fibroblast
Similar to normal 
human keratinocytes
endothelial
Growth in culture Adherent Adherent/monolayer Adherent
Differentiation 
potential
Osteogenic
Adipogenic
Organotypic 
keratinization to 
terminally 
differentiated 
keratinocytes
Angiogenic 
phenotype
Mature vascular 
structures
Doubling time 14 hours 21 hours 12 hours
Established 1943 1988 1983
(1Earle  et  al., 1943,  2Theerakittayakorn and Bunprasert  2011,  3Boucamp et  al.,  1988, 
1997, 4Edgell et al., 1983, 5Ribatti et al., 1999).
1.9 Aim and Objective
Mesenchymal stem cells have been shown to promote skin wound healing in vivo in 
animal models and in humans (Sasaki et al, 2008, Falanga et al, 2007, Vojtassák et al, 
2006). Furthermore,  MSC can be readily isolated from the bone marrow (amongst 
other tissues) of patient donors, culture-expanded  in vitro and then returned to the 
patients after such culture expansion (Ghannam et al, 2010, Centeno et al, 2009, Tarte 
et al, 2009). Thus, MSC represent an attractive option for autologous cell therapies, 
and have been trialled for the treatment of a range of conditions in humans (Horwitz 
et al, 2002, Bajada et al, 2007,  (Zhang et al, 2008,  Tendera  et al, 2009, Hare et al, 
2009).  Whilst  some data suggests that  MSC can differentiate  into skin cell  types, 
including dermal fibroblasts and keratinocytes (Sasaki et al, 2008, Wu et al, 2007), it 
is evident that MSC secrete factors that are capable of stimulating an improved wound 
healing response in the endogenous cells already present (Chen et al, 2007, Kim et al, 
2008). Relatively low numbers of MSC have been found to persist within repaired 
tissues following cell transplantation (Prockop et al, 2007, Caplan and Dennis, 2006) 
and thus it seems likely that the paracrine activity of MSC may be responsible for 
their  enhancement of skin wound healing,  rather than their  differentiation to form 
mature skin cells. 
Therefore, the overriding aim of this thesis was to examine the potential role 
of MSC secreted factors in skin wound healing. In order to address this aim, a number 
of specific objectives were determined, as follows: 
 To develop and characterise an  in vitro model of skin wound healing based 
upon  the  scratch-assay  and  utilising  the  cell  lines,  L929  and  HaCaT,  to 
represent the cellular components of normal skin. 
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 To utilise  this  model  system to  examine  the  effects  of  culture  medium in 
which MSC have been grown (MSC conditioned medium; MSC-CM) upon 
wound  healing  and  L929  dermal  fibroblast  and  HaCaT  keratinocyte  cell 
behaviour. This study has been presented in Chapter 3.
 To  identify  factors  present  in  MSC-CM  that  may  influence  skin  wound 
healing (via immunological techniques and mass spectrometry) and to assess 
their relative contribution. This study has been presented in Chapters 3 and 4.
 To further investigate the effects of factors present within the MSC secretome 
that were found to contribute to the enhancement of skin wound healing by 
assessing their effects singly and in combination, and by comparison with the 
effects of ‘whole’ MSC-CM. This study has been presented in Chapter 5.
 To investigate the potential angiogenic effects of MSC-CM, and individual or 
combined  components  therein,  again  using  the  scratch  assay  and  an 
endothelial cell line, EaHy-926. This study has been presented in Chapter 6.
 To consider how these experiments may inform our understanding of whether 
and how MSC secreted factors may influence skin wound healing, with 
discussion presented throughout the thesis and especially in Chapter 7.
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Chapter 2
Methods
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2.1 Maintenance of cells.
2.1.1. Tissue culture of the tumour derived murine fibroblast cell line, L929:
L929, a dermal fibroblast cell line (Earle, 1943, Sanford et al, 1948), was maintained 
under exponential growth in 25cm2 and 75cm2 tissue culture flasks (Fisher Scientific, 
Leicestershire, UK) in Dulbecco’s Modified Eagle’s Medium (DMEM)/F12 culture 
medium (Invitrogen, Paisley,  UK) supplemented  with 10% (v/v) foetal  calf  serum 
(FCS)  (Invitrogen)  and  1% (v/v)  penicillin  and  streptomycin  (Invitrogen).  Tissue 
culture flasks were incubated at 37°C and in a humidified atmosphere containing 5% 
(v/v) CO2. Passaging was performed at ≈90% confluence by trypsinisation, and cells 
were routinely re-seeded at 1 x 104 cells per cm2. L929-Conditioned medium (CM) 
was generated by initially washing serum-containing cultures in phosphate buffered 
saline (PBS, Invitrogen) prior to incubating the cultures at ≈90% confluence in serum-
free  DMEM/F12  supplemented  with  1%  penicillin/streptomycin  and  1%  ITS-X 
(Insulin, transferrin and selenium, Sigma-Aldrich, Dorset, UK) for 72 hours. The CM 
was then removed and filtered through a 0.2 micron filter (supplier) to remove any 
debris before being stored at -20°C. The L929 cells were then trypsinised (see 2.1.4) 
and a viable cell count performed using trypan blue exclusion (see 2.1.5) to determine 
the number of cells present at the end of the conditioning process.
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2.1.2. Tissue culture of the human keratinocyte cell line, HaCaT.
HaCaT,  a  keratinocyte  cell  line  (Boukamp  et  al,  1988),  was  maintained  and 
conditioned medium generated in much the same way as L929 cells. Hence HaCaT 
cells were routinely kept under exponential growth in 25cm2 and 75cm2 tissue culture 
flasks  in  Dulbecco’s  Modified  Eagle’s  Medium  (DMEM)/F12  culture  medium 
supplemented with 10% (v/v) (FCS) and 1% (v/v) penicillin and streptomycin. Tissue 
culture flasks were incubated at 37°C and in a humidified atmosphere containing 5% 
(v/v) CO2. Passaging was performed at ≈90% confluence by trypsinisation and cells 
were  routinely  re-seeded at  1  x  104 cells  per  cm2.  HaCaT-CM was  generated  by 
incubating  PBS  washed  cells  at  ≈90%  confluence  in  serum-free  DMEM/F12 
supplemented with 1% penicillin/streptomycin and 1% ITS-X for 72 hours. The CM 
was removed and filtered before being stored at -20°C. The HaCaT cells were then 
trypsinised and a viable cell count performed, as for the L929 cultures, to determine 
the number of cells present at the end of the conditioning process.
2.1.3. Tissue culture of the endothelial cell line, EaHy-926:
Similar  to  L929 fibroblasts  and HaCaT keratinocytes,  EaHy-926 endothelial  cells 
(Edgell  et  al, 1983)  were  maintained  at  37°C  and  in  a  humidified  atmosphere 
containing  5% (v/v)  CO2  in  under  exponential  growth in  25cm
2 and 75cm2 tissue 
culture  flasks  (Fisher  Scientific)  in  DMEM/F12  culture  medium  (Invitrogen,) 
supplemented  with  10%  (v/v)  FCS  (Invitrogen)  and  1%  (v/v)  penicillin  and 
streptomycin  (Invitrogen).  Passaging  was  performed  at  ≈90%  confluence  by 
trypsinisation, and cells were routinely re-seeded at 2 x 103 cells per cm2.
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2.1.4.  Isolation and tissue culture  of  primary human mesenchymal stem cells 
(MSC):
MSC were isolated from bone marrow harvested from the iliac crest of donor patients 
aged between 20-80 years (average approx. 47 years) , or from femoral heads excised 
during total  hip replacements,  following local  research ethical  committee approval 
and the patient’s informed consent. The iliac crest bone marrow was removed from 
iliac crests as aspirates using a Jamshedi needle and heparin coated syringe (Becton 
Dickenson Medical  Supplies,  Oxford, UK). These aspirates were approximately 5-
10ml in volume and were then mixed with 10ml PBS and half of the resultant mix 
layered over each of two 10ml Lymphoprep (Fresenius Kabi Norge, AS) aliquots in 
50ml Falcon Blue Max tubes (Becton Dickenson Medical  Supplies).  Mononuclear 
cells  present  within  the  bone  marrow  aspirates  were  isolated  by  density  gradient 
centrifugation  of  both tubes (20 minutes  at  900g),  resulting  in  the formation  of a 
‘buffy coat’, a distinct layer of mononuclear cells within the tubes that is separated 
from fat and erythrocytes. The buffy coats from each tube were collected using 19 
gauge needles and 5ml syringes (Becton Dickenson Medical Supplies) before being 
pooled and added to 20ml of DMEM/F12 supplemented with 20% (v/v) FCS and 1% 
(v/v)  penicillin  and  streptomycin.  The  resulting  cell  suspension  was  once  more 
centrifuged (10 minutes at 750g) and the supernatant discarded to produce a cell pellet 
that was subsequently re-suspended in 2ml of DMEM/F12 supplemented with 20% 
(v/v)  FCS  and  1%  (v/v)  penicillin  and  streptomycin.  A  viable  cell  count  was 
performed using trypan blue exclusion and the cells were seeded into 75cm2 tissue 
culture flasks in 20ml of the same 20% serum containing culture medium at a density 
of 2 x 107 cells/flask. The mononuclear cell-seeded flasks were then incubated for 24 
70
hours at 37°C in a humidified atmosphere containing 5% (v/v) CO2  before any non-
adherent cells were removed by removing the medium and washing the flasks with 
PBS.  The  remaining  adherent  cell  population  was  then  culture  expanded  in 
DMEM/F12  supplemented  with  10%  (v/v)  FCS  and  1%  (v/v)  penicillin  and 
streptomycin at 37°C in a humidified atmosphere containing 5% (v/v) CO2.  As the 
cells reached ≈70% confluence they were passed by trypsinisation and re-seeded at 5 
x 103 cells per cm2 up to a maximum of passage 8. It has previously been shown in 
our group that the cell population obtained by this method of isolation (due to plastic 
adherence)  and monolayer  culture  expansion  is  consistent  with  the  characteristics 
expected  of  mesenchymal  stem cells,  as  laid  out  by  the  International  Society  for 
Cellular  Therapy  (Dominici  et  al,  2006);  they  were  adherent,  fibroblastic  in 
appearance, capable of adipogenic, chondrocytic and osteoblastic differentiation, as 
well as being immunopositive for CD105 and immunonegative for CD34 and CD45 
(Wright et al, 2008). Conditioned media was generated as described for cell lines.
2.1.5. Trypsinisation of cells for passaging.
Adherent  cell  lines  required removing from the surface of tissue culture  flasks in 
order to be used experimentally or seeded into new flasks, to avoid contact inhibition 
and  hence  kept  in  exponential  growth.  This  was  achieved  using  a  serine 
endopeptidase  proteolytic  enzyme,  trypsin,  to  dissociate  adherent  cells  from  the 
culture surface. Culture medium was removed from flasks and the cells were rinsed 
with  PBS before  being  incubated  for  5  minutes  at  37°C in  0.25% (w/v)  trypsin-
ethylendiamine tetra-acetic acid (trypsin-EDTA, Sigma-Aldrich). An equal volume of 
culture medium containing 10% (v/v) FCS was then added to stop the trypsin activity 
and the resulting cell suspension was centrifuged at 1000rpm for 10 minutes to pellet 
the  cells.  The  supernatant  was  discarded  and  the  cell  pellet  re-suspended  in 
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DMEM/F12  supplemented  with  10%  (v/v)  FCS  and  1%  (v/v)  penicillin  and 
streptomycin.  A viable  cell  count  was performed by trypan blue exclusion before 
seeding cells into fresh culture flasks at a seeding density of 1 x 104 cells per cm2, or 
their use experimentally.
2.1.6. Viable cell counting by trypan blue exclusion
Trypan blue is a coloured dye that cannot pass through an intact cell membrane. This 
property  allows  its  use  to  selectively  stain  dead  or  membrane-damaged  cells  a 
distinguishing blue colour (Altman et al, 1993). A 20μl sample of a cell suspension 
was taken and mixed in a small  eppendorf tube (Fisher Scientific,  Loughborough, 
UK) with 20μl of trypan blue solution (Sigma-Aldrich), before the resulting mixture 
was loaded into a standard improved Neubauer haemocytometer (Fisher Scientific). 
Using the  10  x  objective,  cells  were  visible  as  either  unstained  and phase-bright 
(trypan blue negative), i.e. viable, or stained dark blue (trypan blue positive), i.e. non 
viable. The numbers of both types of cells within an area corresponding to a volume 
of 1 x 10-4 cm3 (Figure 2.1) were counted to give a ratio of viable to non-viable cells. 
The concentration of viable cells per ml in the original cell suspension was calculated 
by multiplying the viable cell count by 2 x 104.
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Figure 2.1. Standard Haemocytometer: A counting grid as seen through a 
microscope on a standard haemocytometer. The area bordered in red represents a 
volume of 1 x 10-4 cm2. The number of cells within this area represents 1/1 x 104 of 
the cells present in 1ml of a cell suspension.
2.1.7 Screening of cells for mycoplasma.
Mycoplasma are a large group of micro-organisms that can contaminate cell cultures, 
thereby potentially affecting experimental data, but that are difficult to readily discern 
visibly as they are intracellular. Their lack of a cell wall renders them unaffected by β-
Lactam  antibiotics  such  as  penicillin  and  its  derivatives,  as  these  agents  target 
bacterial  cell  wall  synthesis.  Mycoplasma  contamination  can  not  only  induce 
significant  changes  in  cell  behaviour,  if  sufficiently  severe  it  can  destroy  a  cell 
culture. (Drexler et al, 2002). In response to this potential problem, cell cultures were 
screened for contamination with mycoplasma whenever a new cell line was acquired 
and then routinely in all cell lines within the laboratory every 3-6 months. An adapted 
EZ-PCR mycoplasma test kit protocol (Biological Industries, Israel Biet Haemek Ltd, 
Israel) was used to screen cell cultures. For each culture tested, 0.5-1ml of culture 
medium  was  centrifuged  for  60  seconds  at  250g  to  pellet  cellular  debris.  The 
supernatants were transferred to fresh tubes and centrifuged once more for 10 minutes 
at 15,000-20,000g to pellet any mycoplasma present. Supernatants were discarded and 
the  pellets  re-suspended  in  50ul  of  Polymerase  chain  reaction  (PCR)  buffer  and 
incubated  for  3  minutes  at  95°C  (Hybaid  PCR  sprint  authorised  thermal  cycler, 
Thermo Life Sciences, Basingstoke, UK). Reaction mixtures were prepared in PCR 
tubes by combining 43µl of RNAse free water (Qiagen Ltd, Crawley, UK) with 5µl of 
reaction test kit and 2µl of test sample. These were placed into the thermal cycler 
along with positive and negative controls (Qiagen) and held for 30 seconds at 94°C 
before undergoing 36 cycles of denaturation (94°C for 30 seconds), annealing (60°C 
for 120 seconds) and elongation (72°C for 60 seconds). The final cycle ended with an 
elongation temperature hold of 72°C for 5 minutes. 2% (w/v) agarose gels containing 
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1µl/ml SYBR safe DNA gel stain in 0.5 x TBE buffer (89mM TRIS-borate, 2.5mM 
EDTA,  pH  8.3)  (Sigma-Aldrich)  were  prepared  to  separate  PCR  products  by 
electrophoresis. A 1kb commercial DNA ladder (Cambio, Cambridge, UK) was used 
to determine the size of PCR products. This ladder was diluted to 100µl/ml in RNAse 
free water along with an equal concentration of tracking dye (blue juice, Invitrogen). 
Agarose gels were run at 100 Volts for 1 hour and then visualised under UV light and 
digitised images taken. The positive control for mycoplasma infection gave a visible 
band at 270bp. No cell  cultures demonstrated a matching band and thus all  tested 
negative for mycoplasma infection.
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2.2 Storage of cells.
2.2.1 Cryopreservation of cells
Cells kept for long periods were stored in liquid nitrogen. Cells were trypsinised and 
centrifuged for 10 minutes at 1000rpm to form a cell pellet, which was subsequently 
re-suspended in 1ml aliquots in cold 10% (v/v) dimethyl sulphoxide (DMSO, Sigma-
Aldrich)  in  FCS  at  1x106 cells/ml  and  transferred  into  1.5ml  cryovials  (Fisher 
Scientific).  Cryovials  were  then  frozen  overnight  at  -80°C  in  a  designated 
cryofreezing container, ‘Mr Frosty’ (Genta Medical, York, UK) containing isopropyl 
alcohol (IPA) before transfer to liquid nitrogen storage.
2.2.2 Recovery of cells from liquid nitrogen:
Cryovials recovered from liquid nitrogen were rapidly thawed by placing under a hot 
running tap. 1ml of ice cold DMEM/F12 supplemented with 10% (v/v) FCS and 1% 
(v/v) penicillin and streptomycin was added to the thawed cell suspension drop wise 
over  one minute  and then the resultant  diluted suspension was left  to  stand for a 
further one minute. After this, a further 10ml of cold culture medium was added drop 
wise over ten minutes and then the resulting cell suspension was centrifuged for ten 
minutes  at  1000rpm.  The  cell  pellet  was  then  re-suspended  in  a  further  10ml  of 
culture  medium  and  centrifuged  once  again  as  before  to  remove  any  remaining 
DMSO. Finally, the cell pellet was re-suspended, counted, and the cells seeded into 
tissue culture flasks at a seeding density of either 1 x 104 cells per cm2  (L929 and 
HaCaT cells) or 5 x 103 cells per cm2 (MSC).
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2.3 Experimental procedures.
2.3.1 Coating of culture plates: 
Tissue culture plates (24-well and 96-well, Fisher Scientific) were coated with a range 
of  commercially  available  ECM protein solutions,  i.e.  type-I collagen,  decorin,  or 
fibronectin (all from Sigma-Aldrich). The stock protein solutions were diluted in PBS 
to the required concentration (0.2mg/ml) and an amount sufficient to cover the bottom 
surface was added to each well (50µl for 96-well plates, 500µl for 24-well plates). 
These plates were then refrigerated at 1-5°C for 24 hours before being rinsed three 
times with PBS immediately prior to use. In later experiments, plates were also coated 
with undiluted MSC-CM using the same method.
2.3.2 Fluorescence labelling of L929 and HaCaT cells for co-culture experiments: 
In co-culture  experiments,  different  cell  types  were distinguished by fluorescently 
tagging them different colours, using green and red linker kits (PKH26 or PKH67 
Fluorescent cell linker kit for general membrane labelling, Sigma-Aldrich) according 
to the manufacturers methods.  In brief, cells were removed from culture flasks by 
trypsinisation  and re-suspended in serum-free DMEM/F12 then centrifuged for 10 
minutes at 1000rpm and the supernatant discarded. This step was repeated in order to 
remove all traces of serum from the original culture medium before re-suspending the 
final cell pellet in 1ml of Linker kit diluent-C at 2x the required concentration. 2µl-
4µl  of  PKH26  or  PKH67  dye  was  then  added  to  a  separate  1ml  of  diluent-C 
immediately before use. This solution was added to the cell suspension and incubated 
for five minutes at room temperature, inverting regularly to ensure a homogeneous 
mix, before an equal volume of culture medium with serum was added to stop the 
staining reaction. Labelled cells were then washed three times and checked to make 
sure they were fluorescently stained prior to experimental use.
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2.3.3 Scratch-wound assays: 
The scratch-wound assay is a 2D model of cells migrating to heal a wound (Morley et  
al, 2003, Firth et al, 2008, Smith et al, 2010), wherein confluent cell monolayers are 
scored with a  sterile  point  to  leave  an acellular  strip,  the ‘wound area’,  and then 
observed as they repopulate the wound area; the rate at which they do this “wound 
healing” activity is quantified by image analysis. Prior to performing scratch assays, 
tissue culture plates were protein-coated as described above. Cells were removed from 
culture  flasks  by  trypsinisation  and  rinsed  to  remove  any  traces  of  FCS  by 
centrifugation  at  1000rpm  for  10  minutes  and  re-suspension  in  DMEM/F12 
supplemented with 10% (v/v) FCS and 1% (v/v) penicillin  and streptomycin.  The 
number of viable cells was determined by trypan blue exclusion before cells  were 
seeded into each well to a final density of 2 x 105 viable cells per well in 1ml of 
medium.  In  co-cultures,  where  L929  and  HaCaT  cells  had  been  pre-labelled  by 
fluorescently tagging in order to distinguish them, equal numbers of each cell type 
were used to give this final cell number of  2  x 105 viable cells per well. Seeded 
plates were maintained at 37°C and 5% CO2 for 24 hours to permit cell adhesion and 
the  formation  of  a  confluent  monolayer.  After  24 hours,  the  culture  medium was 
removed from these confluent monolayers, the back of the wells was marked with a 
horizontal  guideline  and the  cell  surface  was  then  scored  vertically  with  a  sterile 
200μl pipette tip to leave a scratch of approximately 0.4mm-0.8mm in width, and then 
the  culture  medium was  immediately  removed  along  with  any dislodged  cells  or 
debris. All wells were then gently rinsed with 0.5ml of PBS, with care taken to avoid 
forcibly jetting the liquid directly onto the cell monolayers. The PBS was removed 
and replaced with either:
(i) fresh serum-supplemented culture medium (10% FCS)
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(ii) with fresh serum-free culture medium
(iii) serum-free culture medium supplemented with either TGF-β1, IL-6, or  
IL-8,
(iv) with conditioned medium which had been generated from L929, HaCaT 
or MSC,  cultures under serum free conditions, as described above. 
Scratch-wound  closure  was  monitored  by  collecting  digitised  images  at  3  hour 
intervals  after  the  scratch  was  performed  until  closure  was  either  complete  or  no 
longer  progressing. Digitised  images  were  captured  with  an  inverted  microscope 
(Inverso  TC100,  Medline  scientific  LTD,  Oxfordshire,  UK)  and  digital  camera 
(ProgRes CF, Jenoptik, Jena, Thuringia,  Germany) under phase or fluorescence by 
aligning the wells in the tissue culture plate such that the horizontal marker line ran 
tangentially  across  the  uppermost  point  of  the  field  of  view  seen  through  the 
microscope (Figure 2.2). This ensured that images would be taken of the same point 
along the scratch length at each subsequent time point.
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Figure 2.2. Orientation of scratch assay: A,  1) A confluent monolayer of cells 
within a 24 well plate. 2) An acellular scratch-wound running from top to bottom 
through the well. 3) A horizontal marker line running from right to left across the 
well. 4) The entire field of view  seen through the microscope at 10 x magnification. 
5) The area of image capture taken by the digital camera. B, The image captured 
during a scratch assay. The scratch width is the mean of the size  of the acellular 
area at three points corresponding to the top (i), middle (ii), and bottom (iii) of the 
image.
2.3.4 MALDI-TOF/TOF mass spectrometry: Mass  spectrometry  is  a  method of 
identifying the chemical structures of large molecules such as peptides by ionising the 
molecules of interest to generate charged particles and measuring the mass to charge 
ratios of these charged molecular fragments. In the case of  MALDI-TOF/TOF mass 
spectrometry,  ions  are  generated  using  a  laser,  whilst  protected  by  a  matrix 
(comprised of a solution of crystalline molecules) to prevent the destruction of the 
molecule of interest, and accelerated towards a detector by an electric field (MALDI: 
Matrix Assisted Laser Desorption/Ionisation). The mass of the ions determined from 
the time taken for the ions to arrive at the detector (TOF: Time of Flight). TOF/TOF 
is a tandem mass spectrometry method where two time-of-flight mass spectrometers 
are used consecutively (Vestal et al, 2005). Media conditioned by MSC n=4 different 
patient donors were each analysed once.
Two ml of MSC-CM was incubated with 40μl of Strataclean resin for 30mins 
at room temperature. Unbound supernatant was removed and 1µl of trypsin (porcine 
sequencing  grade  –  Promega,  Southampton,  UK)  was  added  to  the  resin/bound 
proteins and incubated overnight at 37°C. The sample was centrifuged at 13000rpm 
for  5mins  to  recover  the  tryptic  peptides.  The  tryptic  peptides  (20µl)  were  first 
separated by liquid chromatography (Dionex Ultimate 3000, Dionex, Leeds, UK) on a 
Pepmap C18 column,  200µm x 15cm (Dionex)  at  a flow rate  of 3µl/minute.  The 
eluants used were: A. 0.05% Trifluoroacetic acid (TFA) in water and B. 0.05% TFA 
in 100% acetonitrile. The gradient was run as follows: 5 minutes isocratic pre-run at 
100% A, followed by a linear gradient from 2-50% B over 40 minutes. The column 
was then washed in 100% B for a further 10 minutes. During the elution gradient, a 
sample was spotted at 10 second intervals using a Probot (Dionex) with α-cyano-4-
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hydroxycinnamic acid (CHCA) at 3mg/ml (70% MeCN, 0.1% TFA) at a flow rate of 
1.2ul/min.  Both  MS  and  Tandem  MS  (MS/MS)  analysis  was  performed  on  the 
fractionated  peptides  using  an  Applied  Biosystems  4800  MALDI-TOF/TOF mass 
spectrometer  (Applied  Biosystems  Inc.,  Foster  City,  CA,  USA).  The  mass 
spectrometer  was operated  under  control  of  4000 Series  Explorer  v3.5.2 software 
(Applied Biosystems).  Peak lists  of MS and MS/MS spectra were generated using 
4000 Series Explorer v3.5.2 software after selective labelling of monoisotopic mass 
peaks.  An automated  database  search was run using GPS Explorer  v3.6 (Applied 
Biosystems).  MASCOT was used as the search engine to search NCBInr database 
using  the  following  search  parameters:  precursor  ion  mass  tolerance  of  50ppm, 
fragment  ion  mass  tolerance  of  0.3Da,  the  taxonomy was  selected  as  human  and 
oxidation  of  methionine  residues  were  allowed  as  variable  modifications.  The 
identification  criterion  was  at  least  2  peptides  by  MS/MS  with  total  ion  score 
confidence intervals of at least 95%.
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2.3.5 Cell adherence/spreading:
Twenty four well tissue culture plates were coated in either recombinant or purified 
ECM proteins  (type  I  collagen,  decorin  or  fibronectin)  or  MSC-CM as  described 
above (section 2.3.1). L929 fibroblasts  and HaCaT keratinocytes were seeded at a 
density  of  2x105 cells  per  well  in  serum-free  DMEM/F12 supplemented  with  1% 
penicillin/streptomycin (Sigma-Aldrich) and 1% ITS-X (Sigma-Aldrich). Plates were 
then incubated for 2 hours at 37°C and 5% CO2  and digitised images were captured 
with an inverted microscope (Inverso TC100, Medline Scientific LTD) and digital 
camera (ProgRes CF, Jenoptik).
2.3.6 Cell proliferation: 
L929  and  HaCaT  cell  proliferation  was  investigated  using  the  MTS  (3-(4,  5-
dimethylthiazol-2-yl)-5-(3-carboxymethoxyphenyl)-2-(4-sulfophenyl)-2H-
tetrazolium) assay.  This assay determines cell  number by measuring the degree of 
cellular metabolism within a sample as mitochondrial reductases convert MTS into a 
coloured formazan product (Cory et al. 1991). Cells were seeded into 96 well plates in 
100µl  DMEM/F12  culture  medium  containing  10%  FCS  and  1%  penicillin  and 
streptomycin at a seeding density of 1 x 104 cells per well, incubated for 2 hours at 
37°C  and  5%  CO2 (to  permit  cell  adhesion)  and  then  washed  repeatedly  by 
centrifugation  at  1000rpm  for  10  minutes  and  re-suspension  in  serum  free 
unconditioned  medium.  Cells  were  then  maintained  in  either  serum  free 
unconditioned medium or in each of three separate samples of MSC-CM (i.e. from 3 
different donor MSC cultures). The relative number of viable cells present at the 24, 
48 and 72 hours time-points following this treatment was subsequently determined by 
adding the MTS solution for 3 hours, after which time the absorbance was read at 
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490nm.  The  values  obtained  were  compared  to  a  ‘standard  curve’  of  absorbance 
values for a range of known cell populations to determine the number of viable cells 
present in each experimental well.
2.3.7 Multi-array ELISA
Detection of cytokines within MSC-CM was carried out using an ELISArray kit (SA 
Bioscience, Maryland USA) according to the manufacturer’s instructions: Samples of 
MSC-CM were prepared by centrifugation for 10 minutes at 1000×g to remove any 
particulate material that might be present. The ELISArray kit reagents: wash buffer 
concentrate, assay buffer stock, sample dilution buffer stock and the ELISArray plate 
were thawed and maintained at room temperature whilst the 10% BSA and donkey 
serum were thawed at room temperature and kept on ice until required. 
The wash buffer concentrate was shaken to suspend any precipitate and 50ml 
of wash buffer concentrate was diluted into distilled water to a final volume of 500ml. 
Assay buffer was prepared by diluting 0.6ml of 10% BSA into a final volume of 30ml 
with assay buffer stock, and sample dilution buffer was prepared by dilute 2ml of 
10% BSA into a final volume of 20ml with sample dilution buffer stock.
An antigen standard cocktail was generated by thawing antigen standards on 
ice for 20 minutes and mixed by gentle vortexing.  A concentrated antigen standard 
cocktail  containing  all  12  of  the  antigen  standards  was  prepared  in  a  single  tube 
pipetting 10μl of each antigen standard into the same 880μl volume of the appropriate 
sample dilution buffer to yield 1ml of a concentrated antigen standard cocktail. 200μl 
of  the  concentrated  standard  antigen  cocktail  was  then  diluted  into  800μl  of  the 
sample dilution buffer to form the final antigen standard cocktail. 50μl of assay buffer 
was added each well of the ELISArray plate using a multi-channel pipettor and 50μl 
of the sample dilution buffer into each well of row A in the ELISArray plate to set up 
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the negative control, followed by 50μl of MSC-CM into each well of rows B through 
G. 50μl of the final antigen standard cocktail was added into each well of row H to set 
up the positive control. Thus prepared, the ELISArray plate was gently shaken for 10 
seconds to ensure the complete mixing of the reagents before being allowed to stand 
for 2 hours at room temperature.
Meanwhile, the development solution and stop solution were allowed to warm 
to room temperature in lab bench drawer protected from light, whilst the detection 
antibodies were thawed on ice for 30 minutes, 855μl of assay buffer was added to 
each tube of detection antibody and the resulting solutions were gently mixed before 
being transferred to the appropriate tube of the detection antibody tube strip.
After 2 hours at room temperature, the contents of the ELISArray plate were 
removed form the wells and discarded before washing each well with 350μl of wash 
buffer, gently shaking the plate for 10 seconds and then removing the wash buffer 
from each well and blotting the plate upside down on absorbent paper to remove any 
residual buffer. This wash process was then repeated a further two times for a total of 
three  washes  before transferring 100μl of  the dilute  detection  antibodies  from the 
dilution tube strip to the appropriate rows of the ELISArray plate and again gently 
shaking the plate for 10 seconds to mix the reagents and allowing the plate to stand 
for a further 60 minutes at room temperature.
Whilst the plate was left to stand, avidin-HRP conjugate was thawed on ice for 
20 minutes, mixed gently and then 11μl of the avidin-HRP conjugate added to 11ml 
of  assay  buffer  before  removing  the  contents  of  the  ELISArray  plate  and  again 
washing the plate  as  before:  rinsing  each well  with  350μl  of  wash buffer,  gently 
shaking the plate for 10 seconds and then removing the wash buffer and blotting the 
plate upside down on absorbent paper. 100μl of avidin-HRP was then added to all 
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wells and the plate again shaken for 10 seconds to mix before being allowed to stand 
for  30  minutes  at  room temperature  in  the  dark  and  then  washed  four  times  as 
previously described.
Finally, 100μl of development solution were added to each well, the plate left 
for 15 minutes at room temperature in the dark and then 100μl of stop solution added 
to  each  well.  The  absorbance  of  each  well  was  read  at  450nm  and  570  nm 
immediately after the addition of the stop solution, and the latter subtracted from the 
former to give the final absorbance, ranging from 0.00 to 2.50, for each well.
2.4 Data analysis
2.4.1 Image analysis:
 Digitised images of scratch-wounds were analysed using Image-J software (Collins, 
2007) to measure the width of the scratch at previously defined points along its length 
equating to the top, middle and bottom of the field of view (Figure 2.3.1-B). Images 
of cell adherence/spreading were analysed using the same software to measure the 
area of the imaged cells (Figure 2.3.2).
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2.4.2 Statistical analysis and experimental replicates:
Data has been presented in all Figures as means with error bars to represent standard 
errors of the mean (SEM) derived from the standard deviation (σ) using the formula
 presented as means (± SEM) in text. Statistical analysis of experimental 
data was performed using the Mann-Whitney U test and, when comparing more than 
two means, a non-parametric analysis of variance (ANOVA), i.e. the Kruskal-Wallis 
test,  where  significant  differences  between  individual  means  were  determined  by 
post-hoc analysis using Tukeys HSD (honest significant difference) test. In all cases, a 
95% confidence interval (p<0.05) was considered to be significant, indicated by an 
asterisk within Figures. Experimental procedures using MSC-CM were performed as 
a  single  independent  experiment  using CM generated  from MSC cultures  derived 
from each of  three individual donors, i.e. n=3. All data from experiments examining 
the effects of cytokines and ECM components on L929, HaCaT, or Ea-Hy926 cell 
lines  were  pooled  from  two  independent  experiments,  i.e.  n=2,  normalised  to 
percentage wound closure to account for variability in the values (though not their 
relative magnitudes) observed between these independent experiments; the means ± 
SEM  were  calculated  and  statistical  analysis  performed  using  this  pooled  data. 
Studies performed using  L929, HaCaT, or Ea-Hy926-CM were also performed twice 
i.e.  through  two  independent  experiments  where  data  was  similarly  pooled  and 
analysed. Each independent experiment consisted of at least n=4 internal replicates 
(i.e.  wells).  All  images  shown  of  cells  in  culture  were  drawn  from  single 
representative experiments.
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Figure 2.3. Cell area outlining: An example of the outlines (yellow) used to 
determine the area of cells from digital images.
Chapter 3
An in vitro investigation of the paracrine activity of mesenchymal stem cells on 
skin wounds using the scratch assay.
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3.1 Aims and Background.
The healing of cutaneous wounds requires complex interactions between the dermal 
and epidermal cells,  the extracellular matrix (ECM), and the nervous and vascular 
components of the damaged and surrounding skin (Harding et al, 2002, Metcalf and 
Ferguson, 2007). The precise involvement of many of these various factors has been 
identified  by  a  combination  of  in  vitro and  in  vivo studies.  As  described  in  the 
Introduction,  MSC  have  been  observed  to  promote  skin  wound  healing  in  vivo; 
however  the  mechanisms  responsible  for  such  MSC-enhanced  wound  healing  are 
currently unclear. Despite evidence supporting the capacity of MSC to differentiate or 
trans-differentiate along a variety of dermal and epidermal cell lineages (Sasaki et al, 
2008, Wu et al, 2007; Liu  et al, 2007), it has been suggested that the low levels of 
MSC engraftment after transplantation indicate that their beneficial effects are more 
likely mediated through the secretion of soluble factors rather than through their long-
term presence as cellular components of subsequently repaired tissue (Prockop 2007). 
This  thesis  has sought  to  elucidate,  in  part,  how MSC may influence  skin 
wound healing by affecting the behaviour of resident skin cells. The initial stages of 
this investigation involved the establishment and characterisation of an  in vitro skin 
wound model,  the  scratch  assay.   A confluent  monolayer  of  cells  is  grown on a 
defined surface substrate, in this case type I collagen-coated tissue culture plastic, and 
then scored with a sterile point, i.e. a pipette tip. The remaining adherent cells are then 
observed as they repopulate the scratched area, effectively “healing the wound”. A 
tumour-derived  dermal  fibroblast  cell  line,  L929  (Earle  et  al, 1943),  and  an 
immortalised human keratinocyte cell line, HaCaT (Boucamp et al, 1988) were used 
to  conduct  scratch  assays.  These  skin  cell  lines  were  used  both  because  their 
behaviour  was  considered  likely  to  be  relatively  consistent  from  experiment  to 
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experiment, and also due to difficulties in obtaining sufficient numbers of primary 
skin cells. 
The aim of the first part of this study was to compare how the two skin cell 
types brought about closure of the scratch assay, as single cell type cultures and co-
cultures.  In  particular,  the  study  compared  scratch  assays  of  L929  and  HaCaT 
cultures, and L929: HaCaT co-cultures, in the presence and absence of supplementary 
serum. Subsequently, experiments were performed to examine the influence of MSC-
secreted factors on L929 and HaCaT cells, both as single cell and co-culture scratch 
assays.   These  latter  studies  tested  the  effects  of  serum-free  culture  conditioned 
medium which had been derived from primary cultures of human MSC. Finally, the 
contents  of  the  MSC  conditioned  medium  (MSC-CM)  were  analysed  by  a 
combination of ELISA and mass spectrometry. 
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3.2: L929 fibroblast and HaCaT keratinocyte wound models.
In  the  presence  of  serum,  confluent  monolayers  of  L929  fibroblasts  appeared  to 
respond to the scratch injury and migrate into the scratched area to bring about wound 
closure more rapidly than monolayers of HaCaT keratinocytes (Figure 3.1). This was 
also true in L929: HaCaT co-cultures, where the fibroblasts again appeared to respond 
to the injury and migrate faster than the keratinocytes, such that at wound closure the 
scratched areas were filled almost exclusively with L929 cells (Figure 3.2). There was 
no obvious loss of cell adhesion or viability during the wound closure of either of the 
single cell type scratch assays or in the co-cultures. It was also apparent that the L929 
cells and HaCaT keratinocytes in co-culture were compatible, with no evidence of 
repulsion upon cell-cell contact. 
The  increased  response  of  L929  cells  to  scratch  injuries  was  marked  and 
significant. Hence, 12 hours after scratching, the extent of wound closure was in L929 
cultures was 49% (±5%), compared to only 15% (±3%) in HaCaT cultures (p<0.05, 
Mann Whitney U test).  At this 12 hour time point, the extent of wound closure in 
L929: HaCaT co-cultures was also significantly greater (56% ±4%), than that seen in 
HaCaT cultures (p<0.05 Mann Whitney U test) (Figure 3.3). There was no significant 
difference in wound closure at the 12 hour time point between L929 and co-cultures. 
In similarly designed scratch assays performed in serum free conditions L929 
fibroblasts again appeared to respond to the scratch injury and close scratch wounds 
more rapidly than HaCaT keratinocytes (Figure 3.4). Furthermore, in L929: HaCaT 
co-cultures  the  L929  fibroblasts  also  filled  the  scratched  area  to  the  apparent 
exclusion of HaCaT keratinocytes (Figure 3.5). In serum free conditions, the extent of 
wound closure 12 afters after scratching was  47% (±7%) for L929 cells compared 
with only  15% (±4%) for HaCaT cells  (p<0.05  Mann Whitney U test),  whilst  the 
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extent of closure in co-cultures at the same time point was 56% (±9%) (Figure 3.6). 
There  was  no  significant  difference  in  wound  closure  at  the  12  hour  time  point 
between  L929  and  co-cultures  in  serum  free  conditions,  although  there  was  an 
observable  difference  compared  to  those  scratches  performed  in  the  presence  of 
exogenous serum.
Although the extent of wound closure was similar in serum versus serum free 
conditions at earlier time points (i.e. 12 hours), at later time points it was apparent that 
L929 fibroblasts effected wound closure more rapidly in the presence of serum than 
the absence of serum. Hence in the presence of serum all scratches of L929 fibroblasts 
exceeded 90% wound closure within 21 hours of scratching in all instances, whereas 
this level of wound closure was only seen after 42 hours in serum free conditions. In 
contrast, serum deprivation did not significantly influence the later stages of wound 
closure in HaCaT scratch assays, which achieved >90% wound closure after 48 hours 
in both serum and serum free conditions in all instances. There was no clear loss of 
cell adhesion or decreased cell viability in L929, HaCaT or co-cultures throughout the 
time course.
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L929 HaCaT
0 hr
12 hr
Figure 3.1 L929 fibroblasts closed scratch wounds faster than HaCaT 
keratinocytes. Representative phase contrast images are shown of single cell type 
(L929 or HaCaT) scratch assays immediately following the scratch and 12 hours 
thereafter. Original magnification is x10.  
12 hours12 hours
72 hours
Figure 3.2 In co-cultures, L929 fibroblasts closed scratch wounds faster than HaCaT 
keratinocytes. In co-cultures of L929 fibroblasts and HaCaT keratinocytes, the L929 
fibroblasts (fluorescently tagged green) appeared to migrate faster than the HaCaT 
keratinocytes (fluorescently tagged red) to close scratch wounds, thereby filling the 
scratch area almost to the exclusion of HaCaT cells. Representative digitised images are 
shown of phase constrast microscopy (top left) with green and red fluorescence images 
overlaid at 12 hours after the scratch was formed, along with green and red fluorescence 
images overlaid at wound closure (72 hours in this instance. All images were collected at 
original magnification of x10.
**
Figure 3.3 Scratch wound closure by L929 fibroblasts and HaCaT keratinocytes. 
Twelve hours post-scratch, the extent of wound closure was 49% (±4.6%) for L929 
cells, 15% (±3.4%) for HaCaT and was 56% (±4%) for L929:HaCaT co-cultures. Data 
shown are means ± SEM There was a significant difference by ANOVA (p<0.05). (* 
denotes significance by Tukey's HSD).
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Figure 3.4 In serum free conditions L929 fibroblasts closed scratch wounds 
faster than HaCaT keratinocytes. Representative phase contrast images are 
shown of single cell type (L929 or HaCaT) scratch assays immediately following 
the scratch and 12 hours thereafter. Original magnification is x10.  
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Figure 3.5 In serum free co-cultures L929 fibroblasts closed scratch wounds 
faster than HaCaT keratinocytes. In serum free conditions L929 fibroblasts  
(fluorescently tagged green) appeared to migrate faster than HaCaT keratinocytes 
(fluorescently tagged red) in co-cultures of both cell types, thereby filling the 
scratch area almost to the exclusion of HaCaT cells. Representative digitised 
fluorescent  and phase contrast images are shown of co-culture (both L929 and 
HaCaT) scratch assays immediately following the scratch and representative phase 
contrast images are shown of successive time points thereafter. Original 
magnification is x10.  
*Figure 3.6 Scratch wound closure by L929 fibroblasts and HaCaT keratinocytes 
in serum free conditions. Twelve hours post-scratch, the extent of wound closure in 
serum free conditions was 47% (±6.9%) for L929 cells, 15% (±3.8%) for HaCaT and 
was 56% (±8.8%) for L929:HaCaT co-cultures. There was a significant difference by 
ANOVA (p<0.05). (* denotes significance by Tukey's HSD).
3.3: MSC-CM enhances L929 fibroblast and HaCaT keratinocyte scratch wound 
closure  in vitro.  
MSC-CM significantly enhanced the rate of wound closure in single cell L929 
fibroblast scratch assays in serum-free conditions (Figure 3.7). Hence, 9 hours after 
scratches, all L929 cultures had closed in the presence of serum free MSC-CM (100% 
±0% closure), while those in unconditioned serum free media had only closed by 51% 
(±10%) (p<0.05 Mann Whitney U test) (Figure 3.8). Similarly, serum free MSC-CM 
significantly enhanced the closure of HaCaT keratinocyte scratch assays (Figure 3.9), 
although  these  remained  slower  than  L929  scratch  assays.  After  27  hours,  those 
HaCaT scratch assays performed in serum free MSC-CM were closed by 95% (±3%), 
whereas those performed in unconditioned serum free media had only closed by 57% 
(±8%) (p<0.05 Mann Whitney U test) (Figure 3.10). Scratch assays in co-cultures of 
L929  fibroblasts  and  HaCaT  keratinocytes  were  also  seen  to  close  faster  in  the 
presence of serum free MSC-CM than in unconditioned serum free media. In contrast 
to the co-culture scratch assays in serum free unconditioned media, L929 and HaCaT 
cells both appeared to fill the scratch area in the presence of MSC-CM (Figure 3.11). 
In the L929: HaCaT co-cultures,  the scratches in serum free MSC-CM had closed by 
76%  (±6%) after 12 hours  compared to 35%  (±13%) in unconditioned serum free 
media (p<0.05 Mann Whitney U test) at the same time point (Figure 3.12). 
There was no clear loss of cell adhesion or decreased cell viability in L929, 
HaCaT or co-cultures throughout the time course of these experiments. In addition, 
L929 fibroblasts and HaCaT keratinocytes also appeared compatible in co-culture in 
serum free MSC-CM. To address whether serum free MSC-CM may have stimulated 
cell  proliferation (and to further test that cells  remained viable) in addition to cell 
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migration during wound closure,  L929 fibroblast  and HaCaT keratinocyte  cultures 
were  established  in  96  well  plates  in  serum  free  MSC-CM  versus  serum  free 
unconditioned media.  The MTS assay was then performed to ascertain the relative 
number  of  viable  cells.  There  was  a  non-significant,  but  marked  increase  in  the 
number of both L929 and HaCaT cells present at 72 hours in serum free MSC-CM 
compared  to  serum free  unconditioned  media.  However,  no  marked  increases  in 
viable cell number were seen for either cell type over the first 48 hours of incubation, 
i.e. within the time frame of L929 and HaCaT wound closure in serum-free MSC-CM 
(Figure 3.13). 
In contrast to serum free MSC-CM, neither serum free L929-CM nor serum 
free HaCaT-CM affected the rate of wound closure in scratch assays of either cell 
type at any time during the wound healing process. For example, when wound closure 
of single cell L929 scratch assays was 48% (±7%) in serum free control media (at 12 
hours in this set of experiments),  wound closure was only 43% (±8%) in serum free 
L929-CM and only 42% (±17%) in serum free HaCaT-CM at the same time point. 
Similarly, when wound closure of single cell HaCaT scratch assays was 15% (±4%) 
in serum free control media (also at 12 hours), it was only 14% (±8%) in serum free 
L929-CM and 20% (±5%) in serum free HaCaT-CM (Figure 3.14)
 
101
MSC-CM control
0 hr
9 hr
Figure 3.7 L929 fibroblasts closed scratch wounds faster in the presence of 
MSC-CM than in unconditioned control media. Representative phase contrast 
images are shown of single cell type (L929) scratch assays immediately following 
the scratch and 9 hours thereafter. Original magnification is x10.  
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Figure 3.8 Scratch wound closure by L929 fibroblasts in MSC-CM. Nine hours 
post scratch, L929 fibroblasts had achieved 100% (±0%) wound closure in the 
presence of MCS-CM, while those in unconditioned media had only closed by 51% 
(±10.2%). Data shown are means ± SEM (*= p<0.05 Mann Whitney U test).
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Figure 3.9 HaCaT keratinocytes closed scratch wounds faster in the presence 
of MSC-CM than in unconditioned control media. Representative phase contrast 
images are shown of single cell type (HaCaT) scratch assays immediately following 
the scratch and 27 hours thereafter. Original magnification is x10.  
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Figure 3.10 Scratch wound closure HaCaT keratinocytes in MSC-CM. Twenty 
seven hours post scratch, HaCaT keratinocytes had achieved 95% (±2.8%)  wound 
closure in the presence of MCS-CM, while those in unconditioned media had only 
closed by 57% (±8.3%). Data shown are means ± SEM (*= p<0.05 Mann Whitney 
U test).
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Figure 3.11 L929 fibroblast and HaCaT keratonocyte co-cultures close scratch-
wounds more rapidly in MSC-CM than in unconditioned media. In co-cultures 
of L929 fibroblasts and HaCaT keratinocytes, the L929 fibroblasts (fluorescently 
tagged green) and the HaCaT keratinocytes (fluorescently tagged red) appeared to 
close scratch wounds more rapidly in the presence of MSC-CM than in 
unconditioned control media. Representative digitised images are shown of both 
phase constrast microscopy and digitied images with green and red fluorescence  
overlaid immediately following the scratch and 12 hours thereafter. All images were 
collected at original magnification of x10.
*Figure 3.12 Scratch-wound closure by L929 fibroblasts and HaCaT keratinocyte 
co-cultures in MSC-CM. Twelve hours post scratch, L929:HaCaT co-cultures had 
achieved 76% (±5.7%) wound closure in the presence of MCS-CM, while those in 
unconditioned media had only closed by 35% (±13.3%). Data shown are means ± SEM 
(*= p<0.05 Mann Whitney U test).
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Figure 3.13 MSC-CM did not significantly increase cell number over 72 hours. 
Over 48 hours there was no significant  difference in either L929 fibroblast or 
HaCaT keratinocyte cell number between cultures in MSC-CM (solid line) and 
those in unconditioned control media (broken line). After 72 hours there was a 
marked but not statistically significant difference. Data shown are means ± SEM 
(p>0.05 Mann Whitney U test).
L929
HaCaT
Figure 3.14 Twelve hours post-scratch, neither L929-CM or HaCaT-CM 
enhanced wound closure in cultures of either cell type compared to unconditioned 
media. Data shown are means ± SEM (p>0.05 ANOVAt).
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3.4: The secretome of MSC-CM
Serum free MSC-CM was assayed to determine the presence of secreted cytokines or 
ECM components that may have influenced L929 fibroblast or HaCaT keratinocyte 
cell growth, migration and/or wound closure. Detectable levels of interleukin (IL)-6, 
IL-8,  transforming  growth  factor-β1  (TGF-β1),  monocyte  chemotactic  protein-1 
(MCP-1) and RANTES (Regulated upon Activation, Normal T-cell Expressed, and 
Secreted) were found in the MSC-CM by ELISA (Figure 3.15). In contrast, IL-1a, IL-
1b, IL-4, IL-10, IFN-γ, TNF-α, and growth regulated oncogene-α (GRO-A) were not 
detected.  In  addition,  the  ECM components  collagen  types  I,  V,  VI  and  XII  and 
fibronectin  were  detected  in  serum  free  MSC-CM  by  MALDI-TOF/TOF  mass 
spectrometry,  along with secreted protein acidic and rich in cysteine (SPARC) and 
insulin-like growth factor binding protein-7 (IGFBP-7) (Table 3.1).
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Figure 3.15 Cytokines present in the MSC secretome. ELISA analysis of MSC-
CM showed detectable levels of interleukin (IL)-6, IL-8, transforming growth 
factor-β1 (TGF-β1), monocyte chemotactic protein-1 (MCP-1) and Rantes. IL-1a, 
IL-1b, IL-4, IL-10, interferon-γ (IFN-γ), tumour necrosis factor-α (TNF-α), and 
growth regulated oncogene-α (Gro-A) were not detected. Data shown are means ± 
SEM.
  
TABLE 1: PROTEINS DETECTED IN MSC CONDITIONED MEDIUM 
  VIA MASS SPECTROMETRY (MALDI TOF/TOF) 
    
 
Protein Name 
 
Accession 
Number 
 
Peptide 
Count 
 
Total Ion  
Score C.I.% 
 
Collagen type I (alpha 1 chain) 
 
gi22328092 
 
 
16 
 
 
100 
 
    
Collagen type I (alpha 2 chain) gi48762934 
 
27 100 
    
Collagen type V (alpha 2 chain) gi16197600 
 
3 100 
    
Collagen type VI (alpha 1 chain) gi87196339 
 
10 100 
    
Collagen type XII (alpha 1 long 
isoform) 
gi93141047 
 
6 99.999 
    
Fibronectin 
 
gi4204943 
 
8 
 
99.999 
Fibronectin  (type III domain) gi55667857 
 
2 96.825 
SPARC gi2624793 
 
3 96.613 
Insulin-like growth factor binding 
protein 7 
gi4504619 
 
4 100 
    
 
Table 3.1 Mass spectrometry of MSC-CM. MALDI-TOF/TOF mass spectrometry 
of MSC-CM detected collagen types I, V, VI and XII,  fibronectin, secreted protein 
acidic and rich in cysteine (SPARC) and insulin-like growth factor binding protein-
7 (IGFBP-7).
3.5: Discussion
Cell migration is a rate limiting event in skin wound healing. Hence, the study 
of factors that influence dermal fibroblast and epidermal keratinocyte migration may 
help target therapies for improved cutaneous wound healing. In this set of  in vitro  
investigations, the scratch assay was used to show that L929 fibroblasts migrated to 
effect wound closure more rapidly than HaCaT keratinocytes.  In co-culture, the L929 
fibroblasts were seen to fill the closed scratch almost entirely to the exclusion of the 
HaCaT keratinocytes, both in the presence or absence of serum supplementation. The 
chronology  of  cell  migration  into  human  cutaneous  wounds  is  currently  unclear. 
However,  a  recent  study has  suggested  that  dermal  fibroblasts  along with  dermal 
microvascular  endothelial  cells  may  migrate  into  the  wounded  area  prior  to 
keratinocytes  (Kehe  et  al, 1999).  It  was  further  suggested  that  dermal  fibroblast 
migration is then halted as keratinocytes migrate to initiate re-epithelialisation, after 
which a further wave of fibroblast migration occurs during the tissue remodelling 
stage of wound healing. If this order of skin cell migration is correct, then the novel 
co-culture scratch assay reported here using L929 and HaCaT cell lines may prove 
useful in identifying factors that influence cutaneous wound healing. The interaction 
of  dermal  fibroblasts  and  epidermal  keratinocytes  plays  an  important  role  in  the 
healing process.  Hence, the incorporation of both cell types in this co-culture model 
may be more representative of in vivo skin wound healing than the use of either cell 
type alone. 
The differences in healing rates seen in scratch assays of L929 or HaCaT cells 
as single cell  types  may simply be due to the fact  that  the L929 fibroblasts  were 
murine in origin, whilst the HaCaT keratinocytes were human. Furthermore, L929 is 
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derived from a tumour (Earle et al, 1943) whilst HaCaT is an immortalised cell line 
(Boukamp et al, 1988). As such, these cells may differ in their behaviour from normal 
human cells in vivo.  However, the use of cell lines in this study eliminates potential 
donor  variations  in  primary  skin  cell  cultures,  which  has  thereby allowed for  the 
development of a consistent model to assay the effects of MSC derived factors from a 
number of separate MSC isolates.
The  stimulatory  activity  of  MSC-CM  was  established  in  serum  free 
conditions. Hence, it was possible to identify a number of MSC secreted factors in 
MSC- CM, including factors that are known to promote cutaneous wound healing. 
TGF-β1  has  diverse  roles  in  cutaneous  wound  healing,  including  a  stimulatory 
activity on re-epithelialisation, wound contracture, angiogenesis, scar formation and 
ECM deposition (Barrientos  et al, 2008). In particular, TGF-β1 stimulates increased 
cell migration in dermal fibroblasts (Postlethwaite  et al, 1987) and keratinocytes (Li 
et al, 2006). Studies of knock-out mice have suggested that IL-6 forms an essential 
element  of  the  normal  cutaneous  wound  healing  process  by  influencing  dermal 
fibroblast migration (Luckett-Chastain & Gallucci, 2009), and has also been shown to 
influence keratinocyte migration (Gallucci  et al,2004) and proliferation (Sato  et al, 
1999),  whilst  IL-8  similarly  promotes  skin  re-epithelialisation  by  increasing 
keratinocyte migration (Michel  et al, 1992) and proliferation (Tuschil  et al, 1992). 
MCP-1  and  RANTES  may  also  function  to  promote  dermal  wound  healing  as  a 
chemoattractant to cells of the immune system, particularly macrophages (Dipietro et  
al, 2001)
The  increase  in  L929  and  HaCaT cell  number  over  the  course  of  wound 
closure in co-culture scratch assays was non-significant for either cell type; both in 
serum free unconditioned media or in serum free MSC-CM. This overall lack of an 
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increase  in  cell  number  may  not  preclude  some localised  proliferation,  or  indeed 
enhanced  cell  survival,  around  the  scratch  wound  margins  contributing  to  an 
enhancement in wound closure; nonetheless, the lack of any change in overall cell 
number does seem to support the assertion that increased cell migration may have 
been the main contributing factor.  In addition,  serum free  MSC-CM was found to 
have little effect on L929 or HaCaT cell proliferation or survival, as assessed via the 
MTS assay. The moderate difference seen in the viable cell number present in serum 
free MSC-CM compared with serum free unconditioned media at 72 hours was at a 
time point outside of the time course of scratch wound closure in the presence of 
serum  free  MSC-CM.  Furthermore,  there  were  no  obvious  differences  in  the 
adherence  of  L929  or  HaCaT  cells  in  serum  free  MSC-CM  or  serum  free 
unconditioned  media  in  the  scratch  assays  themselves.  Therefore,  the  activity  of 
serum free MSC-CM on scratch wound closure may be more readily attributed to 
stimulation  of  increased  fibroblast  and  keratinocyte  cell  migration,  rather  than 
increased  cell  proliferation  or  survival.  As  described  above,  several  of  the  MSC 
secreted growth factors and chemokines are likely targets for this stimulatory activity 
of cell migration in L929 and HaCaT scratch assays. The composition of the ECM 
plays a major role in regulating cell migration (Lauffenburger & Horwitz 1996) and a 
number  of  ECM components  in  serum  free  MSC-CM  were  identified  by  mass 
spectrometry (non of the cytokines found to be present using ELISA were detected by 
this method). Prominent amongst these were collagen type I and fibronectin, which 
are well-characterised stimulatory factors of fibroblast and keratinocyte cell adhesion 
and  migration.  The  potential  involvement  of  TGF  beta,  fibronectin,  along  with 
decorin, in enhancing wound closure by L929 and HaCaT cells has been investigated 
in Chapter 4. 
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Also  detected  was  the  extracellular  glycoprotein  SPARC  (osteonectin). 
Elevated levels of SPARC expression have been observed in  cells  at  wound sites 
(Reed  et  al, 1993)  and  it  has  been  demonstrated  that  the  absence  of  SPARC is 
associated  with  impaired  fibroblast  migration  (Basu  et  al, 2001).  Conversely,  the 
absence of SPARC has also been shown to accelerate wound closure in SPARC-null 
mice (Bradshaw et al, 2002), but this study suggested that this effect may have been 
due to  an  associated  reduction  in  collagen  content  in  skin,  which  in  turn  lead  to 
increased wound contractibility. Insulin-like growth factor binding proteins (IGFBP) 
play an important role in skin homeostasis, modulating IGF-mediated enhancement of 
dermal  and  epidermal  cell  migration,  survival  and  proliferation  (Edmonson  et  al, 
2003).  In  particular,  IGFBP-7  has  been  shown  to  regulate  the  proliferation  and 
survival of both HaCaT and primary human keratinocytes  in vitro (Nousbeck  et al, 
2009). This suggests that IGFBP-7 in serum free MSC-CM may have contributed to 
the increased wound closure seen in HaCaT keratinocyte scratch assays.  However, 
further  experiments  that  specifically  target  IGFBP-7  in  MSC-CM are  required  to 
confirm such activity. 
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Chapter 4
An in vitro investigation of the role of individual MSC-CM components on 
wound healing.
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4.1. Aims and Background
Mesenchymal stem cells (MSCs) have been suggested to stimulate wound healing via 
paracrine effects on skin cells. In the previous chapter, ELISA and MALDI-TOF/TOF 
Mass  spectrometry  were  used  to  show  that  MSCs  secrete  the  ECM  proteins 
fibronectin, decorin and collagen type I as well as cytokines such as IL-6, IL-8 and 
TGF- β, amongst other factors. Here, we have investigated the differential effects of 
these  factors  on  wound healing.  Previous  studies  have investigated  the  effects  of 
certain of these factors, e.g. a topical application of fibronectin has been shown to 
enhance  in  vivo wound healing  in rats  (Kwon  et  al, 2007)  and TGF-β1 has been 
shown  to  promote  human  keratinocyte  migration  (Nam  et  al,  2010).  As  healing 
progresses  through  inflammatory  and  remodeling  phases,  levels  of  cytokine 
expression  alters  as  does  ECM  composition,  changing  from  a  matrix  rich  in 
fibronectin to one containing more collagen type I and decorin. Therefore possible 
temporal  and  constituent  variations  in  the  effects  of  wound  healing  mediators 
resulting from different ECM composition may be of interest when considering the 
potential  clinical  application  of  MSC-CM  or  MSC  derived  factors  to  enhance 
cutaneous wound healing.
This chapter has sought to identify the different factors secreted by MSC that 
contribute to the enhancement of scratch wound healing seen in the presence of MSC-
CM. As in the previous chapter the primary investigative technique employed was the 
scratch assay, incorporating the L929 fibroblast cell line and the HaCaT keratinocyte 
cell line. In addition to the effects of various factors on in vitro wound healing, their 
influence on cell adhesion was observed by quantifying the relative degree of cell 
spreading  after  two  hours  in  culture.  These  experiments  were  conducted  in  the 
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absence of supplementary FCS, as the effects of MSC-CM were observed in serum-
free conditions.
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4.2. The effects of MSC secreted cytokines on L929 fibroblasts and HaCaT 
keratinocytes.
Transforming Growth Factor-β1; TGF-β1 supplemented (serum free) media had little 
effect on the rate of scratch wound closure by L929 fibroblasts on collagen (Figure 
4.1). After 12 hours post-scratch l929 fibroblasts had achieved 62% (±9%) closure in 
unsupplemented medium compared to 71% (±8%) in 2ng/ml TGF-β1 supplemented 
medium  and  71% (±9%)  in  8ng/ml  TGF-β1  supplemented  medium  (Figure  4.2). 
(p>0.05 by ANOVA).
However, the rate of closure of scratches of HaCaT keratinocytes on collagen 
was slightly inhibited by TGF-β1 supplemented (serum free) medium at both 2ng/ml 
and  8ng/ml  concentrations  (Figure  4.3)  such  that  after  12  hours  post-scratch  the 
HaCaT keratinocytes  in  unsupplemented  medium had reached 81% (±6%) closure 
compared to 68% (±11%) closure in 2ng/ml TGF-β1 supplemented medium and 65 % 
(±15%) closure in 8ng/ml TGF-β1 supplemented medium (Figure 4.4). (p>0.05 by 
ANOVA).
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Figure 4.1 L929 fibroblasts closed scratch wounds marginally faster in TGF-β1 
supplemented medium than in unsupplemented medium. There was no apparent 
difference between a lower concentration and a higher concentration of TGF-β1 
Representative phase contrast images are shown of single cell type (L929) scratch 
assays immediately following the scratch and 12 hours thereafter. Original 
magnification is x10 (bar = 10μm).  
Figure 4.2 Scratch wound closure by L929 fibroblasts in TGF-β1. Twelve hours post-
scratch, the extent of wound closure was 62% (±9%) for L929 fibroblasts in 
unsupplemented medium,  71% (±8%) for L929 fibroblasts in 2ng/ml TGF-β1 
supplemented medium and 71% (±9%) for L929 fibroblasts cells in 8ng/ml TGF-β1 
supplemented medium . Data shown are means ± SEM. No significant differences were 
found between results (p>0.05 by ANOVA)
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Figure 4.3 HaCaT keratinocytes closed scratch wounds slower in TGF-β1 
supplemented medium than in unsupplemented medium. There was no apparent 
difference between a lower concentration and a higher concentration of TGF-β1 
Representative phase contrast images are shown of single cell type (HaCaT) scratch 
assays immediately following the scratch and 12 hours thereafter. Original 
magnification is x10 (bar = 10μm).
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Figure 4.4 Scratch wound closure by HaCaT keratinocytes in TGF-β1 supplemented 
media.  Twelve hours post-scratch, the extent of wound closure was 81% (±6%) for 
HaCaT keratinocytes in unsupplemented medium,  Whereas scratches in 2ng/ml TGF-β1 
supplemented medium and in 8ng/ml TGF-β1 supplemented medium had reached 68% 
(±11%) closure and 65% (±15%) respectively. Data shown are means ± SEM. No 
significant differences were found between results (p>0.05 by ANOVA).
Interleukin-6; L929  fibroblast  scratch  wounds  closed  at  a  similar  rate  in 
unsupplemented serum free medium or (serum free) media supplemented with either a 
low or  a  high  concentration  of  IL-6  (Figure  4.5).  6  hours  after  scratching,  L929 
fibroblasts in unsupplemented medium had reached 66% (±4%) closure, rising to 98% 
(±1%) by 12 hours post scratch. In comparison, L929 fibroblasts in 10ng/ml IL-6 had 
closed by 80% (±6%)  after 6 hours and 99% (±1%) at 12 hours post scratch whilst 
those in 100ng/ml had closed by 63% (±8%) at 6 hours and 93% (±4%) after 12 hours 
(figure 4.6).  (p<0.05 by ANOVA). Similarly,  HaCaT keratinocyte  scratch wounds 
also closed at a similar rate in unsupplemented medium or IL-6 supplemented media 
(Figure  4.7).  Six  hours  after  scratching,  HaCaT  keratinocytes  in  unsupplemented 
medium had reached 75% (±13%) closure, rising to 90% (±9%) by 12 hours post 
scratch.  In comparison,  HaCaT keratinocytes  in 10ng/ml IL-6 had closed by 62% 
(±13%)  after  6  hours  and  93%  (±7%)  at  12  hours  post  scratch  whilst  those  in 
100ng/ml had closed by 78% (±18%) at 6 hours and 91% (±11%)  after 12 hours 
(Figure 4.8). (p>0.05 by ANOVA).
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Figure 4.5 L929 fibroblasts closed scratch wounds at a similar rate in IL-6 supplemented 
medium than in unsupplemented medium. This was consistent for both a lower concentration 
and a higher concentration of IL-6. Representative phase contrast images are shown of single cell 
type (L929) scratch assays immediately following the scratch and 6 and 12 hours thereafter. 
Original magnification is x10 (bar = 10μm).  
W
o
u
n
d
 c
lo
s
u
re
 (
%
)
Figure 4.6 Scratch-wound closure by L929 fibroblasts in IL-6 supplemented media. Six 
hours post-scratch, the extent of wound closure was 66% (±4%) for L929 Fibroblasts in 
unsupplemented medium,  80% (±6%) for L929 Fibroblasts in 10ng/ml IL-6 supplemented 
medium and 63% (±8%) for L929 Fibroblasts in 100ng/ml IL-6 supplemented medium. 
Twelve hours post-scratch, the extent of wound closure was 98% (±1%) for L929 Fibroblasts 
in unsupplemented medium,  99% (±1%) for L929 Fibroblasts in 10ng/ml IL-6 supplemented 
medium and 93% (±4%) for L929 Fibroblasts in 100ng/ml IL-6 supplemented medium . Data 
shown are means ± SEM. No significant differences were found between results (p>0.05 by 
ANOVA).
W
o
u
n
d
 c
lo
s
u
re
 (
%
)
HaCaT
Figure 4.7 HaCaT keratinocytes closed scratch wounds at a similar rate in IL-6 supplemented 
medium than in unsupplemented medium. This was consistent for both a lower concentration 
and a higher concentration of IL-6. Representative phase contrast images are shown of single cell 
type (HaCaT) scratch assays immediately following the scratch and 6 and 12 hours thereafter. 
Original magnification is x10 (bar = 10μm).  
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Figure 4.8 Scratch-wound closure by HaCaT keratinocytes in IL-6 supplemented media. 
Six hours post-scratch, the extent of wound closure was 75% (±13%) for HaCaT keratinocytes 
in unsupplemented medium,  62% (±13%) for HaCaT keratinocytes in 10ng/ml IL-6 
supplemented medium and 78% (±18%) for HaCaT keratinocytes in 100ng/ml IL-6 
supplemented medium. Twelve hours post-scratch, the extent of wound closure was 90% (±9%) 
for HaCaT keratinocytes in unsupplemented medium,  93% (±7%) for HaCaT keratinocytes in 
10ng/ml IL-6 supplemented medium and 91% (±11%) for HaCaT keratinocytes in 100ng/ml IL-
6 supplemented medium . Data shown are means ± SEM. No significant differences were found 
between results (p>0.05 by ANOVA).
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Interleukin-8; IL-8 appeared to have a transient inhibitory effect on scratch wound 
closure by L929 fibroblasts. Over the first 6 hours, L929 fibroblast scratches in IL-8 
supplemented medium closed more slowly than those in unsupplemented medium, in 
an IL-8 concetration dependant manner. However, this difference was not observed 
after 12 hours (Figure 4.9). At 6 hours post scratch the degree of closure was 97% 
(±2%) in unsupplemented medium, 87% (±5%) in 10ng/ml IL-8 and 69% (±9%) in 
100ng/ml IL-8. After 12 hours the degree of closure had reached 100% (±0%) for 
both unsupplemented  and 10ng/ml  IL-8 supplemented  media,  and 99% (±1%) for 
100ng/ml  medium  (Figure  4.10).  This  inhibitory  effect  of  IL-8  was  statistically 
significant at 6 hours, but not at 12 hours (p<0.05 by ANOVA).
HaCaT keratinocytes also closed scratch wounds more slowly in both 10ng/ml and 
100ng/ml IL-8 supplemented media than in unsupplemented medium (Figure 4.11), 
But  this  effect  was  not  significant  (p>0.05  by  ANOVA).  After  6  hours,  those 
scratches in unsupplemented medium had reached 63% (±16%) closure, rising to 95% 
(±4%)  closure  by  12  hours,  whereas  scratches  in  10ngml  IL-8  had  reached  56% 
(±20%) closure by 6 hours and 81% (±23%) closure after 12 hours. In 100ng/ml IL-8 
the scratches had reached 57% (±20%) closure by 6 hours and 85% (±23%) closure 
by 12 hours (figure 4.12).
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Figure 4.9 L929 fibroblasts closed scratch wounds more slowly in IL-8 supplemented medium 
than in unsupplemented medium over 6 hours. By 12 hours there was no difference between IL-
8 supplemented and unsupplemented medium. This was consistent for both a lower concentration 
and a higher concentration of IL-8. Representative phase contrast images are shown of single cell 
type (L929) scratch assays immediately following the scratch and 6 and 12 hours thereafter. 
Original magnification is x10 (bar = 10μm).  
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Figure 4.10 Scratch-wound closure by L929 fibroblasts in IL-8 supplemented media. 
Six hours post-scratch, the extent of wound closure was 97% (±2%) for L929 fibroblasts in 
unsupplemented medium, compared to 87% (±5%) in 10ng/ml IL-8 supplemented medium 
and 69% (±9%) in 100ng/ml IL-8 supplemented medium. This was a significant dose 
dependent inhibition of L929 scratch wound closure in response to IL-8 over the initial 6 
hours. Twelve hours post-scratch, the extent of wound closure was very similar in all 
conditions; 100% (±0%) in unsupplemented medium,  100% (±0%) in 10ng/ml IL-8 
supplemented medium and 99% (±1%) in 100ng/ml IL-8 supplemented medium. Data 
shown are means ± SEM. Six hour differences were significant (p<0.05 by ANOVA) 
specifically between both 0mg/ml vs 100mg/ml and 10mg/ml vs 100mg/ml IL-8 (Tukey's 
HSD) whilst no significant differences were observed at 12 hours (p>0.05 by ANOVA).
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Figure 4.11 HaCaT keratinocytes closed scratch wounds more slowly in IL-8 supplemented 
medium than in unsupplemented medium. This was consistent for both a lower concentration 
and a higher concentration of IL-8. Representative phase contrast images are shown of single cell 
type (HaCaT) scratch assays immediately following the scratch and 6 and 12 hours thereafter. 
Original magnification is x10 (bar = 10μm).  
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Figure 4.12 Scratch-wound closure by HaCaT keratinocytes in IL-8 supplemented media. 
Six hours post-scratch, the extent of wound closure was 63% (±16%) for HaCaT keratinocytes 
in unsupplemented medium,  56% (±20%) for HaCaT keratinocytes in 10ng/ml IL-8 
supplemented medium and 57% (±20%) for HaCaT keratinocytes in 100ng/ml IL-8 
supplemented medium. Twelve hours post-scratch, the extent of wound closure was 95% (±4%) 
for HaCaT keratinocytes in unsupplemented medium,  81% (±23%) for HaCaT keratinocytes in 
10ng/ml IL-8 supplemented medium and 85% (±23%) for HaCaT keratinocytes in 100ng/ml IL-
8 supplemented medium . Data shown are means ± SEM. No significant differences were found 
between results at either 6 hours or 12 hours (p>0.05 by ANOVA).
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Figure 4.13 Summary of cytokine effects upon scratch-wound closure by skin 
cell lines. (* = p<0.05)
4.3:  The  effects  of  MSC  secreted  extracellular  matrix  proteins  on  L929 
fibroblasts and HaCaT keratinocytes
L929 fibroblasts and HaCaT keratinocytes adhered to 0.2mg/ml type I collagen coated 
tissue culture plastic after 2 hours in culture. In serum free conditions, coating tissue 
culture  plastic  with  0.2mg/ml  fibronectin  instead  of  type  I  collagen  resulted  in 
significantly enhanced adherence of both cell  types  after  2 hours,  observable as a 
greater  degree  of  cell  spreading  (Figure  4.14).  In  contrast,  coating  tissue  culture 
plastic with 0.2ng/ml decorin significantly inhibited the adherence of both cell types 
compared to either collagen or fibronectin. (Figure 4.15) (p<0.05 by ANOVA).
The closure of scratch wounds by L929 fibroblasts was significantly faster on 
0.2mg/ml fibronectin than on 0.2mg/ml type I collagen (figure 4.16) such that after 12 
hours  those  scratches  performed  on  fibronectin  had  reached  88%  (±5%)  closure 
whereas scratches on type I collagen had only reached 62% (±9%) closure. (p<0.05 
Mann  Whitney  U  test)  (Figure  4.17).  Closure  of  scratch  wounds  by  HaCaT 
keratinocytes was also marginally faster on fibronectin than on collagen and scratch 
wounds on either type I collagen or fibronectin closed faster than those on Decorin 
(Figure  4.18).  After  12  hours,  scratch  wounds on  fibronectin  had closed  by 98% 
(±3%) whereas  those on type  I  collagen had closed by 81% (±9%) and those  on 
decorin  only 63% (±8)  (Figure  4.19)  (p<0.05 between decorin  and fibronectin  by 
ANOVA). These assays were all performed in the absence of serum.
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Figure 4.14 Cell spreading on ECM proteins. After 2 hours in culture, both L929 and 
HaCaT cells were observably more spread on fibronectin than on type I collagen and on 
type I collagen than on decorin. Representative phase contrast images are shown of 
single cell type (L929 or HaCaT) . Original magnifications are x10 (bar = 10μm).  
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Figure 4.15 Cell areas on ECM proteins. After 2 hours in culture the average 
cell area was 1250µm2  (±60µm2), for L929 fibroblasts on fibronectin, 790µm2 
(±60µm2), for L929 fibroblasts on decorin and 265µm2  (±10µm2), for L929 
fibroblasts on type I collagen. The average cell area for HaCaT keratinocytes on 
fibronectin was 1060µm2 (±70µm2), 440µm2 (±30µm2) for HaCaT keratinocytes 
on decorin and 930µm2  (±70µm2) for HaCaT keratinocytes on type I collagen. 
Data shown are means ± SEM. There was a significant difference by ANOVA 
(p<0.05). (* denotes significance by Tukey's HSD).
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Figure 4.16 L929 fibroblasts closed scratch wounds faster on fibronectin coated 
plates than on type I collagen coated plates. Representative phase contrast images are 
shown of single cell type (L929) scratch assays immediately following the scratch and 
12 hours thereafter. Original magnification is x10 (bar = 10μm).  
*Figure 4.17 Scratch-wound closure by L929 fibroblasts on type I collagen and fibronectin. 
Twelve hours post-scratch, the extent of wound closure was 62% (±9%) for L929 cells on 
collagen and 88% (±5%) for L929 fibroblasts on fibronectin. Data shown are means ± SEM  
(*=p<0.05 Mann Whitney U test).
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Figure 4.18 HaCaT  keratinocytes closed scratch wounds faster on fibronectin 
coated plates than on collagen coated plates, and faster on both fibronectin and 
type I collagen coated plates than on decorin coated plates. Representative phase 
contrast images are shown of single cell type (HaCaT) scratch assays immediately 
following the scratch and 12 hours thereafter. Original magnification is x10 (bar = 
10μm).  
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Figure 4.19 Scratch-wound closure by HaCaT keratinocytes on ECM proteins. 
Twelve hours post-scratch, the extent of wound closure was 81% (±9%) for HaCaT 
keratinocytes on type I collagen,  63% (±8%) for HaCaT keratinocytes on decorin and 
98% (±3%) for HaCaT keratinocytes cells on fibronectin. Data shown are means ± SEM. 
There was a significant difference by ANOVA (p<0.05); (* denotes significance by 
Tukey's HSD).
*
L929 HaCaT
Dec ▼ ▼
Fib
▲ ▲
Figure 4.20 Summary of decorin and fibronectin effects upon scratch-wound 
closure by skin cell lines compared to type I collagen.
4.4: Discussion
The previous chapter showed MSC secreted factors that enhanced L929 fibroblast and 
HaCaT keratinocyte scratch wound closure, and identified a range of cytokines and 
ECM proteins present in the MSC secretome. This chapter has investigated the effects 
of certain of those factors on L929 fibroblast and HaCaT keratinocyte behaviour  in  
vitro.
Amongst the cytokines found to be present in MSC-CM were the interleukins; 
IL-6 and IL-8, as well as TGF-β1. In these experiments, IL-6 was shown to have little 
observable  effect  upon  the  rate  of  scratch  wound  closure  by  L929  fibroblasts. 
However,  in  vivo experiments  involving  IL-6  knock  out  mice  have  shown  a 
significant delay in cutaneous wound healing in the absence of IL-6 associated with 
reduced  expression  of  α-SMA (smooth  muscle  actin),  a  marker  of  myofibroblast 
differentiation. (Gallucci et al, 2006). It is not known whether or not L929 fibroblasts 
undergo myofibroblastic differentiation when migrating into scratch wounds in our in  
vitro model  of wound healing.  If  they do not,  then  the absence of  this  migratory 
phenotype may go some way towards explaining the lack of an observable cellular 
response  to  IL-6.  Immunostaining  of  IL-6  treated  and  untreated  L929  fibroblast 
cultures  with  an  antibody  for  α-SMA  would  potentially  further  elucidate  the 
mechanisms involved in this phenomenon. This possibility is further discussed below.
Similarly,  IL-6 did  not  appear  to  have any effect  upon the rate  of  scratch 
wound closure by HaCaT keratinocytes. This mirrors observations made by another 
group  using  primary  keratinocytes  isolated  form  IL-6  knock-out  mice  in  which, 
despite  the  role  of  IL-6 in  in  vivo wound healing   mentioned  above,  the  in  vitro 
treatment of cultured keratinocytes with recombinant IL-6 failed to induce a direct 
enhancement  of  either  keratinocyte  migration  or  proliferation.  Instead  IL-6  was 
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shown to indirectly enhance keratinocyte migration by the inducing the production of 
stimulatory factors by fibroblasts (Gallucci  et al, 2004). Whether or not exogenous 
IL-6  would  stimulate  scratch-wound  healing  in  L929  fibroblast  and  HaCaT 
keratinocyte  co-cultures,  despite  having no observable effect  upon either  cell  type 
individually, or whether L929-CM from L929 fibroblasts cultured in the presence of 
IL-6 might  stimulate  HaCaT keratinocyte  migration  and/or  proliferation  may be a 
question worthy of further investigation chapters. IL6 does not appear to account fot 
the effects of MSC-CM
TGF-β1 is  involved in numerous  aspects  of  cutaneous wound healing  in  vivo, 
including  inflammation,  re-epithelialisation  and  ECM  regeneration  (reviewed  in 
Barrientos  et al, 2008). The importance of TGF-β1 in successful wound healing is 
demonstrated  by its  relative  up-regulation  in  normal  ‘acute’  wounds  (Kane  et  al, 
1991), compared to its down-regulation in non-healing ‘chronic’ wounds (Robson, 
1997). In this chapter’s experiments, TGF-β1 was associated with a non-significant 
increase in the rate of scratch wound closure by L929 fibroblasts. TGF-β1 has long 
been known to stimulate fibroblast migration in vitro (Postlethwaite et al, 1987) and is 
involved in the differentiation of normal fibroblasts into myofibroblasts, a migratory 
and contractile  phenotype  associated  with  wound healing  (Serini  et  al, 1998). As 
mentioned  previously,  the  question  of  whether  or  not  L929  fibroblasts  undergo 
myofibroblast differentiation in  in vitro  scratch-wounds, either spontaneously or in 
response to  either  MSC-CM or exogenous TFG-β1 may be  the subject  of  further 
investigation. In addition to enhancing fibroblast migration in vitro, TFG-β1 is known 
to  increase  the  ability  of  myofibroblasts  to  contract  wounds  in  vivo.  Hence  the 
secretion of TFG-β1 by MSC may be potentially beneficial in the healing of chronic 
wounds that show down-regulated TFG-β1 expression.
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TFG-β1 was shown to slightly inhibit the rate of in vitro scratch wound closure by 
HaCaT  keratinocytes  in  these  experiments.  This  seems  contrary  to  previously 
published  studies  that  show  TFG-β1  to  stimulatory  to  keratinocyte  migration 
(Sutherland et al, 2005). This may be due to the difference between the HaCaT cell 
line in our experiments and the primary keratinocytes used by Sutherland et al. It is 
known  that  TFG-β1  drives  HaCaT  keratinocytes  towards  terminal  differentiation 
(Bushke  et  al, 2011)  and this  enhanced differentiation  status  may account  for  the 
absence of a migratory response by these cells to TFG-β1. The expression of various 
keratins  could  be  investigated  to  determine  the  differentiation  status  of  HaCaT 
keratinocytes exposed to either TFG-β1 or MSC-CM. Recent studies have shown that 
co-treatment  of  HaCaT keratinocytes  with  TGF-β1  and  hepatocyte  growth  factor 
(HGF)  results  in  enhanced  keratinocyte  migration  (Nam  et  al, 2010).  As HGF is 
produced by fibroblast in vivo (Zarnegar and Michalopoulos, 1995) this suggests that 
the effects of MSC-secreted TGF-β1 may differ in an in vivo wound healing context 
to  those  observed  in  single  cell  cultues.  TFG-β1  has  also  been  shown  to  alter 
keratinocyte integrin expression towards a more migratory phenotype (Barrientos  et  
al, 2008) and up regulates  the expression of the integrin  receptors  for  fibronectin 
(α5β1 and αVβ6), vitronectin (αVβ1) and collagens, including type I collagen (α2β1), 
stimulating keratinocyte migration towards both collagen and Fibronectin (Zambruno 
et al, 1995, Stepp et al, 2007). It is interesting to note that of these ECM components, 
both type I collagen and fibronectin are strongly and consistently present in the MSC 
secretome. TGF-β1 does not seem to cause the effects of MSC-CM observed in vitro.
IL-8  supplemented  medium  significantly  reduced  the  rate  of  scratch  wound 
closure  by  L929  fibroblasts,  suggesting  that  the  presence  of  IL-8  in  the  MSC 
secretome  does  not  contribute  to  the  associated  enhancement  of  scratch  wound 
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closure in this model system. Whilst it has been previously demonstrated that IL-8 
may enhance fibroblast migration in vitro by reducing the ability of cells to form focal 
adhesions  (Dunlevy  and  Couchman  1995),  and  IL-8  has  also  been  shown  to  be 
chemo-attractant  to  keratinocytes  (Michel  et  al, 1992),  in  some  chronic  wounds, 
elevated levels of IL-8 are associated with impaired wound healing (Ghazarian et al, 
2000) and IL-8 has also been associated with a loss of fibroblast contractile ability in 
wound healing. This may have unwelcome implications for  in vivo  wound healing, 
howver IL-8 is also known to promote angiogenesis (Waugh and Wilson, 2008). As 
poor vascularisation of wound beds is a major cause of the failure of tissue engineered 
skin substitutes in wound healing, the secretion of angiogenic factors by MSC may 
have potential use in improving this method of treating difficult wounds.
There is a possibility that MSC secreted factors could enhance the differentiation 
of L929 fibroblasts by stimulating their differentiation to a migratory myofibroblastic 
phenotype. One study (Joseph  et  al., 2013) has recently shown that L929 fibroblast 
can express alpha SMA and hence it  appears  these cells  may be capable  of  such 
differentiation.  If MSC secreted factors can stimulate myofibroblast differentiation, 
this might reasonably be expected to enhance the rate of wound closure in vivo, if the 
same effect applies to normal human fibroblasts. Within this hypothetical mechanism, 
however,  there  may be  some cause  for  concern  that  this  might  lead  to  excessive 
contracture  of  wound  margins,  leading  to  a  range  of  possible  complications  as 
discussed previously within this thesis. An alternative scenario, in which L929 are 
incapable  of  true  myofibroblast  differentiation,  calls  into  question  the  capacity  of 
these  cells  to  accurately  represent  normal  dermal  fibroblasts  within  this  model. 
Normal dermal fibroblasts are known to be capable of myofibroblast differentiation in 
response  to  factors  found  in  MSC-CM (i.e.  TGF-Beta)  and  this  may  affect  their 
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behaviour  in a  wound healing  context.  In order to investigate these hypotheses  in 
future, immunostaining of L929 cultures during or following scratch-wound healing 
could be undertaken and the results of these investigations might further elucidate the 
effects of MSC-secreted factors within this model of skin wound healing.
The variable effects of the cytokine portion of the MSC secretome implies that 
although MSC-CM enhances the rate of scratch-wound closure by skin cells not all of 
the factors produced by MSC directly contribute to this effect and indeed some may 
be inhibitory to scratch wound closure. Further understanding of those MSC-derived 
factors that are of benefit in a wound healing context compared to those that are not 
may inform more effective use of MSC as a potential therapy for cutaneous wounds, 
perhaps via screening of MSC for favourable secretory profiles or the formulation of 
pharmaceutical  treatments  based  upon  an  optimal  combination  of  MSC  derived 
factors.
As well as cytokines, MSC secrete a range of ECM proteins including type I 
collagen, fibronectin and decorin, which are all major ECM components deposited 
during wound healing (Chen and Abatangelo 1999). Fibronectin is a large dimeric 
glycoprotein involved in cutaneous wound healing, cellular adhesion and migration 
(Yamada, 1991) as well as the induction of fibroblast-myofibroblast differentiation by 
TGF-β1 (Serini  et al, 1998). This chapter’s experiments showed fibronectin to be a 
better substrate for both L929 fibroblast and HaCaT keratinocyte adhesion and scratch 
wound  closure  compared  to  either  type  I  collagen  or  decorin.  This  implies  that 
fibronectin is amongst the MSC-secreted factors that contribute to the enhanced  in  
vitro wound healing observed in Chapter 3. Indeed, previous studies have shown that 
a topical application of plasma fibronectin can enhance the rate of wound healing in  
vivo (Kwon et al, 2007).
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Also present in MSC-CM was the small leucine rich proteoglycan, decorin. Decorin is 
usually associated with type one collagen fibres in normal skin, but is also deposited 
in granulation tissue during wound healing and further up regulated towards the later 
stages (Yeo et al, 1991). This chapter’s experiments found decorin to be inhibitory to 
adherence and wound closure by HaCaT keratinocytes and prohibitively so to L929 
fibroblasts. This, along with the observations made using growth factors discussed 
above, confirms that whilst MSC-CM is beneficial to in vitro wound healing overall, 
it is made up of components with both beneficial and inhibitory effects. Decorin is 
known to be anti-adherent to both human and mouse fibroblasts (Merle  et al, 1997, 
Schmidt et al, 1987) suggesting that decorin would inhibit wound closure. However, 
delayed wound healing was reported in decorin knock out mice compared to wild type 
animals (Järveläinen  et al, 2006) and furthermore a tripeptide copper complex that 
was  shown  to  upregulate  in  vivo decorin  expression  (Siméon  et  al, 2000)  also 
enhanced both acute (Downey et al, 1985) and chronic (Mulder  et al, 1994) wound 
closure in vivo. The role of decorin in wound healing is variable and perhaps requires 
further study, but despite the presence of decorin in the MSC secretome, MSC-CM 
enhances scratch-wound healing by L929 fibroblasts and HaCaT keratinocytes.
The  presence  of  various  growth  factors  and  ECM  proteins  in  the  MSC 
secretome prompted this investigation into the relative contribution of the individual 
factors to the ‘net’ effect of MSC-CM. However, the cytokines involved in  in vivo 
wound  healing  act  in  a  complex  and  combinatorial  fashion  to  influence  cell 
behaviour, for example: IL-6 has been shown to regulate the expression of TGF-β1, 
which was also present in MSC-CM (Luckett-Chastain and Gallucci, 2009). Thus the 
effect of cytokines in isolation may differ significantly from that in the presence of 
one or more other MSC-secreted factors. Similarly, type I collagen, fibronectin and 
149
decorin  are  capable  of  interaction  both  with  each  other  and  with  cytokines,  e.g. 
decorin binds to type one collagen fibres as well as sequestering TGF-β1 (Kresse and 
Schönherr 2001). Additionally,  the effects of surface-bound ECM proteins may not 
equate to the effects of those same proteins when in solution, as in MSC-CM. This 
necessitates the investigation of the actions of these components in combination in 
order to further assess their relative involvement in MSC-CM mediated enhancement 
of scratch wound healing. Informed by the results presented herein, the next chapter 
will attempt to elucidate some of these interactions.
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Chapter 5
The potential role of MSC-secreted fibronectin, during  in vitro scratch wound 
healing.
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5.1: Aims and Background
The previous chapter demonstrated variable effects of individual components of the 
MSC secretome on in vitro scratch-wound closure and the adherence and spreading of 
skin  cells  in  culture.  Of  the  soluble  factors  investigated,  neither  IL-6  nor  IL-8 
enhanced scratch wound closure in either L929 fibroblasts or HaCaT keratinocytes 
used in  these experiments.  The ECM proteoglycan,  decorin,  was inhibitory to  the 
adherence  and  scratch  wound  closure  of  both  cell  types.  Conversely,  the  MSC 
secreted ECM component fibronectin, was shown to have a stimulatory effect upon 
both  L929  fibroblasts  and  HaCaT  keratinocytes,  which  is  similar  to  the  overall 
stimulatory effect of MSC CM reported in Chapter 3. Therefore,  in this chapter, the 
role of fibronectin, and that of the MSC secretome when presented specifically as an 
ECM  substratum,  has  been  investigated  in  more  depth.  Firstly,  the  influence  of 
fibronectin-coating of cultures plates was tested in combination with TGF-β1 (which 
was seen in Chapter 4 to be  stimulatory to L929 fibroblast scratch wound healing, but 
inhibitory  to  HaCaT  keratinocytes  when  collagen  type  I  was  used  as  a  culture 
substrate).  Secondly,  the  effects  of  MSC-CM  on  L929  and  HaCaT  cells  on 
fibronectin-coated plates were examined. Finally, the effects of MSC-CM as a matrix 
substratum were examined directly, by comparing scratch wound closure by L929 and 
HaCaT cells  on culture plates  that  had been coated either  with MSC-CM or with 
unconditioned (control) medium.
152
5.2: The combined effects of fibronectin-coating tissue culture plates and TGF-
β1 treatment  on L929 fibroblasts and HaCaT keratinocytes.
TGF-β1 supplemented  growth medium had no observable  effect  upon the  rate  of 
L929 fibroblast scratch-wound closure on fibronectin-coated tissue culture plates at 
either  a  lower or  a  higher  concentration  of  TGF-β1 compared to  unsupplemented 
medium (Figure 5.1). After 12 hours post-scratching, the degree of scratch wound 
closure had reached 88% (±5%) for L929 fibroblasts  in  unsupplemented  medium, 
93% (±4%) for L929 fibroblasts in 2ng/ml TGF-β1 supplemented medium and 84% 
(±7%) for L929 fibroblasts  in 8ng/ml TGF-β1 supplemented medium, respectively 
(Figure 5.2). No significant differences were found between these results (p>0.05 by 
ANOVA).
In contrast,  TGF-β1 had a concentration-dependent  inhibitory effect  on the 
rate of scratch wound closure of HaCaT keratinocytes on fibronectin-coated plates 
(Figure  5.3).  After  12  hours  post-scratching,  scratch  wounds  in  unsupplemented 
medium  had  closed  by  98%  (±3%),  whereas  scratch  wounds  in  2ng/ml  TGF-β1 
supplemented medium had closed by 77% (±23%), and scratch wounds in 8ng/ml 
TGF-β1  had  only  achieved  53%  (±5%)  of  wound  closure  (Figure  5.4).  This 
concentration-dependent  inhibitory  effect  of  TGF-β1  treatment  was  statistically 
significant (p<0.05 by ANOVA).
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Figure 5.1 L929 fibroblasts on fibronectin closed close scratch wounds at a similar rate in 
TGF-β1 supplemented medium to that in unsupplemented medium. There was little apparent 
difference between a lower concentration and a higher concentration of TGF-β1 Representative 
phase contrast images are shown of single cell type (L929) scratch assays immediately following 
the scratch and 12 hours thereafter. Original magnification is x10 (bar = 10μm).  
Figure 5.2 Scratch-wound closure by l929 fibroblasts in TGF-β1 supplemented media 
on fibronectin. Twelve hours post-scratch, the extent of wound closure was 88% (±5%) for 
L929 fibroblasts in unsupplemented medium,  93% (±4%) for L929 fibroblasts in 2ng/ml 
TGF-β1 supplemented medium and 84% (±7%) for L929 fibroblasts in 8ng/ml TGF-β1 
supplemented medium . Data shown are means ± SEM. No significant differences were 
found between results (p>0.05 by ANOVA).
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Figure 5.3 HaCaT keratinocytes on fibronectin closed scratch wounds slower in TGF-β1 
supplemented medium than in unsupplemented medium. A lower concentration of TGF-β1 
seemed to be less inhibitory to scratch wound closure than a higher concentration of TGF-β1 
Representative phase contrast images are shown of single cell type (HaCaT) scratch assays 
immediately following the scratch and 12 hours thereafter. Original magnification is x10 (bar = 
10μm).  
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Figure 5.4 Scratch-wound closure by HaCaT keratinocytes in TGF-β1 supplemented 
media on fibronectin. Twelve hours post-scratch, the extent of wound closure was 98% 
(±3%) for HaCaT keratinocytes in unsupplemented medium,  77% (±23%) for HaCaT 
keratinocytes in 2ng/ml TGF-β1  supplemented medium and 53% (±5%) for HaCaT 
keratinocytes in 8ng/ml TGF-β1 supplemented medium . Data shown are means ± SEM.  
There was a significant difference by ANOVA (p<0.05); (* denotes significance by 
Tukey's HSD).
**
*
5.3:  The combined effects  of  fibronectin-coating culture plates  and treatment 
with MSC-CM on L929 fibroblasts and HaCaT keratinocytes.
There was a marginal increase if the rate of L929 fibroblast scratch-wound closure in 
the presence of MSC-CM compared to unconditioned medium on fibronectin-coated 
plates (Figure 5.5). Hence, after 12 hours post-scratching the degree of scratch wound 
closure  by  L929  fibroblasts  in  unconditioned  medium  had  reached  88%  (±5%) 
compared  to  99%  (±2%)  for  scratch  wound  closure   in  MSC-CM  (Figure  5.6). 
However, this marginal difference was not   statistically significant (p>0.05  Mann 
Whitney U test).
There was also little observable difference between the rate of scratch wound 
closure  by  HaCaT  keratinocytes  in  unconditioned  medium  versus  MSC-CM  on 
fibronectin-coated culture plates (Figure 5.7). Hence, after 12 hours post-scratching 
wound  closure  by  HaCaT  keratinocytes  on  fibronectin  had  reached  98% (±2)  in 
unconditioned  medium  compared  to  94%  (±6)  in  MSC-CM  (Figure  5.8).  No 
significant differences were found between these values (p>0.05  Mann Whitney U 
test).
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Figure 5.5 Scratch-wound closure by L929 fibroblasts is not enhanced by MSC-CM 
on fibronectin. Scratch-wound closure by L929 fibroblasts on fibronectin was not 
markedly affected by MSC conditioned medium, showing a very slight enhancement 
compared to unconditioned medium. Representative phase contrast images are shown of 
single cell type (L929) scratch assays immediately following the scratch and 12 hours 
thereafter. Original magnification is x10 (bar = 10μm). 
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Figure 5.6 Scratch-wound closure by L929 fibroblasts in MSC-CM on fibronectin. 
After 12 hours L929 fibroblasts on fibronectin had reached 88% (±5%) closure in 
unconditioned medium, compared to 99% (±2%) closure in MSC conditioned  medium. 
Data shown are means ± SEM. No significant differences were found between results by 
Mann Whitney U test.
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Figure 5.7 HaCaT keratinocytes on fibronectin appeared to close scratch wounds at 
a similar rate in MSC conditioned medium and in unconditioned medium. 
Representative phase contrast images are shown of single cell type (HaCaT) scratch assays 
immediately following the scratch and 12 hours thereafter. Original magnification is x10 
(bar = 10μm).  
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Figure 5.8 Scratch-wound closure by HaCaT keratinocytes in MSC-CM on 
fibronectin. After 12 hours HaCaT keratinocytes on fibronectin had reached 98% (±2%) 
closure in unconditioned medium, compared to 94% (±6%) closure in MSC conditioned  
medium. Data shown are means ± SEM.  No significant differences were found between 
results by Mann Whitney U test.
5.4:  The  effects  of  coating  tissue  culture  plates  with  MSC-CM  on  L929 
fibroblasts and HaCaT keratinocytes.
L929 fibroblasts closed scratch wounds on serum free MSC-CM coated tissue culture 
plates  faster than on unconditioned serum free medium-coated plates (Figure 5.9). 
Hence, after 6 hours post scratching, the degree of scratch wound closure by L929 
fibroblasts on unconditioned medium-coated tissue culture plastic had reached 41% 
(±9%) compared to 54% (±6%) on MSC-CM. After 12 hours, L929 fibroblasts on 
unconditioned medium-coated tissue culture plastic had reached 70% (±13%) scratch 
wound closure compared to 83% (±4%) on MSC-CM coated plates (Figure 5.10). 
These differences were not significant, but came close to significance at the 12 hour 
time point  (p=0.057 Mann Whitney U test).
HaCaT keratinocyte scratch-wounds closed at a similar rate on culture plates 
coated in (serum free) unconditioned medium and MSC-CM. In both cases, scratch 
wound closure was near to completion within 6 hours (Figure 5.11). Hence, after 6 
hours post-scratching, HaCaT keratinocytes on unconditioned medium-coated tissue 
culture  plastic  had  reached  84%  (±6%)  compared  to  88%  (±4%)  on  MSC-CM, 
respectively. After 12 hours post-scratching, the degree of scratch-wound closure on 
unconditioned  medium-coated  tissue  culture  plastic  had  reached  96%  (±1%), 
compared to  98% (±1%) on MSC-CM, respectively (Figure 5.12).  The difference 
between these values was not statistically significant (p>0.05 Mann Whitney U test).
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Figure 5.9 L929 fibroblasts on MSC-CM coated tissue culture plastic closed scratch 
wounds faster than on plastic coated in unconditioned medium. Representative phase 
contrast images are shown of single cell type (L929) scratch assays immediately following the 
scratch and 6 and 12 hours thereafter. Original magnification is x10 (bar = 10μm).  
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Figure 5.10 Scratch-wound closure by L929 fibroblasts on MSC-CM coated plates. 
After 6 hours L929 fibroblasts on unconditioned medium-coated tissue culture plastic had 
reached 41% (±9%), compared to 54% (±6%) on MSC-CM. After 12 hours L929 fibroblasts 
on unconditioned medium-coated tissue culture plastic had reached 70% (±13%), compared 
to 83% (±4%) on MSC-CM. Data shown are means ± SEM. No significant differences were 
found between results, although Control vs. MSC-CM was near significant (p=0.057) by 
Mann Whitney U test.
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Figure 5.11 HaCaT keratinocytes on MSC-CM coated tissue culture plastic closed scratch 
wounds at a similar rate to cells on plastic coated in unconditioned medium. Representative 
phase contrast images are shown of single cell type (HaCaT) scratch assays immediately 
following the scratch and 6 and 12 hours thereafter. Original magnification is x10 (bar = 10μm).  
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Figure 5.12 Scratch-wound closure by HaCaT keratinocytes on MSC-CM coated 
plates. After 6 hours HaCaT keratinocytes on unconditioned medium-coated tissue culture 
plastic had reached 84% (±6%), compared to 88% (±4%) on MSC-CM. After 12 hours 
HaCaT keratinocytes on unconditioned medium-coated tissue culture plastic had reached 
96% (±1%), compared to 98% (±1%) on MSC-CM. Data shown are means ± SEM  (No 
significant differences were found between results by  Mann Whitney U test).
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5.5: Soluble ECM proteins
L929 fibroblasts closed scratch wounds on uncoated tissue culture plates faster in the 
absence  of  exogenous  ECM  proteins  than  inthepresence  of  either  decorin  or 
fibronectin (Figure 5.13). Hence, after 12 hours post scratching, the degree of scratch 
wound closure by L929 fibroblasts in unconditioned medium had reached 98% (±3%) 
compared to 62% (±15%) in fibronectin supplemented medium and 47% (±16%) in 
decorin supplemented medium (Figure 5.14). These differences were not statistically 
significant (ANOVA).
Similarly, the presence of both soluble fibronectin and decorin within culture 
medium retarded the rate of scratch wound closure by HaCaT Keratinocytes, such that 
after  12  hours  post  scratching  of  scratch  wound  closure  by  L929  fibroblasts  in 
unconditioned  medium  had  reached  89%  (±5%)  compared  to  18%  (±6%)  in 
fibronectin supplemented medium and 37% (±6%) in decorin supplemented medium 
(Figure 5.14). These differences were statistically significant (p<0.05 by ANOVA).
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Figure 5.13. Soluble decorin and fibronectin reduced scratch wound 
closure by L929 fibroblasts compared to unsupplemented medium. Both 
ECM proteins at 0.2mg/ml were associated with a reduction in the rate of 
scratch wound closure by L929 fibroblasts. Representative phase contrast 
images are shown of single cell type (L929) scratch assays immediately 
following the scratch and 12 hours thereafter. Original magnification is x10 
(bar = 10μm). 
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Figure 5.14. Scratch-wound closure by L929 fibroblasts in Decorin and 
fibronectin supplemented media. Twelve hours post-scratch, the extent of wound 
closure was 62% (±15%) for L929 fibroblasts in 0.2mg/ml decorin supplemented 
medium,  47% (±16%) for L929 fibroblasts in 0.2mg/ml fibronectin supplemented 
medium and 98% (±3%) for L929 fibroblasts in unsupplemented medium. Data 
shown are means ± SEM. There was a significant difference by ANOVA (p<0.05); 
(* denotes significance by Tukey's HSD).
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Figure 5.15. Scratch wound closure by HaCaT keratinocytes was 
retarded in the presence of soluble ECM proteins compared to 
unsupplemented medium. Both soluble decorin and fibronectin at 
0.2mg/ml were associated with a reduction in the rate of scratch wound 
closure by HaCaT keratinocytes. Representative phase contrast images are 
shown of single cell type (HaCaT) scratch assays immediately following the 
scratch and 12 hours thereafter. Original magnification is x10 (bar = 10μm). 
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Figure 5.16. Scratch-wound closure by HaCaT keratinocytes in Decorin and 
fibronectin supplemented media. Twelve hours post-scratch, the extent of wound 
closure was 37% (±6%) for HaCaT keratinocytes in 0.2mg/ml decorin 
supplemented medium,  18% (±6%) for HaCaT keratinocytes in 0.2mg/ml 
fibronectin supplemented medium and 89% (±5%) for HaCaT keratinocytes in 
unsupplemented medium. Data shown are means ± SEM. There was a significant 
difference by ANOVA (p<0.05); (* denotes significance by Tukey's HSD).
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5.5: Discussion
Cell  motility in wound healing is  partially dependent  upon the remodelling of the 
ECM (Gailit  & Clark,  1996)  as  well  as  the  expression  of  various  growth factors 
(Moulin, 1995). The ECM protein fibronectin and the growth factor TGF-β1 are both 
secreted by MSC, and are also present during cutaneous wound healing  in vivo. In 
Chapter 4, coating tissue culture plates with fibronectin was shown to enhance the rate 
of  both  L929  fibroblast  and  HaCaT  keratinocyte  migration  into  scratch-wounds, 
compared to their rates of migration on type I collagen.  TGF-β1 was also shown to 
enhance the migration  of  L929 fibroblasts,  but  to  inhibit  the migration  of HaCaT 
keratinocytes on type I collagen. As MSC were shown to secrete fibronectin and also 
TGF-β1 (in Chapter 3), this set of experiments investigated the effects of both of these 
MSC-secreted proteins in combination. 
Whilst fibronectin and TGF-β1 were each shown to enhance L929 fibroblast 
migration  individually,  the  combination  of  TGF-β1  supplemented  media  with 
fibronectin-coated tissue culture plates did not result in any further enhancement of 
L929  fibroblast  migration  compared  to  fibronectin  in  the  absence  of  TGF-β1. 
However, the rate of scratch-wound closure by L929 fibroblasts in the presence of 
both TGF-β1 and fibronectin was somewhat greater than in the presence of TGF-β1 
and type  I  collagen.  This,  along with  the greater  enhancement  of  L929 fibroblast 
scratch  wound  closure  by  fibronectin  than  TGF-β1  compared  to  their  respective 
controls, suggests that fibronectin may have played a greater role than TGF-β1 in the 
improved rate of L929 fibroblast migration observed in the presence of MSC-CM. 
Interestingly,  as  well  as  containing  fibronectin,  MSC-CM has  been shown to  up-
regulate the deposition of fibronectin and other ECM components such as elastin and 
type  I  collagen  by  fibroblasts  (Jeon  et  al,  2010).  As  fibronectin  improved  the 
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migration of both L929 fibroblasts (and, indeed, HaCaT keratinocytes), this trophic 
activity would be expected to further encourage the potential use of MSC-CM in the 
treatment of cutaneous wounds.  
TGF-β1  treatment  significantly  inhibited  the  migration  of  HaCaT 
keratinocytes  on  fibronectin-coated  tissue  culture  plates.  This  matches  the 
observations  of  the  previous  chapter,  wherein  TGF-β1  also  inhibited  the  rate  of 
HaCaT keratinocyte  migration  upon  type  I  collagen-coated  plates.  The  effects  of 
TGF-β1  on  keratinocytes  during  wound  healing  are  somewhat  uncertain,  and 
published investigations into the problem have yielded contradictory results. Studies 
have reported a TGF-β1 mediated  enhancement  of  keratinocyte  migration  in  vitro 
using both transwell  migration  assays  (Decline  et al,  2003, Decline and Rouselle, 
2000)  and  using  time-lapse  video  microscopy  (Sutherland  et  al, 2005),  and  the 
addition  of  a  TGF-β1  neutralising  antibody  to  murine  keratinocyte  cultures 
significantly inhibited keratinocyte migration (Stepp  et al, 2007). Conversely, other 
studies have suggested that impaired TGF-β1 signal transduction results in accelerated 
wound healing and re-epithelialisation in vivo (Ashcroft et al, 1999, Hosokawa et al, 
2005). As previously suggested in Chapter four, the ability of TGF-β1 to drive HaCaT 
keratinocytes towards terminal differentiation (Bushke et al, 2011) may contribute to 
the inhibitory effect of TGF-β1 on HaCaT keratinocyte migration on fibronectin as 
well as on type I collagen observed in this investigation, i.e. the keratinocytes would 
become less migratory as they begin to form a full and mature epithelial layer. 
MSC-CM  had  no  discernible  effect  upon  L929  fibroblast  scratch-wound 
closure  on  fibronectin-coated  tissue  culture  plates  compared  to  unconditioned 
(control) medium. This was in sharp contrast to those scratch assays performed on 
type I collagen-coated tissue culture plastic, where MSC-CM significantly improved 
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the rate of L929 fibroblast scratch-wound closure compared to unconditioned medium 
(Chapter 3). The rate of L929 fibroblast scratch-wound closure on fibronectin in both 
unconditioned medium and MSC-CM was similar to that on type I collagen in MSC-
CM, and all of these were similarly greater than those in unconditioned medium on 
type I collagen. Therefore,  it  seems reasonable to suggest that the majority of the 
MSC-CM mediated enhancement of L929 fibroblast scratch-wound closure may be 
due  to  the  effects  of  fibronectin.  This  hypothesis  is  supported  by  the  previous 
observation that TGF-β1, which was the only other MSC-CM component examined 
that enhanced L929 fibroblast migration, had no further stimulatory effect upon L929 
fibroblasts  in  the  presence  of  fibronectin.  Similarly,  HaCaT keratinocyte  scratch-
wounds did not close any faster  in MSC-CM compared to unconditioned medium 
when these  assays  were performed  on fibronectin-coated  tissue  culture  plates.  As 
fibronectin was the only component of MSC-CM that had any stimulatory effect upon 
HaCaT  keratinocyte  migration  when  applied  individually,  and  fibronectin-coating 
alone was associated with a similar rate of HaCaT scratch-wound closure to that seen 
in the presence of MSC-CM, this seems to suggest that the ability of MSC-CM to 
enhance  HaCaT keratinocyte  scratch-wound  closure  may  also  be  dependent  upon 
fibronectin as a major contributory factor.
Blocking antibodies for integrin receptors for fibronectin, such as α5β1 and/or 
αVβ6, could be used to test the hypothesis that fibronectin as an ECM substratum is 
an  essential  mediator  of  MSC-CM  enhancement  of  L929  fibroblasts  and  HaCaT 
keratinocyte scratch-wound closure, i.e. if the blocking of the integrin receptors for 
fibronectin  resulted in a  diminished response to  MSC-CM, this  could confirm the 
essentiality of fibronectin to the ability of MSC-CM to stimulate skin cell migration 
via cell-matrix interactions and hence enhance wound healing in vitro.
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In  Chapter  4,  coating  tissue  culture  plates  with  fibronectin  was  shown  to 
enhance L929 fibroblast and HaCaT keratinocyte migration compared to when the 
culture plates were coated with type I collagen.  Thus it  was hypothesised that the 
enhancement of L929 fibroblast and HaCaT keratinocytes migration seen in MSC-
CM versus unconditioned medium was due to MSC-secreted fibronectin becoming 
deposited upon the culture plate surface and acting in a similar way to the fibronectin-
coated plates used in Chapter 4. To investigate this hypothesis, tissue culture plates 
were coated in MSC-CM in the same manner as with fibronectin and type I collagen 
previously,  and washed before cells  were introduced in order to remove any non-
bound growth factors or cytokines that may influence cell behaviour, hence leaving 
behind only that  portion  of  the MSC secretome that  would bind to  tissue culture 
plastic. L929 fibroblast scratch-wound closure was faster on tissue culture plates that 
were coated in MSC-CM compared with those coated with unconditioned medium, 
although not to the same degree as was observed in experiments using whole MSC-
CM, whilst HaCaT keratinocytes closed scratch-wounds at a similar rate in MSC-CM 
coated  culture  plates  or   those  coated  with  unconditioned  medium.  This  partial 
enhancement of L929 fibroblast migration, and the lack of an observable response by 
HaCaT keratinocytes, suggests that, whilst the result presented in this chapter imply 
that  there  may  be  an  important  role  for  fibronectin  in  the  MSC-CM  mediated 
enhancement of scratch-wound closure by both cell types, the portion of MSC-CM 
that deposits upon the tissue culture surface is not entirely responsible for the effects 
of  MSC-CM on L929 fibroblasts,  and may not  significantly contribute  to  HaCaT 
keratinocyte  migration  at  all.  Immuno-staining  of  MSC-CM  coated  tissue  culture 
plastic  for  MSC-secreted  ECM  proteins  such  as  type  I  collagen,  decorin  and 
fibronectin,  along  with  other  secretome  components,  would  help  elucidate  which 
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factors were present in the surface-bound portion of MSC-CM. In addition,  if  the 
effects of MSC-CM are not dependent upon surface-bound proteins, yet fibronectin 
was  seen  to  have  a  stimulatory  effect  upon  both  L929  fibroblast  and  HaCaT 
keratinocyte  scratch-wound closure,  then scratch assays  performed upon these cell 
types using culture medium supplemented with fibronectin in solution compared to 
both MSC-CM and unconditioned medium, might have been expected to demonstrate 
whether or not fibronectin may be acting as a soluble stimulatory factor, influencing 
cell  migration  via  a  paracrine  mechanism  rather  than  simply  acting  as  a  more 
permissive substrate for cellular migration. The results of these experiments suggest 
that soluble fibronectin is not directly stimulatory to skin cell migration in this model 
system, as medium supplemented with fibronectin (and indeed decorin) was seen to 
result in a retardation of the rate of scratch wound closure by both L929 fibroblasts 
and HaCaT keratinocytes.
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Chapter 6
The Effects of MSC Secreted Factors on Endothelial Cells
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6.1: Aims and Background
Chapter 1 discussed how the effectiveness of wound healing, particularly for chronic 
wounds such as pressure ulcers, depends on a good vascular supply to the wound bed. 
Indeed, many potential  therapies for severe or chronic cutaneous wounds fail  as a 
result of poor vasculature (Laschke  et al, 2006, Jain  et al, 2005), with the obvious 
implication that strategies that improve blood vessel growth into the wound bed will 
promote wound healing. Chapters 3-5 demonstrated that MSC-CM were stimulatory 
to skin cells, specifically L929 fibroblasts and HaCaT keratinocytes, and then further 
examined which of the individual components of the MSC secretome identified by 
ELISA and mass spectrometry may be active in this role. However, the effects of 
MSC secreted factors on endothelial cells had not been examined, even though there 
is evidence to suggest that MSC are pro-angiogenic through their paracrine activity 
(Kinnaird et al, 2004, Beckermann et al, 2008, Zackarek et al, 2007) and that MSC 
are capable of endothelial differentiation (Oswald et al, 2004, Jazyayeri et al, 2008), 
although the engraftment into new vasculature has shown to be low in vivo (Tomita et  
al, 2002). Therefore, in this section of the study, the effects of MSC-CM were tested 
against  an endothelial  cell  line,  EaHy926 cells  (Edgell  et  al,  1983).  This  analysis 
included  assaying  the  effects  of  individual  MSC-CM from 3  different  donors  on 
EaHy926 cell adhesion and migration on a range of ECM protein substrates, again 
using the scratch assay, along with further identification of individual components of 
the MSC secretome present in each donor.
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6.2: The effects of MSC-CM upon EaHy-926 cell adherence and migration.
MSC-CM significantly  enhanced  the  rate  of  scratch  wound closure  by EaHy-926 
endothelial cells (Figures 6.1-6.2), such that after 6 hours post scratching, EaHy-926 
endothelial  cells  in  the presence of MSC-CM had closed scratch wounds by 35% 
(±2%), whilst cells in unconditioned (control) medium had only closed the scratch 
wounds by 20% (±1%). After 12 hours post scratching, EaHy-926 endothelial cells 
had  closed  scratch  wounds  by  56% (±3%),  in  MSC-CM  compared  with  cells  in 
unconditioned  (control)  medium,  which  had  only  closed  scratch  wounds  by  30% 
(±3%). In both cases, these differences between the extent of scratch wound closure in 
MSC-CM  versus  unconditioned  (control)  medium  were  significant  (*=p<0.05  by 
Mann Whitney U test).
No similar enhancement in scratch wound closure was observed when MSC-
CM was used to coat tissue culture plates to form an ECM substrate, rather than as 
culture  medium  (Figures  6.3-6.4).  Hence,  at  6  hours  post  scratching  EaHy-926 
endothelial  cells had closed scratch wounds by a similar degree in both MSC-CM 
coated and unconditioned (control) medium coated culture plates, at 24% (±2%) and 
21% (±2%),  respectively.  Similarly,  after  12 hours  post  scratching,  the  degree  of 
scratch wound closure by EaHy-926 endothelial cells was 36% (±2%) in MSC-CM 
coated  culture  plates  and  34%  (±3%)  in  culture  plates  coated  in  unconditioned 
(control)  medium.  No  significant  differences  were  found  between  these  values 
(p>0.05 Mann Whitney U test). 
However,  MSC-CM  coating  of  culture  plates  did  result  in  a  significant 
increase in the degree of EaHy-926 cell spreading such that after 4 hours post-seeding 
the average cell  area on MSC-CM coated culture  plates  was 1322µm2 (±140µm2) 
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compared to 389µm2 (±30µm2) on culture plates coated with unconditioned (control) 
medium (Figure 6.5-6.6). 
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Figure 6.1 EaHy-926 endothelial cells closed scratch wounds faster in MSC-CM than in 
unconditioned medium. Representative phase contrast images are shown of single cell type 
(EaHy-926) scratch assays immediately following the scratch and 6 and 12 hours thereafter. 
Original magnification is x10 (bar = 100μm).  
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Figure 6.2 Scratch-wound closure by EaHy-926 endothelial cells in MSC-CM. After 6 
hours EaHy-926 endothelial cells in unconditioned (control) medium had reached 20% 
(±1%), compared to 35% (±2%) in MSC-CM. After 12 hours EaHy-926 endothelial cells in 
unconditioned medium had reached 30% (±3%), compared to 56% (±3%) in MSC-CM. 
Data shown are means ± SEM. (* = p<0.05 by Mann Whitney U test).
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Figure 6.3 EaHy-926 endothelial cells on MSC-CM coated tissue culture plates closed 
scratch wounds at a similar rate to cells on plates coated in unconditioned medium. 
Representative phase contrast images are shown of single cell type (EaHy-926) scratch assays 
immediately following the scratch and 6 and 12 hours thereafter. Original magnification is x10 
(bar = 100μm).  
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Figure 6.4 Scratch-wound closure by EaHy-926 endothelial cells on MSC-CM coated 
plates. After 6 hours EaHy-926 endothelial cells on unconditioned medium-coated tissue 
culture plastic had reached 21% (±2%), compared to 24% (±%) on MSC-CM. After 12 
hours EaHy-926 endothelial cells on unconditioned medium-coated tissue culture plastic 
had reached 34% (±3%), compared to 36% (±2%) on MSC-CM. Data shown are means ± 
SEM  (No significant differences were found between results by  Mann Whitney U test).
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Figure 6.5 MSC-CM coating of culture plates influences EaHy-926 
endothelial cell adherence and spreading. After 4 hours in culture EaHy-926 
endothelial cells were observably more spread on culture plates coated with  
MSC-CM than on plates coated with unconditioned (control) medium. 
Representative phase contrast images are shown of EaHy-926 endothelial cells 
immediately following seeding or 4 hours thereafter.
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Figure 6.6  Cell areas on MSC-CM coated plates. After 4 hours in culture the 
average cell area was 1322µm2 (±140µm2), for EaHy-926 endothelial cells on MSC-
CM coated culture plates and 389µm2 (±30µm2) for EaHy-926 endothelial cells on 
unconditioned (control) medium coated culture plates. Data shown are means ± 
SEM in relative units (*=p<0.05 Mann Whitney U test).
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6.3: The ECM protein content of MSC-CM from 3 separate donors.
The  MSC-CM,  derived  from  n=3  donors,  that  demonstrated  an  enhancement  of 
EaHy926 cell migration in scratch wound assays, and of cell adhesion when used to 
coat culture plates, was examined by MALDI/TOF/TOF mass spectrometry. All three 
MSC-CM were found to contain fibronectin, collagen type I, collagen type VI, and 
lumican, whilst cartilage oligomeric matrix protein (COMP) and SPARC were present 
in two out of three MSC-CM and laminin,  decorin, heparan sulphate proteoglycan 
(HSPG) and IGFBP-7 were each only observed in one MSC-CM (Table 6.1). Hence, 
there  was  some  similarity  but  also  clear  donor-donor  variability  in  the  ECM 
components  of  the  MSC  secretome.  Experiments  were  therefore  performed  to 
examine  the  effects  of  some  of  the  individual  ECM  components  identified, 
particularly fibronectin, collagen type 1 and decorin, on EaHy926 cells, much as had 
been performed previously with L929 fibroblasts and HaCaT keratinocytes.
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TABLE 6.1 PROTEINS DETECTED IN MSC CONDITIONED 
MEDIUM VIA MASS SPECTROMETRY      (MALDI-TOF/TOF)
MSC-CM 1 MSC-CM 2 MSC-CM 3
Fibronectin Fibronectin Fibronectin
Collagen type I Collagen type I Collagen type I
Collagen type VI Collagen type VI Collagen type VI
Laminin - -
Cartilage oligomeric 
matrix protein 
Cartilage oligomeric 
matrix protein 
Lumican Lumican Lumican 
- - Decorin 
- - HSPG
SPARC - SPARC
IGFBP-7 - -
Table 6.1 Mass spectrometry of MSC-CM from 3 separate donors. MALDI-
TOF/TOF mass spectrometry of MSC-CM detected variable protein content 
between media conditioned by MSC from three different patient donors.
6.4: The effects of ECM proteins on EaHy-926 endothelial cells.
EaHy-926  cells  adhered  more  readily  to  fibronectin-coated  culture  plates  than  to 
culture plates coated in either decorin or collagen type I  to the degree that after four 
hours post-seeding those cells  in fibronectin coated plates had spread significantly 
further than cells in either collagen type I or decorin coated plates (Figures 6.7-6.8).
The coating of culture plates with these individual ECM proteins also affected 
the rate of migration of EaHy-926 cells in the presence and absence of MSC-CM (as 
culture  medium),  and  as  determined  by  scratch  assays.  Hence,  in  unconditioned 
(control)  medium  after  both  6  and  12  hours  post  scratching,  EaHy-926  cells  in 
fibronectin  coated  plates  were  observably  more  advanced  in  closing  the  scratch 
wound areas  than those cells  in plates  coated in  either  collagen type  I  or decorin 
(Figure 6.9). In these unconditioned (control) medium cultures, scratch wound closure 
by the EaHy-926 cells in fibronectin coated culture plates was 24% (±2%) after 6 
hours post scratching, compared with 20% (±1%) in collagen type I coated culture 
plates and 19% (±1%) in decorin coated culture plates. After 12 hours post scratching 
in the same unconditioned (control) medium conditions, the extent of scratch wound 
closure in  fibronectin,  collagen type  I  and decorin coated culture plates  was 35% 
(±4%), 26% (±2%), and 26% (±1%), respectively (Figure 6.10). . 
Fibronectin was also the most favourable culture substrate for EaHy-926 cells 
in the presence of MSC-CM. However, MSC-CM enhanced scratch wound closure 
whichever of the ECM components had been used to coat the culture plates. Hence, at 
6 hours post scratching, the extent of scratch wound closure in MSC-CM was  35% 
(±2%) (versus 24% (±2%) in control medium) on fibronectin coated culture plates, 
32% (±1%) (versus 20% (±1%) in control medium) on collagen type I coated culture 
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plates,  and 25% (±1%) (versus  19% (±1%) in control  medium on decorin  coated 
culture plates. A similar relationship between the effects of coating the culture plates 
with these ECM components and the effects of MSC-CM on EaHy926 scratch wound 
closure was observed at 12 hours post scratching (Figure 6.10).   
In MSC-CM or unconditioned (control)  medium, scratch wound closure by 
EaHy-926  cells  was  significantly  enhanced  in  fibronectin  coated  culture  plates 
compared to wound closure in decorin coated culture plates, but not collagen type I 
coated culture plates at 6 hours post scratching (p<0.05 by ANOVA). At 12 hours 
post  scratching,  scratch  wound  closure  was  significantly  enhanced  in  fibronectin 
coated culture plates compared to both decorin or collagen type I coated culture plates 
(p<0.05 by ANOVA), in MSC-CM or unconditioned (control)  medium. EaHy-926 
scratch  wound  closure  was  significantly  greater  at  both  6  and  12  hours  post 
scratching,  in MSC-CM compared to unconditioned (control) medium, irrespective of 
the ECM component used to coat the culture plates (p<0.05 by ANOVA).
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Figure 6.7 ECM protein coating of culture plates influences EaHy-926 
endothelial cells adherence and spreading. After 4 hours in culture EaHy-926 
endothelial cells were observably more spread on culture plates coated with  
fibronectin than on plates coated with type I collagen or decorin. Representative 
phase contrast images are shown of EaHy-926 endothelial cells immediately 
following seeding or 4 hours thereafter.
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Figure 6.8 Cell areas on ECM proteins. After 4 hours in culture the average cell 
area was  551µm2  (±58µm2), for EaHy-926 endothelial cells on type I collagen, 
495µm2  (±64µm2), for EaHy-926 endothelial cells on decorin and 887µm2 
(±90µm2), for EaHy-926 endothelial cells on fibronectin. Data shown are means ± 
SEM in relative units. There was a significant difference by ANOVA (p<0.05); (* 
denotes significance by Tukey's HSD).
*
*
Figure 6.9 EaHy-926 endothelial cells closed scratch wounds faster in MSC-CM than in 
unconditioned medium on type I collagen, fibronectin, and decorin coated culture plates. 
Representative phase contrast images are shown of single cell type (EaHy-926) scratch assays 
immediately following the scratch and 6 and 12 hours thereafter. Original magnification is x10 
(bar = 100μm).  
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Figure 6.10 Scratch-wound closure by EaHy-926 endothelial cells in MSC-CM upon 
ECM protein coated culture plates. After both 6 hours and 12 hours EaHy-926 
endothelial cells in MSC-CM (black bars) had closed scratch wounds by a significantly 
greater degree than those in unconditioned control medium (white bars). After 6 hours 
EaHy-926 endothelial cells in unconditioned medium on fibronectin coated culture plates 
had closed scratch wounds by a significantly greater degree than those on culture plates 
coated in decorin. By 12 hours post-scratching, EaHy-926 endothelial cells on plates coated 
in both collagen and fibronectin had closed scratch wounds by a significantly greater degree 
than those on decorin coated culture plates. Data shown are means ± SEM. There were 
significant differences by ANOVA (p<0.05); (* denotes significance by Tukey's HSD).
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6.5: Discussion
In previous chapters MSC-CM has been shown to promote the migration of skin cells 
in an in  vitro wound healing model, and the potentially beneficial individual factors 
within the ‘whole’ MSC-CM have been tested to elucidate their relative contribution 
to this effect. However, as described in Chapter one of this thesis, cutaneous wound 
healing in vivo is a complex process influenced not only by the migration of dermal 
and epidermal  skin cells,  but  also  by a host  of  cellular  events  including amongst 
others,  angiogenesis;  the formation of  new vasculature within the wound area.  If 
MSC can stimulate endothelial  cells  and contribute  to  angiogenesis,  as the results 
presented in this thesis as well as numerous previous reports (Beckermann et al, 2008, 
Zacharek  et al,  2007) suggest,  this supports their  potential  use in the treatment of 
cutaneous  wounds.  Similarly,  poor  vascularisation  of  the  wound  bed  has  been 
implicated in the failure of both conventional skin grafts and tissue engineered skin 
substitutes. Hence, treatment with MSC along with or prior to skin grafting might be 
considered to improve the condition of the wound bed, increasing the likelihood of a 
successful graft. In this chapter, the effects of MSC-CM upon an endothelial cell line, 
EaHy-926, have been investigated using the scratch assay, as well as evaluating the 
effects of individual ECM proteins found in MSC-CM (by mass spectrometry).
In these  experiments,  MSC-CM was found to be stimulatory to  EaHy-926 
endothelial cell migration in vitro. This is similar to previous studies in which MSC-
CM has been shown to stimulate angiogenesis in vitro. For example, Beckermann and 
co-workers observed enhanced sprouting of human vascular endothelial  cells  from 
spheroid cultures in collagen gels in the presence of MSC-CM (Beckermann  et al, 
2008),  whilst  another  group  have  reported  that  MSC-CM  enhanced  the  tubule 
196
formation  by  murine  endothelial  cells  in  matrigel  assays  (Zacharek  et  al,  2007). 
Interestingly, one study reports that co-culture of MSC with endothelial cell tubules 
resulted  in  the  degradation  of  capillary  networks  and the  apoptosis  of  endothelial 
cells, whereas MSC-CM did not exhibit this anti-angiogenic effect (Otsu et al, 2008). 
This last finding supports the investigation of MSC-CM as a pro-angiogenic agent 
within  this  chapter,  and hence of  using  MSC secreted  factors  to  treat  wounds  as 
opposed to cell transplantation. 
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Mass spectrometry of MSC-CM revealed the presence of collagen types I and 
VI, as well as fibronectin and lumican in medium conditioned by each of the three 
MSC  examined,  and  laminin,  decorin,  COMP,  SPARC,  heparan  sulphate 
proteoglycan (HSPG) and IGFBP-1 in one or two but not all three of the MSC-CM 
samples. Of these ECM components, fibronectin, collagen and laminin are known to 
promote or support angiogenesis (Campbell  et al, 2010). Fibronectin contains RGD 
protein motifs known to mediate angiogenesis by integrin receptor signalling. RGD 
motifs bind to α5β1 integrin receptors, amongst others, and these have been shown to 
be essential for the proper formation of vasculature in knock out mouse models  in  
vivo (Yang et al, 1993, Goh et al, 1997, Francis et al, 2002). Similarly, the selective 
inhibition of α1β1 integrin receptors for collagen results in impaired angiogenesis in 
ex  vivo chorioallantoic  membrane  (CAM)  assays  (Marcinkiewicz  et  al,  2003). 
Laminin peptides have also been shown to be pro-angiogenic both in vitro (Malinda 
et al, 1999) and in vivo (Kibbey et al, 1992). Conversely decorin and lumican, another 
small  leucine rich proteoglycan (SLRP),  have been shown to inhibit  angiogenesis. 
Decorin inhibits endothelial cell migration and tubule formation in vitro (Davies et al, 
2001)  and inhibits  the pro-angiogenic  effects  of  VEGF (Sulochanaet  et  al,  2005). 
Lumican interferes with α2β1 receptor activity and inhibits angiogenesis both in vitro 
and  in vivo  (Niewiarowska  et al, 2011,  Albig  et al, 2007). As previously presented 
within this thesis, MSC-CM contains factors that are both stimulatory and inhibitory 
to  cellular  processes  involved in  wound healing,  and the  presence  of decorin  and 
lumican within the MSC secretome suggest that this is also the case for the effects of 
MSC-CM on endothelial  cell  migration.  However,  similar  to  the results  shown in 
Chapter 3 using L929 fibroblasts and HaCaT keratinocytes, the net effect of ‘whole’ 
conditioned medium was stimulatory overall to EaHy-926 cells, suggesting that the 
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stimulatory  factors  present  overcome  any  inhibitory  effects  of  other  factors  also 
secreted by MSC.
Also  similar  to  the  results  observed  in  scratch-wound  assays  using  L929 
fibroblasts  presented in previous chapters within this thesis,  fibronectin coating of 
tissue culture plates lead to an enhancement of EaHy-926 endothelial cell migration 
compared  to  either  type  I  collagen  or  decorin.  This  suggests  that  fibronectin 
contributes  to  the  MSC-CM mediated  enhancement  of  endothelial  cell  migration. 
However, the addition of MSC-CM to endothelial cell scratch assays performed upon 
fibronectin  coated  culture  plates  (and  indeed  upon  plates  coated  in  collagen  and 
decorin) resulted in a further enhancement of endothelial cell migration compared to 
unconditioned  medium.  This  shows  that  whilst  fibronectin  contributes  to  the 
enhancement of endothelial cell migration, it may not be responsible for the entire 
effect. Further experiments investigating the effects of MSC secreted growth factors 
and cytokines individually, and in combination,, may reveal the relative contribution 
of MSC secreted factors to the enhancement of endothelial  cell  migration,  as was 
investigated in Chapters 4-5 for L929 and HaCaT cells. For example, IL-8, shown to 
be secreted by MSC in Chapter 3 of this thesis, and in previous studies (Chen et al, 
2008), is known to promote angiogenesis  in vivo  (Waugh and Wilson 2008). MSC 
have also been consistently shown to secrete VEGF (Chen et al, 2008, Beckermann et  
al, 2008, Wu et al, 2007), an essential mediator of angiogenesis (reviewed extensively 
in  Ferarra,  2009).  Therefore,  it  seems  reasonable  to  expect  that  these  factors 
especially would be likely to contribute to the MSC-CM mediated enhancement of 
EaHy-926 endothelial cell migration and this warrants further investigation.
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The next chapter will discuss in more detail the summary findings of this thesis and 
consider how these findings relate to the wider field, and how this work informs the 
use of the MSC secretome as a potential therapy for cutaneous wound healing.
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Chapter 7
Discussion
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7.1: Summary of Results
The results  presented within this  thesis  have shown that  the skin cell  lines,  L929 
fibroblasts and HaCaT keratinocytes, representing the cellular portion of the dermis 
and  epidermis,  respectively,  migrate  in  vitro to  close  a  scratch  wound,  and  that 
treatment with MSC-CM accelerates their closure of the wound. Proliferation of both 
cell types was enhanced by MSC-CM over 72 hours, but these proliferative increases 
were not statistically significant and were not within the time course of scratch wound 
closure. Therefore, it is reasonable to conclude that MSC secrete factors that enhance 
skin  cell  migration.  Medium  conditioned  by  either  L929  fibroblasts  or  HaCaT 
keratinocytes failed to elicit any similar enhancement of the rate of migration of either 
cell type. 
When analysed using ELISA and mass spectrometry, MSC-CM was found to 
contain  cytokines  and ECM components  (notably fibronectin,  collagen type  I  and 
decorin) that are known to play a part in cutaneous wound healing. These factors were 
individually applied to scratch wounds. TGF-β1 was found to enhance the migration 
of  L929 fibroblasts,  but  slowed the  migration  of  HaCaT keratinocytes.  The other 
cytokines  investigated,  IL-6 and IL-8,  either  had no effect  (IL-6)  or  inhibited  the 
migration of both cell types (IL-8). The ECM protein, fibronectin, was used to coat 
the surface of the culture plates, and this significantly enhanced the adherence and 
migration of both cell types compared to collagen type I. Conversely decorin, a SLRP, 
inhibited the adherence of both cell types, and the migration of HaCaT keratinocytes; 
the inhibitory effect of decorin upon L929 fibroblasts was so severe as to prevent the 
assessment of the rate of migration under these conditions. 
202
When two of the MSC secreted factors that were most stimulatory to scratch 
wound  closure  were  examined  in  combination,  i.e.  TGF-β1  and  fibronectin,  the 
presence of TGF-β1 failed to elicit any further enhancement of the migration of L929 
fibroblasts when compared with their rate of migration on fibronectin alone. Similar 
to the results  observed using TGF-β1 supplemented medium on a collagen coated 
culture surface, TGF-β1 inhibited HaCaT keratinocyte migration upon fibronectin in a 
concentration-dependent manner up to a maximum inhibition of 47 percentile points 
(53% closure compared to 100% after 12 hours in culture) at 8ng/ml of TGF-β1. The 
addition  of  MSC-CM  did  not  elicit  any  significant  enhancement  of  the  rate  of 
migration  of  L929  fibroblasts  on  fibronectin  coated  culture  surfaces.  HaCaT 
keratinocyte migration was not significantly enhanced by MSC-CM in the presence 
fibronectin in this instance. MSC-CM was also used to coat culture surfaces prior to 
scratch-wounding. This MSC-CM coating lead to an enhancement of L929 fibroblast 
migration compared to that on surfaces coated with unconditioned culture medium, 
but had no observable effect upon HaCaT keratinocyte migration.  The presence of 
EMC proteins (decorin and fibronectin) as supplements in growth medium reduced 
the rate of scratch wound closure by both L929 fibroblasts and HaCaT keratinocytes.
Similar  to  the  effects  of  MSC-CM  on  L929  fibroblasts  and  HaCaT 
keratinocytes, MSC-CM enhanced the rate of migration of EaHy-926 endothelial cells 
on culture plates  coated in  either  collagen type  I,  decorin,  or fibronectin.  Coating 
culture surfaces with MSC-CM also enhanced the adherence of EaHy-926 cells, as 
observed  by  the  degree  of  cell  spreading.  Fibronectin  coating  of  culture  plates 
enhanced  the  rate  of  migration  of  EaHy-926 endothelial  cells  compared  to  either 
decorin or type I collagen, as well as their adherence to the culture surface.
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7.2: How representative is the model system of cutaneous wound healing?
The majority of the results presented within this thesis were obtained using an in vitro 
model  of  wound  healing,  the  scratch  assay.  Briefly,  this  model  incorporated  a 
confluent monolayer of cells grown upon collagen type I coated tissue culture plastic. 
The cell layer was then scored with a sterile point to produce a ‘wound-area’ and the 
cells were observed as they repopulated the scratch.  
Cell lines were used in this assay to represent the major cellular components 
of the dermis and epidermis - L929 fibroblasts and HaCaT keratinocytes - along with 
wound vasculature using EaHy-926 cells. L929 is a sub-clone (number 929; Sanford 
et al, 1948) of a fibroblast cell line that was originally established by Earle and co-
workers in the 1940s (WR Earle, 1943). L929 fibroblasts are capable of myofibroblast 
differentiation,  as  seen  in  human  dermal  fibroblasts  in  wounded  skin  in  vivo 
(Nakamura, et al, 2004), but are murine in origin, and thus may differ markedly from 
human fibroblasts. Particulary relevant to this investigation, the receptors expressed 
by a mouse cell line may not recognise human cytokines such as those secreted by the 
human  MSC used  in  these  experiments.  HaCaT is  a  spontaneously  immortalised 
human keratinocyte cell line, (Boukamp et al, 1988). HaCaT cells have been shown to 
be  capable  of  differentiation  in  organotypic  co-cultures  to  form  a  multilayered, 
differentiated epidermis in vitro similar to that formed by normal human keratinocytes 
in  living  skin  (Kehe et  al,  1999).  However,  HaCaT keratinocytes  have a reduced 
expression  of  receptors  for  keratinocyte  growth  factor  (KGF)  and  granulocyte-
macrophage  colony-stimulating  factor  (GM-CSF)  compared  to  normal  human 
keratinocytes,  which results in delayed formation of a multilayered epithelium and 
their  incomplete  differentiation  (Maas-Szabowski  et  al,  2003,  Stark  et  al,  2004). 
EaHy-926 cells are derived from a hybridoma of primary human vascular endothelial 
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cells  with human lung carcinoma cells (Edgell  et al, 1983), and as such may also 
differ  from  primary  human  endothelial  cells.  Additionally,  the  oncogenic 
transformation of cells may involve the activation of cells by autocrine growth factor 
stimulation.
Therefore, it is important to note that these cell lines may not entirely replicate 
the behaviour of primary human cells  in vivo  and that further work to validate the 
results are of clear benefit.  However, the main purpose of these experiments was to 
use a consistent model of skin wound healing to assess the effects of MSC secreted 
factors.  The use  of  cell  lines,  as  opposed to  primary  fibroblasts,  keratinocytes  or 
endothelial cells, removed the possibility of inter-donor variability that these primary 
cells would likely present, such that the effects of the MSC-CM, which in itself was 
derived from primary normal human cells  and was therefore likely to be variable, 
could be quantified independently of this confounding factor.
The use of an in vitro model, such as the 2-dimensional scratch wound assay, 
cannot accurately replicate the conditions of living, wounded skin. In addition to the 
cell  types  that  have  been  used  in  this  work,  cutaneous  wound  healing  in  vivo is 
dependent upon numerous other cell types, i.e. neutrophils and macrophages for the 
removal of foreign material  and potential  pathogens, Langerhans cells  for immune 
surveillance,  neural  cells  for  re-innervation  within  the  wound  area,  melanocytes, 
sweat glands, and all the components of hair follicles. Furthermore, circulatory and 
haemostatic factors such as thrombus formation, immune and inflammatory events, 
i.e. complement activation, and a complex microenvironment involving numerous and 
temporally variable ECM proteins, degradatory enzymes, and trophic factors are all 
aspects of the normal wound healing process that are unrepresented within this model 
system.  These  conditions  could  be  more  accurately  replicated  in  experiments 
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undertaken using animal models, but due to the associated cost, ethical considerations 
and a perceived need for consistency in order to analyse potentially variable MSC, an 
in vitro methodology has been preferred for the work presented within this thesis. 
The results presented within this thesis support the hypothesis that MSC-CM 
can  stimulate  a  response  from the  cell  populations  present  within  skin  that  may 
enhance  processes  associated  with  cutaneous  wound  healing.  Reepithelialisation, 
leading to the re-establishment of the barrier function of skin, is dependent upon the 
migration of keratinocytes into the wound area, migration of fibroblasts is associated 
with the contraction of wound margins,  and the recruitment of endothelial  cells  is 
required for the vascularisation of a wound area, or the bed in which a graft may be 
applied. The data presented in this thesis suggest that MSC secretions would enhance 
each of these activities. In addition, the numerous factors detected within MSC-CM in 
this study are known to play significant roles within in vivo wound healing. Therefore, 
this  body  of  work  supports  the  hypothesis  that  MSC-secreted  factors  may  be 
beneficial to wound healing. However, further study is required using primary human 
responder cells or in vivo models in order to verify this conclusion.
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7.3: What are the advantages of using MSC secreted components?
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Mesenchymal  stem cells  have shown potential  to  assist  in the repair  of numerous 
damaged tissues,  either  through their  differentiation potential  or paracrine activity. 
Several studies have demonstrated that MSC can enhance cutaneous wound healing 
(Sasaki  et al, 2008, Falanga  et al, 2007, Vojtassák  et al, 2006) and MSC secreted 
factors can elicit this enhancement in the absence of the MSC themselves (Chen et al, 
2008,  Kim  et  al,  2007).  The  results  presented  within  this  thesis  support  the 
interpretation that it is the paracrine activity of MSC that is effective in skin wound 
healing. This has important applications to the nature of the therapeutic use of MSC. 
Whilst,  thus  far,  clinical  trials  involving MSC transplantation  into human patients 
have demonstrated safety (Ghannam  et al, 2010, Centeno  et al, 2009, Tarte  et al, 
2009),  reports  exist  that  suggest  MSC  are  capable  of  undergoing  spontaneous 
malignant transformation in vitro (Rubio et al, 2005, Rubio et al, 2008, Rosland et al, 
2009) and can form solid tumours  in vivo  (Wang  et al, 2005, Li  et al, 2007). The 
possible malignant transformation of human MSC remains a topic of some debate and 
two of the aforementioned papers were since retracted by multiple  of the original 
authors  following  the  identification  of  cross-contamination  of  MSC cultures  with 
tumour  cell  lines  (De la  Fuente  et  al,  2010,  Torsvick  et  al,  2010).  Human  MSC 
transformation appears to be something of a rarity stemming from exceptional periods 
in  culture  (Lazennec  and  Jorgensen,  2008).  Nonetheless,  the  possibility  of  such 
malignancy arising from MSC culture raises a serious caveat regarding the clinical 
use of MSC. If,  as these results  and other previous reports  suggest,  the beneficial 
effects of MSC may be harnessed from their secreted components without the need to 
transplant  living  cells,  then  this  would  circumvent  the  question  of  spontaneous 
malignant MSC transformation and the associated risk to patients.
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The results presented within this thesis support the hypothesis that MSC-CM 
can  stimulate  a  response  from the  cell  populations  present  within  skin  that  may 
enhance processes associated with cutaneous wound healing. Reepithelialisation, the 
essential the re-establishment of the barrier function of skin, is dependent upon the 
migration  of  keratinocytes  into  the  wound  area.  The  migration  of  fibroblasts  is 
associated with the contraction of  wound margins, and the recruitment of endothelial 
cells is required for the vascularisation of a wound area, or the bed in which a graft 
may be applied. In addition to the reported effects of MSC-CM upon the cell lines, the 
numerous factors detected within MSC-CM in this study are known to play significant 
roles  within  in  vivo wound  healing  and  have  in  many  instances  been  shown  to 
stimulate  cell  responses  in  in  vitro models  by  other  investigations  referred  to 
throughout this thesis. This body of work, to which this thesis contributes, supports 
the hypothesis that MSC-secreted factors may be beneficial to wound healing in the 
absence of the cells themselves.
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7.4: Why investigate co-cultures of L929 fibroblasts and HaCaT keratinocytes? 
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Beginning  with  the  initial  development  of  skin,  the  behaviour  of  the  dermal  and 
epidermal  cells  that  make  up  the  organ  are  intrinsically  liked  to  one  another. 
Intracellular  signalling  between  the  mesenchymal  and epithelial  cells  (via  TGF-β, 
BMP  and  Notch)  determines  the  formation  of  the  epidermis,  hair  follicles  and 
sebaceous  glands  from  epithelial  precursors  (Fuchs  and  Horsley,  2008).  This 
interaction continues and is essential for both the maintenance of skin homoeostasis 
and the process of skin wound healing. Keratinocytes have been shown to modulate 
the production and degradation of collagen by dermal fibroblasts through TNF-α and 
IL-1 signalling and the regulation of MMP expression (Tandara and Mustoe, 2011), 
and fibroblasts have been shown to profoundly influence keratinocyte proliferation 
and differentiation as well as their deposition of basement proteins (El Ghalbzouri et  
al 2002).  Paracrine interaction  between dermal  and epidermal  cell  types  has  been 
shown to affect their behaviour in in vitro models of skin wound healing. In fibroblast 
and keratinocyte co-culture experiments, fibroblasts were shown to up regulate the 
expression of IL-1 receptor compared to mono-cultures, whilst keratinocytes showed 
increased expression of IL-1. Similarly keratinocytes in co-culture up regulated KGF 
receptor whilst fibroblasts increased their expression of KGF (Maas-Szabowski et al, 
2000).  The  presence  of  both  cell  types  lead  to  enhanced  cell  migration  and 
proliferation. Observing the effects of this interaction  in vitro, Maas-Szabowski and 
co-workers suggested  that epidermal tissue regeneration in organotypic co-cultures is 
regulated by keratinocyte derived interleukin-1 signalling, which induces keratinocyte 
growth  factor  expression  in  co-cultured  fibroblasts.  Similarly,  as  previously 
mentioned,  the enhancement of skin wound healing by IL-6 observed  in vivo  was 
shown  in  vitro to  be  dependent  on  paracrine  interactions  between fibroblasts  and 
keratinocytes,  as  IL-6 induced the  secretion  of  keratinocyte-stimulating  factors  by 
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fibroblast cells, whilst having no effect on keratinocyte mono-cultures (Gallucci et al, 
2004).
The  MSC-CM  mediated  in  vitro enhancement  of  skin  wound  healing 
demonstrated within Chapter 3 of this thesis was observed in both fibroblasts and 
keratinocytes. The migration of both of these cell types is essential for effective  in  
vivo wound healing,  as  fibroblasts  move into the wounded skin from surrounding 
undamaged  tissue  and  contract  the  wound  margins,  reducing  the  area,  whilst 
keratinocytes migrate across granulation tissue and new ECM to re-epithelialise the 
wound  surface  (Sorrell  &  Caplan  2004).  As  these  processes  are  directly  related 
(fibroblast migration contributes to reducing the area that needs covering by migrating 
keratinocytes), it seems reasonable to speculate as to whether enhancing the migration 
of either cell type individually would lead to the other becoming the limiting factor to 
the overall rate of wound healing. By this argument, the enhancement of the rate of 
migration of both fibroblasts  and keratinocytes (as was seen in this  in vitro model) 
might contribute further to the healing of cutaneous wounds than an enhancement of 
the migration of either cell type individually.
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7.5: The influence of MSC secreted cytokines on wound healing
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Of the MSC-secreted cytokines investigated within this thesis, some displayed little or 
no enhancement of skin wound healing, and indeed appeared to be actively inhibitory 
to  the  migration  of  L929  fibroblasts  and/or  HaCaT keratinocytes.  This  inhibitory 
activity  may have unwelcome  implications  for  the  use  of  MSC-CM to  treat  skin 
wounds  clinically,  as  impaired  fibroblast  and keratinocyte  migration  would  likely 
limit the rate of wound healing. However, it is important to note that the migration of 
these cells is only one important aspect in the complex process of cutaneous wound 
repair and that the overall wound healing activity of the MSC-secreted cytokines may 
well differ  in vivo through their effects on other aspects of the healing process. For 
example,  IL-8  was  shown  to  inhibit  L929  fibroblast  scratch  wound  closure 
significantly, and to also inhibit scratch wound closure by HaCaT keratinocytes, albeit 
to  a  lesser  degree.  Despite  this  finding,  suggesting  an  inhibitory  activity  for  the 
chemokine,  IL-8 is  thought  to  play  a  role  in  numerous  stages  of  wound healing,  
essentially including chemoattraction of neutrophils (Baggolini et al., 1994, Schroder 
et al., 1993). Overall IL-8 expression reaches peak levels within one day of wound 
occurrence and correlates with the rapid influx of neutrophils to the wound area, along 
an increasing IL-8 concentration gradient (Engelhardt et al., 1998). Initially expressed 
by skin cells in response to PDGF,   IL-8 is subsequently secreted by neutrophils, 
further stimulating neutrophil recruitment (Clark, 1993). This increased expression of 
IL-8 normally resolves within 4 days of wound healing, often corresponding with the 
complete reepithelialisation of normal wounds (Engelhardt et al., 1998). Contrary to 
the  current  findings,  IL-8  has  been  shown  to  be  involved  in  the  stimulation  of 
keratinocyte  migration  and proliferation  (Rennekamff  et  al., 1997,  2000).  Topical 
application of IL-8 enhanced the rate of reepithelialisation and reduced the degree of 
contracture in in vivo wounds, despite having no effect upon the migration of cultured 
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keratinocytes  in  vitro (Rennekampff  et  al., 2000).  In  contrast,  excessive  IL-8  is 
associated with non-healing wounds, and has been shown to retard the proliferation of 
keratinocytes  and  to  impair  the  contractile  activity  of  dermal  fibroblasts  in  vitro 
(Iocono  et al., 2000). Diminished expression of IL-8 is associated with the scarless 
wound  healing  characteristic  of  foetal  wounds  (Liechty  et  al., 1998),  whereas  a 
topical application of IL-8 has been shown to reduce wound contracture and in vivo as 
is  consistent  with  the  aforementioned  in  vitro study  by  Ionoco  and  co  workers 
(Rennekampff et al., 2000). 
IL-8 is known to promote angiogenesis  in vivo (Waugh and Wilson, 2008). As the 
vascularisation of the wound area is also an important  factor in successful wound 
healing,  and,  indeed,  a  lack  of  neo-vasculature  is  characteristic  of  non-healing 
‘chronic’ wounds, it is possible that the presence of IL-8 in MSC-CM may contribute 
to  the  overall  wound healing  effects  of  MSC secreted  factors  in  vivo  through its 
angiogenic activity. There exist various techniques available for the investigation of 
this  hypothesis,  including  ex vivo  angiogenesis  models,  e.g. the chick CAM assay 
(Okamoto  et al.,  1988, Ribatti  et al., 2011), in  vitro assays, e.g. tubule formation in 
Matrigel (Khoo et al., 2011), as well as the use of in vivo wound healing models, e.g. 
following the creating of defined skin wounds in rodents or larger bodied animals. 
Hence,  in  clinical  wound  healing,  MSC  secreted  IL-8  could  have  particular  and 
important applications, e.g. in promoting angiogenesis to increase the success of skin 
grafts  and  following  the  application  of  tissue  engineered  constructs,  as  well  as 
enhancing  the  proliferation  and  migration  of  keratinocytes,  thereby  accelerating 
reepithelialisation.  However,  such  potential  advantages  must  be  balanced  with  a 
consideration  of  the  aforementioned  inhibitory  actions  of  IL-8  upon  wound 
contraction and its association, in excess, with non-healing wounds.
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Similarly,  IL-6  did  not  elicit  any  enhancement  of  skin  wound  healing  in  these 
experiments, but as mentioned in Chapter 4, has been shown to induce fibroblasts to 
produce factors capable of stimulating keratinocyte migration (Gallucci  et al, 2004). 
This being the case, it seems reasonable to suggest that the presence of IL-6 in MSC-
CM might contribute to skin wound healing in an  in vivo scenario where both cell 
types are present, yet not appear to influence an in vitro assay such as this one, using 
single cell cultures. MCP-1 and RANTES, which were secreted cytokines both found 
in MSC-CM by ELISA, were not investigated using this  model,  as they were not 
expected to influence L929 fibroblast or HaCaT keratinocyte behaviour. Rather, these 
factors  are  thought  to  influence  cutaneous  wound  healing  in  vivo  by  attracting 
macrophages and other immune cells  to the wound site, that were not used in the 
model system (Dipietro et al, 2001).
Transforming Growth Factor (TGF)-β1 marginally enhanced the migration of 
L929  fibroblasts  on  collagen  coated  culture  surfaces,  but  had  no  effect  on  their 
migration on fibronectin coated surfaces. TGF-β1 also inhibited the rate of migration 
of HaCaT keratinocytes. Cytokines can often induce different effects when present in 
different combinations, but if this is indeed the same effect that TGF-β1 has when 
present in MSC-CM, it stands to reason that another factor or combination of factors 
within the MSC secretome may stimulate HaCaT keratinocyte migration sufficiently 
to ameliorate this inhibitory effect, resulting in the overall enhancement of HaCaT 
keratinocyte migration seen in the presence of ‘whole’ MSC-CM.
Although not represented in this model system, scarring is an important aspect 
of cutaneous skin wound healing. The balance of growth factors within the wound 
milieu is especially relevant to the degree of scarring that remains after wound closure 
in  vivo. Specifically,  the balance  of TGF-β1 to TGF-β3 appears  to  influence scar 
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formation, with the scarless wound healing associated with foetal skin repair being 
characterised by a reduction in the former, and an increase in the latter. Similarly, the 
addition of exogenous TGF-β3, or the neutralisation of TGF-β1 has been shown to 
reduce scarring in adult rodents (Shah  et al, 1994, Shah  et al, 1995). With this in 
mind,  there  may  be  a  possibility  that  TGF-β1  present  within  MSC-CM  could 
contribute to more severe scarring if used to treat wounds clinically. In many cases 
this would be undesirable, especially in the case of wounds that occur over joints and 
following severe burns, as these are prone to contractures that in addition to being 
aesthetically unpleasant can be physically disabling.  However,  in the case of non-
healing chronic wounds it may be that overcoming the impaired healing process and 
achieving  the  complete  closure  of  a  persistent  wound could  render  the  degree  of 
scarring a secondary concern. Conversely,  it could be possible that the addition of 
exogenous  TGF-β3  to  MSC-CM  (or  incorporated  into  an  MSC-CM  derived 
therapeutic agent) might allow for the balancing of these growth factors in such a way 
as to reduce or even eliminate excessive scarring following wound healing, or the 
contracture  often  seen  around  the  margins  of  autologous  skin  grafts  or  tissue 
engineered constructs.
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7.6 The influence of MSC secreted extracellular matrix on wound healing
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The  four  MSC-CM  analysed  by  MALDI-TOF/TOF  mass  spectrometry  showed  a 
degree of variation in the detectable ECM components, and whilst collagen type I, 
collagen type VI and fibronectin were detected in each, collgen type V, collagen Type 
XII and laminin were only detected in 1/4 samples,   COMP and  IGFBP-7 in 2/4 
samples, Lumican and SPARK in 3/4 samples each. These different compositions of 
MSC-CM  might  go  some  way  to  explaining  the  degree  of  variability  between 
individual  MSC-CM and their  effects  upon skin cell  behaviour  within the models 
described in this thesis. Of the MSC secreted ECM components examined, fibronectin 
appeared  to  have  the  greatest  beneficial  effect,  whereas  decorin  was  inhibitory. 
Coating  culture  surfaces  with  fibronectin  significantly  enhanced  L929  fibroblasts 
ability to adhere to the surface, and also enhanced the rate of migration of these cells 
into  the  wound  area.  The  degree  of  enhancement  of  L929  migration  seen  in  the 
presence of fibronectin was equivalent to the enhancement by MSC-CM, and indeed 
neither the addition of exogenous TGF-β1 nor the addition of ‘whole’ MSC-CM to 
scratch wounds performed upon fibronectin coated culture surfaces managed to elicit 
any  further  enhancement  of  L929  fibroblast  migration.  Similarly,  HaCaT 
keratinocytes closed scratch wounds at a similar rate in MSC-CM or unconditioned 
medium when upon fibronectin coated culture surfaces. This suggests that the MSC-
CM mediated enhancement of scratch wound closure described in Chapter 3 may be 
mostly  due  to  the  presence  of  fibronectin  within  the  MSC secretome.  This  is  in 
agreement with a previous report showing that a topical  application of fibronectin 
enhanced  wound  healing  in  vivo  in  rodents  (Kwon  et  al, 2007).  It  would  be  of 
enormous  interest  to  compare  the  effects  of  topical  fibronectin,  MSC-CM  and, 
perhaps MSC (i.e. the cells themselves), upon cutaneous wound healing in vivo. The 
incorporation of MSC into such a comparative study would allow the contribution of 
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any engraftment and/or differentiation of these cells into skin tissues, or effects driven 
by direct contact between MSC and the local skin cell populations, to be taken into 
consideration.  This  will  also  inform our  knowledge  of  the  efficacy  of  MSC cell 
transplantation, compared with that of an application of MSC-CM or fibronectin.
It is possible that the influence of fibronectin upon cutaneous wound healing 
might  be  somewhat  lessened  in  the  case  of  chronic  wounds,  where  the  over-
expression of proteolytic enzymes may lead to its degradation before any beneficial 
effects  can  be  conferred.  That  said,  the  various  protein  domains  that  comprise 
fibronectin are known to influence a range of cell functions including cell adhesion, 
cell  migration,  cell  proliferation,  cell  differentiation,  chemotaxis,  tissue-remodeling 
and overall wound healing (Grinnell, 1984, Pankov and Yamada, 2002). In one recent 
study, a recombinant protein comprising two fibronectin derived adhesion motifs for 
integrins, Pro-His-Ser-Arg-Asn (PHSRN) and Arg-Gly-Asp (RGD) was reported to 
improve  fibroblast  and  keratinocyte  migration  and  adherence  in  vitro,  as  well  as 
enhancing skin wound healing  in vivo in rabbits (Jung  et al, 2007). Therefore, the 
nature and/or degree of any proteolytic digestion, the location of cleavage sites, and 
the resulting breakdown products that are generated might  influence the effects  of 
fibronectin upon cutaneous wound healing in the presence of the proteinases that are 
over-expressed in chronic wounds. 
The inhibitory effect of decorin on fibroblasts and keratinocytes seen in these 
investigations may be of relevance in vivo. Decorin binds to both collagen type I, and 
is  upregulated  in  wound  healing  (Yeo  et  al, 1991).  As  discussed  in  Chapter  4, 
previous  studies  suggest  variable  effects  of  decorin,  on  skin  cells  and on overall 
wound healing (Merle et al, 1997, Schmidt et al, 1987, Järveläinen et al, 2006). This 
suggests that decorin is involved in processes that affect cutaneous wound healing and 
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that the nature of this influence warrants further study. However, in the context of 
‘whole’ MSC-CM the influence of potentially inhibitory factors does not prevent an 
overall enhancement of the rate of wound healing.
The results observed in experiments involving both soluble and surface bound 
fibronectin  and decorin suggest a regulatory role  for each molecule  in  the wound 
healing response, and possibly a competitive adhesion blocking affect in the case of 
soluble fibronectin. These data seem to show that neither meolecule accounts for the 
effects of MSC-CM observed  in vitro,  although fibronectin may contribute to some 
degree.
221
7.7 The effects of MSC secreted factors on endothelial cells
Angiogenesis,  the  formation  of  new  vasculature,  depends  on  endothelial  cell 
migration and the actions of endothelial cell chemotactic factors (Folkman and Shing, 
1992, Lanza, et al, 2007, Ferrara, 2009, Waugh and Wilson, 2008), and ECM proteins 
(Campbell  et al, 2010). Many of these pro-angiogenic factors have been found to be 
present  within  the  MSC  secretome,  both  within  this  thesis,e.g.  IL-8,  collagens, 
fibronectin  and  laminin,  and  in  previous  studies,  e.g.  VEGF (Chen  et  al.,  2008). 
VEGF was  not  detected  in  the  current  study either  by ELISA or  using  MALDI-
TOF/TOF; this may have been due to differences in experimental protocol, e.g. in the 
generation of the MSC CM or limitations of the assay techniques used. As described 
previously,  angiogenesis is an important feature of skin wound healing.  Therefore, 
this thesis has investigated the effects of MSC secreted factors upon the adhesion and 
migration  of  EaHy-926  cells,  an  endothelial  cell  line  (Edgell  et  al,  1983).  These 
experiments  showed  that  MSC-CM  enhanced  both  the  rate  of  endothelial  cell 
migration and the adherence of these cells to their culture surface, and that this effect 
was in part, but not entirely, mediated by the presence of fibronectin within the MSC 
secretome, as detected by MALDI/TOF/TOF mass spectrometry. Other studies have 
also highlighted a role for fibronectin in stimulating angiogenesis (Yang et al, 1993, 
Goh  et  al, 1997,  Francis  et  al, 2002),  demonstrating  that  RGD  peptides  within 
fibronectin  can  trigger  integrin  receptors  that  mediate  the  angiogenic  actions  of 
endothelial cells. The effects of MSC-CM upon endothelial cell migration were not 
entirely reproduced by fibronectin, as suggested by the further enhancement of EaHy-
926 endothelial cell migration by MSC-CM, compared to unconditioned medium, in 
the presence of exogenous fibronectin. Interleukin (IL)-8, VEGF, and laminin, also, 
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have  all  been  shown to  be  stimulatory  to  endothelial  cells  (Malinda  et  al,  1999, 
Kibbey et al, 1992, Ferrara, 2009, Waugh and Wilson, 2008). Investigations presented 
within Chapters 3 and 6 of this  thesis  as well  as other studies (Chen  et al, 2008, 
Beckermann et al, 2008, Wu et al, 2007) have found these factors to be present within 
MSC-CM. It seems likely that some or all of these known mediators of angiogenesis 
might contribute to the effects of MSC-CM upon EaHy926 endothelial cells. 
In addition to insufficient vascularisation of wound beds contributing to the failure of 
grafts  used  to  treat  cutaneous  wounds,  any  engineered  skin  tissue  constructs 
containing living cells are limited to a 3mm3 volume in the absence of vasculature if 
the  cells  are  to  be maintained  by the  diffusion  of  nutrition  from the  surrounding 
tissues (Folkman and Hochberg,  1973).  If  the incorporation of MSC or MSC-CM 
derived factors into tissue engineered skin constructs could stimulate the formation of 
new vasculature into the graft, this would increase the amount of viable engineered 
tissue  that  could  be  implanted,  potentially  enhancing  the  effectiveness  of  tissue 
engineering strategies for cutaneous wound healing. It is has also been shown that as 
well  as  MSC  secreting  fibronectin  and  collagen  (ECM  proteins  that  promote 
angiogenesis),  the presence of MSC supports the survival of blood vessels formed 
within fibronectin and collagen rich environments (Koike et al, 2004). 
Overall, the data presented here supports the hypothesis that MSC may stimulate the 
formation  of new vasculature,  and that this  may be an important  aspect  of MSC-
mediated enhancement of wound healing. These findings also lends further support to 
the potential use of MSC as a clinical therapeutic agent for the treatment of severe or 
chronic cutaneous wounds, or in conjunction with conventional or tissue engineered 
skin grafts.
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7.8: Conclusion
The  results  presented  within  this  thesis  demonstrate  an  MSC-CM  mediated 
enhancement  of  skin  cell  migration,  consistent  with  previous  reports  that  MSC 
secreted factors promote skin wound healing, and reveal a range of components of the 
MSC secretome that  may contribute  to  this  effect.  In  particular,  fibronectin  when 
present as a substratum for cells appeared to be beneficial, stimulating scratch wound 
closure by all  cell  types  investigated,  although it's  presence as a  soluble factor  in 
culture medium had no beneficial effects upon scratch closure. This work is clearly 
limited to a simple model wound healing and cell migration, the scratch assay.  As 
such  the  results  presented  herein  are  not  necessarily  representative  of  the  full 
spectrum of in vivo processes involved in wound healing, but, nonetheless, the study 
reveals specific effects of MSC-CM and its constituent components upon the specific 
aspects  of  wound  healing  that  are  modelled  by  this  system.  Additionally,  the 
experiments presented in this thesis were performed independently either twice and 
the  data  pooled,  or  only  once  but  using   three  individual  donor's  MSC cultures. 
Therefore  further  independent  experimentation  is  required  to  establish  the 
reproducibility  of  these  findings.  The  study  is  further  limited  by  the  use  of 
transformed cell lines to model the behaviour of primary cells in vivo, and particularly 
by the use of a murine transformed cell  line in a system that is otherwise largely 
composed of human cells or derived factors. Whilst the cell lines used will not be 
fully representative of the behaviour of untransformed cells, and indeed may show 
limited responsiveness to stimulatory factors for this reason, their use did allow for a 
more consistent evaluation of the potentially variable factor, MSC-CM. which would 
not necessarily have been the case using normal human fibroblasts and keratinocytes. 
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Further work is now required to establish that normal human skin cells respond to 
MSC secreted factors in a similar manner and to identify which factors contribute to 
this stimulatory effect and the precise mechanisms involved. To validate these results, 
as  well  as  future  factors  of  interest,  it  would  be  advantageous  to  develop  more 
sophisticated in vitro models of wound healing or examine in vivo.
Pursuant  to  the  eventual  goal  of  MSC-derived  therapies  of  skin  wound 
healing, future investigation should also attempt to evaluate the most effective method 
of delivering this beneficial effect within a clinical context. Topical applications of 
MSC-CM, or of selected stimulatory factors, to a wound site may be effective, but 
equally, the delivery of living cells within biomaterial scaffolds, potentially acting as 
a ‘cytokine factory,’ might also enhance wound healing. A comparison of the efficacy 
of a range of such methods would inform the clinical utilisation of the ability of MSC 
derived factors to stimulate cutaneous wound healing.
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Summary model diagram.
Representative illustration summarizing the effects of MSC-CM, and MSC-secreted 
cytokines  and  ECM  proteins  upon  the  experimental  cell  lines  under  various  test 
conditions  as  investigated  within  this  thesis.  ▲ represents  a  stimulatory  effect,▼ 
represents an inhibition, ▬ represents no observable/significant effect.
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We have used in vitro scratch assays to examine the relative contribution of dermal fibroblasts and
keratinocytes in the wound repair process and to test the influence of mesenchymal stem cell
(MSC) secreted factors on both skin cell types. Scratch assays were established using single cell
and co-cultures of L929 fibroblasts and HaCaT keratinocytes, with wound closure monitored via
time-lapse microscopy. Both in serum supplemented and serum free conditions, wound closure
was faster in L929 fibroblast than HaCaT keratinocyte scratch assays, and in co-culture the L929
fibroblasts lead the way in closing the scratches. MSC-CM generated under serum free conditions
significantly enhanced the wound closure rate of both skin cell types separately and in co-culture,
whereas conditioned medium from L929 or HaCaT cultures had no significant effect. This
enhancement of wound closure in the presence of MSC-CM was due to accelerated cell migration
rather than increased cell proliferation. A number of wound healing mediators were identified in
MSC-CM, including TGF-β1, the chemokines IL-6, IL-8, MCP-1 and RANTES, and collagen type I,
fibronectin, SPARC and IGFBP-7. This study suggests that the trophic activity of MSC may play a
role in skin wound closure by affecting both dermal fibroblast and keratinocyte migration, along
with a contribution to the formation of extracellular matrix.
© 2010 Elsevier Inc. All rights reserved.
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Introduction
Skin damage can occur as a result of burns, cuts, abrasions and
ulcers to varying degrees of severity. If not repaired, any breach of
the skin may compromise its barrier function and expose the
body's tissues to microbial infections and mechanical damage. The
healing of cutaneous wounds requires complex interactions
between the dermal and epidermal cells, the extracellular matrix
(ECM), and the nervous and vascular components of the damaged
and surrounding skin [1,2]. In the course of wound healing,
keratinocytes migrate from the basal population around the
wound edge to cover the lesion and restore the barrier function
of the skin and, once the wound area is covered, contact inhibition
triggers their differentiation to a basal phenotype of stratified
squamous keratinizing epidermal cells [2]. Also migrating into the
wound site are dermal fibroblasts. The dermal fibroblasts
differentiate into myofibroblasts in response to macrophage-
derived cytokines such as TGF-β1, which is dependent on their
contact with fibronectin [3]. The myofibroblasts also synthesise
provisional ECM composed of fibronectin and hyaluronan and
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provide the motive force required for skin wound contraction [4].
As wound healing progresses, the myofibroblasts begin to die via
apoptosis and are replaced by a second wave of dermal fibroblasts
from the surrounding tissue, which produce a new collagenous
ECM [5].
Mesenchymal stem cells are multipotent cells derived from a
variety of tissues [6–8] which have been reported to have
therapeutic potential following transplantation in humans with
osteogenesis imperfecta [9], bone fracture [10], traumatic brain
injury [11], stroke [12], amyotrophic lateral sclerosis [13], graft-
versus-host disease [14,15], or myocardial infarction [16,17]. In
injuries to skin, pre-clinical animal studies have shown that MSC
transplantation enhances wound healing [18], and two reports
have suggested that increased wound healing also occurs when
MSC are applied to humans with acute wounds (after treatment
for skin cancer) [19] or with lower extremity chronic skin wounds
[19,20]. The mechanisms responsible for enhanced wound healing
in the skin include the possible trans-differentiation of MSC to
form cells of epidermal and dermal lineages [18,21], along with
restorative paracrine effects of MSC synthesised growth factors
[21]. However, despite evidence supporting the capacity of MSC to
differentiate or trans-differentiate along a variety of cell lineages
[22], the low levels of MSC engraftment after transplantation may
indicate that their beneficial effects are more likely mediated via
their secretion of soluble factors than via their long-term presence
in repaired tissue [23]. For example, Chen et al. demonstrated that
growth medium conditioned by murine bone marrow-derived
MSC contained high levels of secreted cytokines and was sufficient
to stimulate macrophage and endothelial migration and enhance
cutaneous wound healing in vivo in Balb/C mice [24]. In other
studies, Kim et al. have shown that adipose-derived MSC also
stimulated human dermal fibroblasts via paracrine effects and
significantly reduced the wound size and promoted re-epithelia-
lisation in an in vivo model [25].
In this study, we have examined the effects of culture medium
conditioned by human bone marrow-derived MSC on an in vitro
skin wound healingmodel. We have used the scratch wound assay
[26,27], wherein a confluent monolayer of L929 dermal fibroblasts
and/or HaCaT keratinocytes was scored with a sterile point and
the cells were observed using time-lapse microscopy as they
repopulated the scratch area, effectively healing the wound.
Through this analysis we have shown that MSC secreted factors
in culture that stimulated L929 fibroblast and HaCaT keratinocyte
migration to enhance wound closure. We have subsequently
identified a number of targets present in MSC-CM that may bring
about this effect. In addition, we report that MSC also synthesised
several ECM proteins that may contribute directly to tissue
formation in the wound healing response.
Materials and methods
Cell culture
The L929 dermal fibroblast cell line [28] and HaCaT keratinocyte cell
line [29] were used as cell model systems, where stocks of both cell
types were maintained under exponential growth in DMEM/F12
(Invitrogen, Paisley UK) culture medium, supplemented with 10%
foetal calf serum (FCS) and antibiotics (penicillin/streptomycin —
Invitrogen), at 37 °C and in a humidified atmosphere containing 5%
CO2. Human MSC were derived from iliac crest biopsies and
expanded in monolayer culture through passage II. The MSC
characterisation that we have performed of these stromal cell
populations at passage II–III has been described previously. In brief,
these cells have been shown to be CD34 immunonegative, CD45
immunonegative and CD105 immunopositive by flow cytometry,
and were capable of chondrogenic, osteoblastic and adipogenic
differentiation using established protocols [30]. Conditioned medi-
um was generated from MSC cultures in serum free DMEM/F12
medium supplemented with insulin, transferring, selenium (ITS-X,
Invitrogen) and antibiotics when cultures were approximately 70%
confluent, then removed after 72 h and all cellular debris were
removed by filtration (0.2 μ filter). The number of MSC present in
theseMSC cultureswas 698,500 (±19,020) (mean±SEM) per flask.
Serum free conditioned medium (DMEM/F12/ with ITS-X) was
similarly generated after 72 h from L929 and HaCaT cultures when
approximately 70% confluent,which in both cases equated to greater
than 1 million cells per flask.
Scratch wound assays
24 well tissue culture plates were collagen-coated by incubation in
0.2 mg/ml of collagen type I solution (Sigma, Dorset UK) for 2 h at
37 °C before rinsing with phosphate buffered saline (PBS, Invitro-
gen). In co-culture experiments, different cell types were distin-
guished by fluorescent tagging, using green and red linker kits
(PKH26 or PKH67, Sigma). Each well was seeded with cells
(keratinocytes, fibroblasts or both) to a final density of 100,000
cells per well (with co-cultures containing equal numbers of each
cell type) and these were maintained at 37 °C and 5% CO2 for 24 h
to permit cell adhesion and the formation of a confluent
monolayer. These confluent monolayers were then scored with a
sterile pipette tip to leave a scratch of approximately 0.4–0.5 mm
in width. Culture medium was then immediately removed (along
with any dislodged cells). The removedmediumwas replacedwith
(i) a fresh serum supplemented culture medium (10% FCS), or (ii)
with a fresh serum free culture medium, or (iii) with the
conditioned medium which had been generated from MSC
cultures under serum free conditions (MSC-CM) or L929-CM or
HaCaT-CM, as described above. All scratch assays were performed
in quadruplicate.
Microscopy, image capture and analysis
Wound closure was monitored by collecting digitised images at
various time intervals after the scratch was performed until
closure was either complete or no longer progressing. Digitised
images were captured with an inverted microscope (Nikon Eclipse
TS100, Nikon, Kingston-upon-Thames, UK) and digital camera
(C4742-95, Hamamatsu photonics, Welwyn Garden City, Hert-
fordshire, UK) under phase or fluorescence. The digitised images
were then analysed using Image-J software [31] to measure the
width of the scratch at previously defined points along its length,
i.e. at 0.01, 0.15, and 0.3 mm along the vertical axis of the image
(which equated to the top, middle and bottom of the field of view).
Digitised images were also obtained using the Cell IQ automated
image capture system, (Chip-Man Technologies, Tampere,
Finland) in which pre-selected fields were imaged using phase
and red and green fluorescence microscopy on a continuous loop
until wound closure was complete. Data has been presented as the
1272 E X P E R I M E N T A L C E L L R E S E A R C H 3 1 6 ( 2 0 1 0 ) 1 2 7 1 – 1 2 8 1
extent of wound closure, i.e. the percentage by which the original
scratch width has decreased for each given time point. During
these scratch assays L929 and HaCaT cell numbers weremonitored
using the Cell IQ automated cell counting and tracking protocol
(Chip-Man Technologies).
Cell proliferation
The influence of MSC-CM on L929 and HaCaT cell proliferation was
tested using the MTS (3-(4, 5-dimethylthiazol-2-yl)-5-(3-carbox-
ymethoxyphenyl)-2-(4-sulfophenyl)-2H-tetrazolium) assay [32].
Fig. 1 – L929 dermal fibroblasts closed scratch assay woundsmore rapidly than HaCaT keratinocytes. a) The extent of wound closure
in scratch assays of L929 fibroblasts or HaCaT keratinocytes at 12 h in cultures with 10% FCS. Data shown are the means (±SEM),
*p<0.05. b) In serum supplemented co-cultures, the L929 fibroblasts migrated into the “wound area” more rapidly than HaCaT
keratinocytes when in co-cultures. Representative images are shown of the progression of wound closure at 12 h and 72 h, at which
time the L929 fibroblasts (fluorescently-labelled green) can be seen to fill the wound area almost to the exclusion of the HaCaT
keratinocytes (fluorescently-labelled red). Original magnification ×100.
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Fig. 2 – L929 dermal fibroblasts closed scratch assay wounds more rapidly than HaCaT keratinocytes in the absence of serum. a) The
extent of wound closure in scratch assays of L929 fibroblasts or HaCaT keratinocytes at 12 h in cultures without serum
supplementation. Data shown aremeans±SEM, *p<0.05. b) In serum free co-cultures, similar to the serum supplemented cultures,
the L929 fibroblasts (fluorescently-labelled green) migrated into the “wound area” prior to the HaCaT keratinocytes
(fluorescently-labelled red), such that at complete closure the fibroblasts appeared to fill the wound. Representative images are
shown of the progression of wound closure throughout the time course of wound closure. Original magnification ×100.
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Cells were seeded into 96 well plates in the DMEM/F12 culture
medium containing 10% FCS at a seeding density of 10,000 cells per
well, incubated for 2 h at 37 °C (to permit cell adhesion) and then
washed repeatedly in serum free medium. Cells were then main-
tained in either serum free medium or in each of the three separate
samples of MSC-CM (i.e. from 3 different donor MSC cultures). The
relativenumber of viable cells present at the24, 48and72 hour time-
points following this treatment was subsequently determined by
adding theMTS solution for 3 h, the absorbancewas read at 490 nm.
Each assay was performed with 5 replicate wells for each condition.
Fig. 3 –MSC-CM enhanced the rate of wound closure by L929 fibroblasts. a) Representative time-lapse images of L929 scratch assays
immediately after the scratches had been made and then after 9 h in the presence of serum free MSC-CM versus control medium.
In the presence of MSC-CM, wound closure was complete at this time. Original magnification ×100. b) There was a significant
increase in the extent of wound closure in L929 scratch assays inMSC-CM comparedwith the controlmedium at 9 h. Data shown are
means±SEM, *p<0.05.
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Analysis of MSC-CM content
Cytokines and matrix molecules in MSC-CM were analysed by
commercial ELISA multi arrays (SA Biosciences, Frederick, MD,
USA) according to the manufacturer's guidelines, and MALDI-TOF/
TOF mass spectrometry. For MALDI-TOF/TOF mass spectrometry,
2 ml of medium was incubated with 40 μl of Strataclean resin for
30 min at room temperature. Unbound supernatant was removed
Fig. 4 –MSC-CM enhanced the rate of wound closure by HaCaT keratinocytes. a) Representative time-lapse images of HaCaT scratch
assays immediately after the scratches had been made and then after 27 h in the presence of serum free MSC-CM versus control
medium. In the presence of MSC-CM, wound closure was nearly complete at this time. Original magnification ×100. b) There was a
significant increase in the extent of wound closure in HaCaT scratch assays in MSC-CM compared with the control medium at 27 h.
Data shown are means±SEM, *p<0.05.
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and 1 µg of trypsin (porcine sequencing grade — Promega,
Southampton, UK) was added to the resin/bound proteins and
incubated overnight at 37 °C. The sample was centrifuged at
13,000 rpm for 5 min to recover the tryptic peptides. The tryptic
peptides (20 µl) were first separated by liquid chromatography
(Dionex Ultimate 3000, Dionex, Leeds, UK) on a Pepmap C18
column, 200 µm×15 cm (Dionex) at a flow rate of 3 µl/min. The
eluants used were: A. 0.05% TFA in water and B. 0.05% TFA in 100%
acetonitrile. The gradient was run as follows: 5 min of isocratic
pre-run at 100% A, followed by a linear gradient from 2 to 50% B
over 40 min. The column was then washed in 100% B for a further
10 min. During the elution gradient, the sample was spotted at
10 second intervals using a Probot (Dionex) with α-cyano-4-
hydroxycinnamic acid (CHCA) at 3 mg/ml (70% MeCN, 0.1% TFA)
at a flow rate of 1.2 μl/min. Both MS and MS/MS analyses were
performed on the fractionated peptides using an Applied Biosys-
tems 4800 MALDI-TOF/TOF mass spectrometer (Applied Biosys-
tems Inc., Foster City, CA, USA). The mass spectrometer was
operated under control of 4000 Series Explorer v3.5.2 software
(Applied Biosystems). Peak lists of MS and MS/MS spectra were
generated using the 4000 Series Explorer v3.5.2 software after
selective labelling of monoisotopic mass peaks. An automated
Fig. 5 – MSC-CM enhanced the rate of wound closure in L929
fibroblast and HaCaT keratinocyte co-cultures.
a) Representative images of scratch assays of L929 fibroblast
(fluorescently-labelled green) and HaCaT keratinocyte
(fluorescently-labelled red) co-cultures immediately after the
scratches had been made (fluorescence images) and then after
12 h (fluorescence and phase images) in the presence of serum
free MSC-CM versus control medium. Original magnification
×100. b) There was a significant increase in the extent of wound
closure in L929 and HaCaT co-culture scratch assays in MSC-CM
compared with the control medium at 12 h. Data shown are
means±SEM, *p<0.05. Fig. 6 – The influence of MSC-CM on L929 fibroblast and HaCaT
keratinocyte cell proliferation/survival. Data shown indicates
the viable cell number in L929 fibroblast (a) and HaCaT
keratinocyte (b) cultures maintained in serum free MSC-CM
(solid line) versus control medium (dotted line) over a 3 day
time course. As shown, there was a non-significant increase in
viable L929 and HaCaT cell number in MSC-CM after 72 h, which
was beyond the time course for wound closure by each cell type
in the presence of MSC-CM. (c) The number of L929 fibroblasts
(green) and HaCaT keratinocytes (red) present in the field of
view in L929: HaCaT co-culture scratch assays in MSC-CM. There
was a slight, but non-significant increase in L929 cell numbers
and no increase in HaCaT cell numbers over the course of
wound closure. Data shown are means±SEM.
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database search was run using GPS Explorer v3.6 (Applied
Biosystems). MASCOT was used as the search engine to search
NCBInr database using the following search parameters: precursor
ion mass tolerance of 50 ppm, fragment ion mass tolerance of
0.3 Da, the taxonomy was selected as human and oxidation of
methionine residues was allowed as variable modifications. The
identification criterionwas at least 2 peptides byMS/MSwith total
ion score confidence intervals of at least 95%.
Statistical analysis
Data presented in this study are means±standard error of the mean.
These data were tested for normal distribution by Kolmogorov–
Smirnov test using Analyse-it software. As all data were shown to be
not normally distributed the non-parametric Mann–Whitney U test
was used to determine significant differences between samples.
Results
In the presence of serum, L929 fibroblasts effected wound closure
more rapidly than HaCaT keratinocytes in single cell type scratch
assays. At 12 h when the extent of wound closure was 49% (±5%)
for L929 scratch assays, the extent of closure for HaCaT scratch
assays was only 15% (±3%) (Fig. 1a). Furthermore, complete
wound closure of all scratches was seen in L929 cultures by 72 h,
compared with only half of the scratches for HaCaT. In co-cultures,
the L929 fibroblasts migrated faster than the HaCaT keratinocytes
to fill the scratch area. Hence, at 12 h the L929 cells were seen to
have migrated further into the scratched areas than HaCaT cells,
and by wound closure (72 h) the scratched areas were filled
almost exclusively with L929 cells (Fig. 1b). L929 fibroblasts also
closed scratch wounds significantly more rapidly than HaCaT
keratinocytes under serum free conditions. Hence, at 12 h the
extent of wound closure of serum free L929 scratch assays was 47%
(±7%) compared with 16% (±4%) for wound closure of HaCaT
scratch assays (Fig. 2a). In addition, in serum free L929: HaCaT co-
culture scratch assays, the L929 cells were the first to migrate into
the scratch and filled the area at wound closure (Fig. 2b).
When L929 fibroblast (Fig. 3) and HaCaT keratinocyte (Fig. 4)
scratch assays were performed in MSC-CM which had been
generated under serum free conditions, there was a significantly
enhanced rate of wound closure for both cell types. Hence, when
wound closure of L929 scratch assays was 51% (±10%) in serum
free control medium (at the 9 hour time point in this set of
experiments), it was 100% (±0%) in the presence of serum free
MSC-CM. Similarly, when wound closure of HaCaT scratch assays
was 57% (±8%) in serum free control medium (at the 27 hour time
point in this set of experiments), it was 95% (±3%) in serum free
MSC-CM. In contrast, neither L929-CM nor HaCaT-CM positively
affected the rate of wound closure in scratch assays of either cell
type at any time during the wound healing process. For example,
when wound closure of L929 scratch assays was 48% (±7%) in
serum free control medium (at 12 h in this set of experiments), it
was only 43% (±8%) in L929-CM and only 42% (±17%) in HaCaT-
CM. Similarly, when wound closure of HaCaT scratch assays was
15% (±4%) in serum free control medium (also at 12 h), it was
only 14% (±8%) in L929-CM and 20% (±5%) in HaCaT-CM.
Scratch assay of L929 and HaCaT co-cultures closed signifi-
cantly faster in the presence of serum free MSC-CM than in serum
free control media (Fig. 5). Hence, after 12 h wound closure in
L929:HaCaT co-culture scratch assays was 76% (±6%) in the
presence of MSC-CM compared with 35% (±13%) in serum free
control medium.
To address whether MSC-CM may have stimulated skin cell
proliferation or survival in addition to cell migration duringwound
closure, L929 fibroblast and HaCaT keratinocyte cultures were
established in 96 well plates in MSC-CM versus serum free control
medium. The MTS assay was then performed to ascertain viable
cell number. There was a non-significant, but marked increase in
the number of L929 and HaCaT cells present at 72 h in MSC-CM
versus control (Figs. 6a–b). However, no marked increases in
viable cell number were seen for either cell type in the first 48 h,
i.e. within the time frame of L929 and HaCaT wound closure in
serum freeMSC-CM. Cell proliferation was also monitored in L929:
Table 1 – Proteins detected in MSC conditioned medium via mass spectrometry (MALDI-TOF/TOF).
Protein name Accession number Peptide count Total ion score C.I.%
Collagen type I (alpha 1 chain) gi22328092 16 100
Collagen type I (alpha 2 chain) gi48762934 27 100
Collagen type V (alpha 2 chain) gi16197600 3 100
Collagen type VI (alpha 1 chain gi87196339 10 100
Collagen type XII (alpha 1 long isoform) gi93141047 6 99.999
Fibronectin gi4204943 8 99.999
Fibronectin (type III domain) gi55667857 2 96.825
SPARC gi2624793 3 96.613
Insulin-like growth factor binding protein 7 gi4504619 4 100
Fig. 7 – Growth factors and chemokines detected in MSC-CM by
ELISAmulti-array. Detectable levels of TGF-β1, IL-6, IL-8, MCP-1
and RANTESwere seen in serum freeMSC-CM. Relative cytokine
levels have been expressed as arbitrary absorbance units
normalised for MSC cell number. Data shown are means±SEM.
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HaCaT co-cultures in situ using the Cell IQ image analysis system.
This demonstrated firstly that in the presence of MSC-CM there
was no overgrowth of L929 cells at the time point that the
scratcheswere established, and secondly, that the increased rate of
wound closure seen in MSC-CM compared to serum free control
medium was not due to any marked increase in the rates of either
L929 or HaCaT cell proliferation in situ (Fig. 6c).
MSC-CM was assayed to determine the presence of secreted
cytokines or ECM components that may have influenced L929
fibroblast or HaCaT keratinocyte cell growth or migration.
Detectable levels of interleukin (IL)-6, IL-8, transforming growth
factor-β1 (TGF-β1), monocyte chemotactic protein-1 (MCP-1) and
Rantes were found in the MSC-CM by ELISA (Fig. 7). In contrast, IL-
1a, IL-1b, IL-4, IL-10, interferon-γ (IFN-γ), tumour necrosis factor-
α (TNF-α), and growth regulated oncogene-α (Gro-A) were not
detected. In addition, the ECM components collagen types I, V, VI
and XII, and fibronectin were detected in MSC-CM by MALDI-TOF/
TOF mass spectrometry, along with secreted protein acidic and
rich in cysteine (SPARC) and insulin-like growth factor binding
protein-7 (IGFBP-7) (Table 1).
Discussion
Cell migration is a rate limiting event in skin wound healing.
Hence, the study of factors that influence dermal fibroblast and
epidermal keratinocyte migration may help target therapies for
improved cutaneous wound healing. In this set of investigations
we have used the scratch assay to show that L929 fibroblasts
migrated to effect wound closure more rapidly than HaCaT
keratinocytes. In co-culture, the L929 fibroblasts were seen to fill
the closed scratch almost entirely to the exclusion of the HaCaT
keratinocytes, both in the presence or absence of serum supple-
mentation. The chronology of cell migration into human cutaneous
wounds is currently unclear. However, a recent study has
suggested that dermal fibroblasts alongwith dermalmicrovascular
endothelial cells may migrate into the wounded area prior to
keratinocytes [33]. It was further suggested that dermal fibroblast
migration is then halted as keratinocytes migrate to initiate re-
epithelialisation, after which a further wave of fibroblast migration
occurs during the tissue remodelling stage of wound healing. If this
order of skin cell migration is correct, then the novel co-culture
scratch assay we have reported here using L929 and HaCaT cell
lines may prove useful for future studies of factors that influence
cutaneous wound healing. The interaction of dermal fibroblasts
and epidermal keratinocytes plays an important role in the healing
process. Hence, the incorporation of both cell types in this co-
culture model may be more representative of in vivo skin wound
healing than the use of either cell type alone. A mix of L929
fibroblasts and HaCaT keratinocytes was evidently present in the
scratch assays reported here. Whilst this differs significantly from
the ordered separation into dermal and epidermal layers in
undamaged skin, the usual compartmentalisation of these cell
types is likely to be somewhat disrupted in cutaneous wounds.
The differences in healing rates we have seen in scratch assays
of L929 or HaCaT cells as single cell types may simply be due to the
fact that the L929 fibroblasts were murine in origin, whilst the
HaCaT keratinocytes were human. Furthermore, L929 is derived
from a tumour [28] whilst HaCaT is an immortalised cell line [29].
As such, these cells may differ in their behaviour from normal
human cells in vivo. However, both cell types have been utilised in
previous studies as in vitromodels of skin cell behaviour [34]. Their
particular use in this study eliminates potential donor variations in
primary skin cell cultures, which has thereby allowed for the
development of a consistent model to assay the effects of MSC
derived factors. Further study of primary human dermal fibro-
blasts and human epidermal keratinocytes, either singly or in co-
culture, may help to validate the model.
A recent study by Smith et al. [35] demonstrated that co-culture
of murine MSC with human dermal fibroblasts, where each cell
type was separated in a modified Boyden chamber in the presence
of bovine and equine serum, enhanced dermal fibroblast migration
and proliferation. The response of the dermal fibroblasts included
altered expression of genes involved in cell-matrix interactions.
However, the MSC secreted factors which may have brought about
these effects were not examined. We have similarly shown that
conditioned medium obtained from serum free MSC cultures
(MSC-CM) significantly promoted L929 fibroblast and HaCaT
keratinocyte scratch wound closure compared with non-condi-
tioned control medium. This stimulatory activity supports the
application of MSC as a therapeutic agent in cutaneous wound
healing. In addition, as we established serum free conditions in
which to perform these experiments, we were able to identify a
number of MSC secreted factors in MSC-CM that are known to
promote cutaneous wound healing. TGF-β1 has diverse roles in
cutaneous wound healing, including a stimulatory activity on re-
epithelialisation, wound contracture, angiogenesis, scar formation
and ECM deposition [36]. In particular, TGF-β1 stimulates
increased cell migration in dermal fibroblasts [37] and keratino-
cytes [38]. Studies of knock-out mice have suggested that IL-6
forms an essential element of the normal cutaneous wound
healing process by influencing dermal fibroblast migration [39],
and has also been shown to stimulate keratinocyte migration [40]
and proliferation [41], whilst IL-8 similarly promotes skin re-
epithelialisation by increasing keratinocyte migration [42] and
proliferation [43]. MCP-1 and RANTES may also function to
promote dermal wound healing as a chemoattractant to cells of
the immune system, particularly macrophages [44].
The increase in L929 and HaCaT cell number over the course of
wound closure in co-culture scratch assays was non-significant for
either cell type, both in control medium or in MSC-CM. This
suggests that increased migration of these cells, as opposed to
increased proliferation, was themain factor in the enhanced rate of
wound closure in MSC-CM. In addition, MSC-CM was found to
have little effect on L929 or HaCaT cell proliferation or survival, as
assessed via the MTS assay. The moderate difference seen in the
viable cell number present in MSC-CM compared with control
medium at 72 h was at a time point outside of the time course of
scratch wound closure in the presence of MSC-CM. Furthermore,
there were no obvious differences in the adherence of L929 or
HaCaT cells in MSC-CM or control medium in the scratch assays
themselves. Therefore, the activity of MSC-CM on scratch wound
closure may more readily be attributed to stimulation of increased
fibroblast and keratinocyte cell migration, rather than on cell
proliferation or survival. As described above, several of the MSC
secreted growth factors and chemokines are likely targets for this
stimulatory activity of cell migration in L929 and HaCaT scratch
assays, although further experiments, e.g. with the use of
neutralising antibodies are required to identify their precise
activity.
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The composition of the extracellular matrix (ECM) plays a major
role in regulating cell migration [45] and a number of ECM
components in MSC-CM were identified by mass spectrometry.
Prominent amongst these are collagen type I and fibronectin, which
are well-characterised stimulatory factors of fibroblast and kerati-
nocyte cell adhesion and migration. However, as the tissue culture
plates were already pre-coated in collagen type I, any additive effect
from these ECM components in MSC-CM may have been small or
negligible. Also detected was the extracellular glycoprotein SPARC
(osteonectin/BM-40). Elevated levels of SPARC expression have
been observed in cells at wound sites [46] and it has been
demonstrated that the absence of SPARC is associatedwith impaired
fibroblast migration [47]. Conversely, the absence of SPARC has also
been shown to accelerate wound closure in SPARC-null mice [48],
but this study suggested that this effect may have been due to an
associated reduction in collagen content in the skin, which in turn
leads to increased wound contractibility. Insulin-like growth factor
binding proteins (IGFBP) play an important role in skin homeostasis,
modulating IGF-mediated enhancement of dermal and epidermal
cell migration, survival and proliferation [49]. In particular, IGFBP-7
has been shown to regulate the proliferation and survival of both
HaCaT and primary human keratinocytes in vitro [50]. This suggests
that IGFBP-7 in MSC-CM may have contributed to the increased
wound closure seen in HaCaT keratinocyte scratch assays. However,
further experiments that specifically target IGFBP-7 in MSC-CM are
required to confirm such activity.
In summary, we have adapted an established in vitro model of
skin wound healing; this was with a view to investigating the
potential use of MSC for cell therapies of cutaneous wounds. The
study has demonstrated that L929 fibroblasts and HaCaT kerati-
nocytes bring about wound closure in scratch assays under serum
and serum free conditions, where the L929 fibroblasts pioneered
the wound healing process. We then used serum free scratch
assays in order to dissect the response of the L929 fibroblasts and
HaCaT keratinocytes to MSC secreted factors, and hence we have
shown that MSC-CM stimulated wound closure for both cell types.
Furthermore, we have identified a number of MSC secreted targets
for this activity which can be tested using the model system. These
studies provide a novel model system for the in vitro study of cell
synthesised soluble factors that may influence skin wound healing
and provide insight into the potential mechanisms whereby MSC
transplantation is therapeutic.
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Appendix ii
MALDI-TOF/TOF Mass spectrometry of MSC-CM
MSC-1
Ran
k
Protein Name Accession 
Number
Protein 
MW
Protein 
PI
Peptide 
Count
Total Ion 
Score
Total Ion 
Score 
C.I. %
1 alpha 2 type I collagen [Homo sapiens] gi|48762934 129235.4 9.08 27 622.5189 100
2 Collagen, type I, alpha 1 [Homo sapiens] gi|22328092 138925.6 5.7 16 431.0589 100
3 alpha 1 (I) chain propeptide gi|180392 98494.94 6.47 11 247.0944 100
4 hypothetical protein [Homo sapiens] gi|31873670 268733.5 5.36 18 235.1445 100
5 collagen, type VI, alpha 1 precursor [Homo sapiens] gi|87196339 108462 5.26 10 158.2444 100
6 precursor polypeptide (AA -31 to 1139) [Homo sapiens] gi|37465 129269.5 4.71 7 104.71 100
7 insulin-like growth factor binding protein 7 [Homo sapiens] gi|4504619 29111.44 8.25 4 92.01 100
8 type V preprocollagen alpha 2 chain [Homo sapiens] gi|16197600 128743.2 6.36 3 84.16 100
9 collagen, type XII, alpha 1 long isoform precursor [Homo 
sapiens]
gi|93141047 332940.5 5.38 6 80.47444 99.99992
10 actin, gamma 2 propeptide [Homo sapiens] gi|4501889 41849.79 5.31 3 77.75 99.99985
11 fibronectin [Homo sapiens] gi|4204943 41344.68 9.32 8 75.73443 99.99977
12 pro-alpha-1 collagen type 1 [Homo sapiens] gi|179630 3768.75 4.66 3 75.41 99.99975
13 actin, gamma 1 propeptide [Homo sapiens] gi|4501887 41765.79 5.31 3 72.69 99.99953
14 aldolase A [Homo sapiens] gi|4557305 39395.3 8.3 3 40.92444 99.29309
15 Chain A, Crystal Structure Of Recombinant Human 
Triosephosphate Isomerase At 2.8 Angstroms Resoluti
gi|999892 26521.7 6.51 1 35.38 97.46599
16 fibronectin type III domain containing 1 [Homo sapiens] gi|55667857 66828.44 6.55 2 34.4 96.82453
17 titin [Homo sapiens] gi|1212992 2991589 6.35 10 34.26688 96.72569
18 Chain A, Bm-40, FsEC DOMAIN PAIR gi|2624793 27054.1 5.53 3 34.12 96.61305
19 Chain A, The Crystal Structure Of Human Supernatant 
Protein Factor
gi|38492593 45895.12 7.92 3 33.11 95.72626
20 unnamed protein product [Homo sapiens] gi|21750712 14218.59 10.58 1 32.1 94.60727
21 tumor necrosis factor gi|339992 41974.87 4.9 2 31.3 93.51651
22 unnamed protein product [Homo sapiens] gi|16552261 47458.89 5.01 4 30.69 92.5388
23 heparan sulfate proteoglycan perlecan [Homo sapiens] gi|11602963 466304.2 6.03 4 29.96 91.17309
24 alpha2-HS glycoprotein [Homo sapiens] gi|2521981 35640.84 5.2 1 29.4 89.95827
25 BIGH3 [Homo sapiens] gi|2996636 56311.16 6.97 2 28.91 88.75891
26 vimentin [Homo sapiens] gi|5030431 41537.03 4.82 4 28.17 86.67066
27 HCNP [Homo sapiens] gi|9295341 98809.95 8.16 2 27.65444 84.99056
28 hypothetical protein [Homo sapiens] gi|31874769 35774.97 8.51 3 27.53444 84.57006
29 KIAA0434 [Homo sapiens] gi|2662149 170583.5 8.48 3 27.5 84.4472
30 unnamed protein product [Homo sapiens] gi|30076 100613.6 9.1 3 26.66 81.12841
31 thrombospondin 2 precursor [Homo sapiens] gi|40317628 129907.8 4.62 5 26.23 79.16428
32 KIAA0959 protein [Homo sapiens] gi|4589562 91698.93 6.26 1 25.28 74.06965
33 Nebulin gi|19856971 772727.3 9.1 4 25.09444 72.93772
34 asparaginyl-tRNA synthetase [Homo sapiens] gi|4758762 62902.61 5.9 1 24.85 71.37085
35 SPECC1 protein [Homo sapiens] gi|29477171 79033.8 5.31 1 24.16 66.44104
36 Dombrock blood group carrier molecule [Homo sapiens] gi|20385823 35883.5 9.24 3 24.06 65.65936
37 E3 ligase for inhibin receptor [Homo sapiens] gi|30060232 289429.5 5.29 2 24.04 65.50085
38 alpha-1 (III) collagen [Homo sapiens] gi|930045 96442.1 9.28 4 23.99 65.10135
39 FLJ00343 protein [Homo sapiens] gi|21748542 281254.3 5.77 6 23.24 58.52289
40 Latent-transforming growth factor beta-binding protein 2 
precursor (LTBP-2)
gi|41017299 194936 5.08 2 22.69 52.92304
41 zinc finger CCCH-type containing 12B [Homo sapiens] gi|57471635 77506.44 8.66 1 22.41 49.78789
42 unnamed protein product [Homo sapiens] gi|34535472 87569.53 6.82 2 21.86 43.00872
43 T-cell antigen receptor chain (VJC) [Mus musculus] gi|296757 34266.33 8.31 1 21.78 41.94918
44 Na,K-ATPase alpha-4 subunit [Homo sapiens] gi|17148771 8127.467 10.1 1 21.72 41.14159
45 CCNL1 [Homo sapiens] gi|37182448 34668.16 11.43 1 21.65 40.18522
46 RU1 [Homo sapiens] gi|6635353 98167.24 5.86 2 21.55 38.79198
47 TAGLN [Homo sapiens] gi|49168456 22536.4 8.87 2 21.54 38.65088
48 immunoglobulin kappa chain [Homo sapiens] gi|11137043 9962.874 6.48 2 20.97 30.04668
49 type II hair keratin 3 [Homo sapiens] gi|7161767 54160.51 5.54 2 20.97 30.04665
50 hypothetical protein [Homo sapiens] gi|21740227 55327.56 9.69 1 20.92444 29.30895
51 INT4 protein [Homo sapiens] gi|14124974 88834.93 5.69 1 20.8 27.2541
52 kinesin family member 5B [Homo sapiens] gi|4758648 109616.8 6.12 1 20.64 24.52406
53 lipocalin 9 [Homo sapiens] gi|48717447 20272.04 5.72 1 20.64 24.52406
54 monocyte/macrophage serine-esterase 1 [Homo sapiens] gi|1335304 55567.32 5.66 1 20.55 22.94363
55 Olfactory receptor 1N2 gi|38372758 35160.13 7.98 1 20.34 19.12609
56 RUN and SH3 domain containing 2 [Homo sapiens] gi|55741719 161094.5 6.17 2 20.21 16.66862
57 kinase suppressor of ras 2 [Homo sapiens] gi|34222393 93525.83 9.18 1 20.15 15.50938
58 EGF-like-domain, multiple 7 [Homo sapiens] gi|15214507 29612.41 8.58 1 20.01444 12.83053
59 vinculin isoform meta-VCL [Homo sapiens] gi|7669550 123721.8 5.5 2 19.95 11.52748
60 ZNF557 protein [Homo sapiens] gi|12804323 42925.05 9.12 1 19.82 8.839124
61 p21 (CDKN1A)-activated kinase 3 [Pan troglodytes] gi|57113963 62270.5 5.33 1 19.66 5.418004
62 Sam68-like phosphotyrosine protein beta [Homo sapiens] gi|4091776 29340.57 9.59 2 19.53 2.544
63 steerin2 protein [Homo sapiens] gi|27526777 267948.1 9.15 6 19.12 0
64 fusion protein [Homo sapiens] gi|408993 11748.92 7.88 1 19 0
MSC-2
Ran
k
Protein Name Accession 
Number
Protein PI Peptide 
Count
Total 
Ion 
Score
Total Ion Score 
C.I. %
1 alpha 2 type I collagen precursor [Homo sapiens] gi|48762934 9.08 31 1014.
354
100
2 Collagen, type I, alpha 1 [Homo sapiens] gi|22328092 5.7 12 296.8
544
100
3 collagen, type VI, alpha 1 precursor [Homo sapiens] gi|87196339 5.26 6 177.6
8
100
4 Transferrin [Homo sapiens] gi|37747855 6.97 4 170.7
3
100
5 cartilage oligomeric matrix protein precursor [Homo sapiens] gi|40217843 4.36 6 166.3
6
100
6 fibronectin precursor [Homo sapiens] gi|31397 5.45 7 128.4
8
100
7 alpha 1 (I) chain propeptide [Homo sapiens] gi|180392 6.47 7 127.8
2
100
8 hemopexin precursor [Homo sapiens] gi|386789 6.57 5 104.6
1
100
9 Chain D, Human Insulin Hexamers With Chain B His Mutated 
To Tyr Complexed With Phenol
gi|5542375 5.41 3 87.31 100
10 tumor necrosis factor gi|339992 4.9 3 83.9 99.99990815
11 actin, gamma 1 propeptide [Homo sapiens] gi|4501887 5.31 3 81.66 99.99984616
12 albumin, isoform CRA_k [Homo sapiens] gi|119626074 5.97 3 60.07 99.97781459
13 Chain B, Structural Properties Of The B25tyr-Nme-B26phe 
Insulin Mutant.
gi|61680182 6.9 2 56.38 99.9481119
14 Chain B, Nmr Structure Of Human Insulin Mutant His-B10-
Asp, Val-B12- Aba, Pro-B28-Lys, Lys-B29-Pro,
gi|159163040 5.44 2 52.33 99.86815389
15 complement component 1, s subcomponent precursor [Homo 
sapiens]
gi|4502495 4.86 2 50.28 99.78861819
16 lumican gi|642534 6.16 2 43.24 98.93077937
17 anti-colorectal carcinoma heavy chain [Homo sapiens] gi|425518 6.22 1 42.94 98.85430864
18 immunoglobulin heavy chain constant region gamma 4 
[Homo sapiens]
gi|12054078 7.16 1 39.22 97.301842
19 Chain B, Solution Structure Of The Monomeric [thr(B27)-
>pro,Pro(B28)- >thr] Insulin Mutant (Pt Insulin)
gi|159162548 6.9 2 39.15 97.25800066
20 EGF-containing fibulin-like extracellular matrix protein 1 
precursor [Homo sapiens]
gi|9665262 4.95 1 31.23 83.01492202
21 putative [Homo sapiens] gi|553734 9.79 1 30.24 78.66623425
22 prominin 1 isoform 2 [Homo sapiens] gi|224994189 6.97 1 30.17 78.31958996
23 actin, beta-like 2 [Homo sapiens] gi|63055057 5.39 3 26.53 49.87347235
24 tRNA isopentenylpyrophosphate transferase isoform 5 [Homo 
sapiens]
gi|58041802 8.93 1 26.41 48.46912528
25 PREDICTED: similar to microtubule-associated proteins 
1A/1B light chain 3 [Homo sapiens]
gi|169183885 10.52 1 24.6 21.82507718
26 macrophin 1 isoform 4 [Homo sapiens] gi|17426161 5.05 1 24.4 18.1407922
27 keratin 1 [Homo sapiens] gi|7331218 8.16 1 22.96 0
28 KIAA0184 [Homo sapiens] gi|1136428 6.99 1 22.54 0
29 biglycan [Homo sapiens] gi|179433 6.83 1 22.5 0
30 unnamed protein product [Homo sapiens] gi|21752990 8.35 1 22.47 0
31 HECT domain containing 3 [Homo sapiens] gi|118835514 5.47 1 21.25
444
0
32 La ribonucleoprotein domain family member 2 isoform 1 
[Homo sapiens]
gi|30061567 7.33 2 22.01 0
33 inter-alpha (globulin) inhibitor H4 isoform 1 precursor [Homo 
sapiens]
gi|31542984 6.51 1 21.61 0
34 hypothetical protein [Homo sapiens] gi|21739834 5.64 1 21.29 0
35 insulin-like growth factor binding protein 6 [Homo sapiens] gi|183894 8.15 1 21.19 0
36 heparan sulfate proteoglycan [Homo sapiens] gi|184427 6.05 1 19.94 0
37 unnamed protein product [Homo sapiens] gi|194388696 11.79 1 19.72 0
38 ATF6 [Homo sapiens] gi|3953531 8.36 1 19.72 0
39 nucleobindin 1 variant [Homo sapiens] gi|62897169 5.15 2 18.83 0
40 unnamed protein product [Homo sapiens] gi|158256468 5.89 1 18.75 0
41 transcription factor ELYS [Homo sapiens] gi|17298096 6.19 1 18.6 0
42 hypothetical protein [Homo sapiens] gi|7018446 8.24 1 18.58 0
43 NIPSNAP2 protein [Homo sapiens] gi|2769254 9.42 1 18.56 0
44 fms-related tyrosine kinase 4 isoform 2 precursor [Homo 
sapiens]
gi|103472027 5.89 1 18.53 0
45 nesprin-1 beta [Homo sapiens] gi|17861386 5.13 2 18.50
444
0
46 unnamed protein product [Homo sapiens] gi|21748720 6.68 1 18.41 0
47 Chain A, Crystal Structure Of Human Dna Ligase I Bound To 
5'- Adenylated, Nicked Dna
gi|56967028 5.79 1 18.13 0
48 alpha-1 (III) collagen [Homo sapiens] gi|930045 9.28 1 17.9 0
49 hypothetical protein, similar to (U32865) linotte protein 
[Drosophila melanogaster] [Homo sapiens]
gi|5102582 6.8 1 17.89 0
50 KIAA1973 protein [Homo sapiens] gi|18916849 8.57 1 17.38 0
MSC-3
Ran
k
Protein Name Accession 
Number
Protein PI Peptide 
Count
Total 
Ion 
Score
Total Ion Score 
C.I. %
1 fibronectin precursor [Homo sapiens] gi|31397 5.45 24 464.9
989
100
2 RecName: Full=Collagen alpha-2(I) chain; AltName: 
Full=Alpha-2 type I collagen; Flags: Precursor
gi|124056488 9.08 18 328.4
245
100
3 Chain A, Apo-Human Serum Transferrin (Non-Glycosylated) gi|110590597 6.58 11 238.5
689
100
4 Transferrin [Homo sapiens] gi|37747855 6.97 11 230.8
9
100
5 hemopexin precursor [Homo sapiens] gi|386789 6.57 9 210.8
1
100
6 keratin 1 [Homo sapiens] gi|119395750 8.15 5 127.1
689
100
7 Collagen, type I, alpha 1 [Homo sapiens] gi|22328092 5.7 8 119.58
44
100
8 Chain D, Human Insulin Hexamers With Chain B His Mutated 
To Tyr Complexed With Phenol
gi|5542375 5.41 2 79.27 99.99974
9 anti-colorectal carcinoma heavy chain [Homo sapiens] gi|425518 6.22 2 75.7 99.9994
10 Chain B, Structural Properties Of The B25tyr-Nme-B26phe 
Insulin Mutant.
gi|61680182 6.9 2 51.32 99.83606
11 collagen, type VI, alpha 1 precursor [Homo sapiens] gi|87196339 5.26 4 47.42 99.59758
12 Chain B, Solution Structure Of The Monomeric [thr(B27)-
>pro,Pro(B28)- >thr] Insulin Mutant (Pt Insulin)
gi|159162548 6.9 2 46.6 99.51395
13 lumican gi|642534 6.16 2 39.01 97.20953
14 Chain B, Nmr Structure Of Human Insulin Mutant Ile-A2-Ala, 
His-B10- Asp, Pro-B28-Lys, Lys-B29-Pro, 15 Structures
gi|159162579 5.44 1 36.43 94.94552
15 Chain A, Structure Of A Novel Extracellular Ca2+-Binding 
Module In Bm-40(Slash)sparc(Slash)osteonec
gi|157833849 5.01 2 34.25 91.65019
16 albumin preproprotein [Homo sapiens] gi|4502027 5.92 3 33.53 90.14454
17 Chain B, Orientation In Solution Of Mmp-3 Catalytic Domain 
And N- Timp-1 From Residual Dipolar Coup
gi|34811011 8.27 1 32.71 88.09644
18 KIAA0184 [Homo sapiens] gi|1136428 6.99 1 30.79 81.47848
19 unnamed protein product [Homo sapiens] gi|158255712 5.39 1 29.91 77.31824
20 tumor necrosis factor gi|339992 4.9 1 29.51 75.12995
21 unnamed protein product [Homo sapiens] gi|194388696 11.79 1 27.21 57.76458
22 ATF6 [Homo sapiens] gi|3953531 8.36 1 27.21 57.76458
23 ankyrin repeat and SOCS box-containing protein 1 [Homo 
sapiens]
gi|94721248 8.55 1 27 55.67214
24 alpha2-HS glycoprotein [Homo sapiens] gi|2521981 5.2 2 26.74 52.93731
25 biglycan [Homo sapiens] gi|179433 6.83 2 26.65 51.95184
26 NOL1/NOP2/Sun domain family, member 4 [Homo sapiens] gi|15680185 8.47 2 24.97
444
29.33038
27 insulin-like growth factor binding protein 7 [Homo sapiens] gi|4504619 8.25 3 24.97 29.25809
28 putative [Homo sapiens] gi|553734 9.79 1 24.75 25.58222
29 Ig gamma 2 H chain, BUR [human, Peptide Mutant, 348 aa] gi|243169 6.22 1 24.41 19.52208
30 actin, gamma 1 propeptide [Homo sapiens] gi|4501887 5.31 2 24.36 18.59021
31 hypothetical protein [Homo sapiens] gi|7018446 8.24 1 23.35 0
32 chitinase 3-like 1 precursor [Homo sapiens] gi|144226251 8.69 2 23.32 0
33 retinoic acid induced 16 [Homo sapiens] gi|89337270 5.27 3 23.32 0
34 HECT domain containing 3 [Homo sapiens] gi|118835514 5.47 1 21.40
444
0
35 enyol-CoA: hydratase/3-hydroxyacyl-CoA dehydrogenase 
[Homo sapiens]
gi|452045 9.22 1 22.12 0
36 nebulin isoform 3 [Homo sapiens] gi|115527120 9.11 3 21.50
566
0
37 KIAA0368 protein [Homo sapiens] gi|122937211 8.95 2 20.56 0
38 La ribonucleoprotein domain family, member 6 isoform 1 
[Homo sapiens]
gi|37537710 8.39 1 20.13 0
39 malate dehydrogenase 1, NAD (soluble), isoform CRA_d gi|119620368 7.62 1 19.86 0
[Homo sapiens]
40 kinesin family member 27 [Homo sapiens] gi|30794488 6.9 2 19.00
444
0
41 Chain A, Gelatinase A (Full-Length) gi|5822007 5.2 2 18.97 0
42 plasminogen activator inhibitor type 1, member 2 isoform b 
precursor [Homo sapiens]
gi|211904152 9.42 2 18.88 0
43 CALU [Homo sapiens] gi|49456627 4.48 2 18.83 0
44 prominin 1 isoform 2 [Homo sapiens] gi|224994189 6.97 1 18.7 0
45 insulin-like growth factor-binding protein [Homo sapiens] gi|183116 9.03 1 18.48 0
46 fms-related tyrosine kinase 4 isoform 2 precursor [Homo 
sapiens]
gi|103472027 5.89 1 17.92 0
47 hypothetical protein, similar to (U32865) linotte protein 
[Drosophila melanogaster] [Homo sapiens]
gi|5102582 6.8 1 17.9 0
48 inter-alpha (globulin) inhibitor H4 isoform 1 precursor [Homo 
sapiens]
gi|31542984 6.51 2 17.61 0
49 apoptotic cysteine protease proMch4 gi|1498324 5.97 1 17.5 0
50 hCG1648444 [Homo sapiens] gi|119602744 6.8 1 17.49 0
51 KiSS-1 metastasis-suppressor, isoform CRA_a [Homo 
sapiens]
gi|119611912 9.82 1 17.23 0
52 unnamed protein product [Homo sapiens] gi|194385514 6.44 1 17.12 0
53 Hsp70 subfamily B suppressor 1-like protein isoform 3 [Homo 
sapiens]
gi|223633995 5.63 1 17.06 0
54 RecName: Full=Mucin-19; Short=MUC-19; Flags: Precursor gi|193806311 4.95 2 17.04 0
55 NY-REN-62 antigen [Homo sapiens] gi|5360129 7.79 1 16.13 0
56 cyclic nucleotide-gated cation channel [Homo sapiens] gi|4261908 8.58 1 15.85 0
57 hCG1784572 [Homo sapiens] gi|119583243 6.13 1 15.84 0
58 unnamed protein product [Homo sapiens] gi|34531210 9.18 1 15.83 0
59 mitogen-activated protein kinase 8 isoform JNK1 alpha2 
[Homo sapiens]
gi|20986523 6.43 2 15.73 0
60 tubby like protein 4 isoform 2 [Homo sapiens] gi|55953102 6.02 1 15.4 0
61 PREDICTED: transmembrane protein 46-like [Homo sapiens] gi|169215850 11.24 2 15.16 0
62 cytochrome P450, family 4, subfamily F, polypeptide 22 
[Homo sapiens]
gi|158138530 8.95 1 14.94 0
63 hypothetical protein [Homo sapiens] gi|21739834 5.64 1 14.69 0
64 uridine-cytidine kinase 1-like 1 [Homo sapiens] gi|57863312 6.93 1 14.65 0
65 immunoglobulin variable region VL kappa domain [Homo gi|51103549 5.69 1 14.64 0
sapiens]
66 hCG2028661 [Homo sapiens] gi|119601280 11.79 1 14.54 0
67 plasma membrane Ca2+ pumping ATPase [Homo sapiens] gi|190133 5.69 1 14.5 0
68 unnamed protein product [Homo sapiens] gi|158258353 6.96 1 14.5 0
69 hCG1814189 [Homo sapiens] gi|119602137 5.76 1 14.48 0
70 protein kinase LYK5, isoform CRA_f [Homo sapiens] gi|119614694 7.05 1 14.46 0
71 beta-mannosidase [Homo sapiens] gi|2145100 5.32 1 14.41 0
72 thyroid hormone receptor interactor 10, isoform CRA_a 
[Homo sapiens]
gi|119589466 5.84 1 14.4 0
73 5'-nucleotidase domain containing 3, isoform CRA_c [Homo 
sapiens]
gi|119618123 8.46 1 14.37 0
74 PREDICTED: similar to tropomyosin 3, gamma isoform 5 
[Pan troglodytes]
gi|114559859 4.72 2 14.33 0
75 keratin associated protein 19-3 [Homo sapiens] gi|119630302 11.92 1 14.32 0
76 Chain A, Crystal Structure Of The Ubc Domain Of Baculoviral 
Iap Repeat-Containing Protein 6
gi|171849089 6.8 1 14.12 0
77 retinoblastoma-binding protein 6 isoform 1 [Homo sapiens] gi|33620769 9.65 1 13.95 0
78 astrotactin 2 isoform b [Homo sapiens] gi|46488917 5.63 1 13.85 0
79 hypothetical protein [Homo sapiens] gi|193227749 9.57 1 13.85 0
80 immunoglobulin heavy chain variable region [Homo sapiens] gi|13487739 9.38 1 13.74 0
81 vacuolar protein sorting 13B (yeast), isoform CRA_b [Homo 
sapiens]
gi|119612193 6.23 2 13.7 0
82 BIGH3 [Homo sapiens] gi|3282161 8.91 1 13.7 0
83 unnamed protein product [Homo sapiens] gi|158254782 6.34 1 13.68 0
84 KIAA0863 protein [Homo sapiens] gi|40788964 9.44 1 13.66 0
85 Chain B, Crystal Structure Of Protein Phosphatase 2a (Pp2a) 
Holoenzyme With The Catalytic Subunit Carboxyl Terminus 
Truncated
gi|122921195 6.27 2 13.62 0
86 regulatory factor X domain containing 2 [Homo sapiens] gi|148613886 6.14 1 13.59 0
87 unnamed protein product [Homo sapiens] gi|158256468 5.89 1 13.57 0
88 prickle homolog 1 [Homo sapiens] gi|222136678 5.84 1 13.47 0
89 R29893_1 [Homo sapiens] gi|2887499 9.95 1 13.4 0
90 RNA binding motif protein 6 [Homo sapiens] gi|5032033 5.93 1 13.27 0
91 tRNA aspartic acid methyltransferase 1 variant 5 [Homo 
sapiens]
gi|167887558 9.3 1 13.19 0
92 unnamed protein product [Homo sapiens] gi|21758244 9.6 1 13.15 0
93 tropomyosin (227 AA) [Homo sapiens] gi|825723 4.77 1 13.08 0
94 rcTPM3 [Homo sapiens] gi|83674986 4.77 1 13.08 0
95 beta chain HLA-DQ molecule [Homo sapiens] gi|2654381 7.98 1 13.02 0
96 RNF3A-2 [Homo sapiens] gi|33150610 8.77 1 12.75 0
97 tetratricopeptide repeat domain 4 [Homo sapiens] gi|56204887 7.95 1 12.7 0
98 keratin 8 [Homo sapiens] gi|4504919 5.52 2 12.69 0
99 unnamed protein product [Homo sapiens] gi|21752990 8.35 1 12.57 0
100 immunoglobulin heavy chain variable region [Homo sapiens] gi|70798061 9.26 1 12.55 0
MSC-4
Ran
k
Protein Name Accession 
Number
Protein PI Peptide 
Count
Total 
Ion 
Score
Total Ion Score 
C.I. %
1 alpha 2 type I collagen precursor [Homo sapiens] gi|48762934 9.08 37 1523.
264
100
2 Collagen, type I, alpha 1 [Homo sapiens] gi|22328092 5.7 27 952.0
89
100
3 fibronectin precursor [Homo sapiens] gi|31397 5.45 20 612.2
056
100
4 alpha 1 (I) chain propeptide [Homo sapiens] gi|180392 6.47 21 550.1
378
100
5 hypothetical protein [Homo sapiens] gi|51476364 5.77 18 496.0
657
100
6 collagen, type VI, alpha 1 precursor [Homo sapiens] gi|87196339 5.26 8 220.0
9
100
7 Transferrin [Homo sapiens] gi|37747855 6.97 5 203.5 100
8 Chain A, Apo-Human Serum Transferrin (Non-Glycosylated) gi|110590597 6.58 5 202.3
244
100
9 cartilage oligomeric matrix protein precursor [Homo sapiens] gi|40217843 4.36 4 178.1
8
100
10 hemopexin precursor [Homo sapiens] gi|386789 6.57 6 168.2
8
100
11 keratin 1 [Homo sapiens] gi|7331218 8.16 3 164.5
044
100
12 collagen, type II, alpha 1 (primary osteoarthritis, 
spondyloepiphyseal dysplasia, congenital), isof
gi|119578373 8.49 5 104.0
8
100
13 plasminogen activator inhibitor type 1, member 2 isoform b 
precursor [Homo sapiens]
gi|211904152 9.42 2 101.2 100
14 transferrin gi|553788 6 4 97.67 100
15 actin, gamma 1 propeptide [Homo sapiens] gi|4501887 5.31 2 97.66 100
16 alpha-1 (III) collagen [Homo sapiens] gi|930045 9.28 2 90.28
444
100
17 cathepsin B preproprotein [Homo sapiens] gi|4503139 5.88 2 83.06 99.99988
18 Chain D, Human Insulin Hexamers With Chain B His Mutated gi|5542375 5.41 2 80.44 99.99979
To Tyr Complexed With Phenol
19 Chain A, Gelatinase A (Full-Length) gi|5822007 5.2 2 78.98 99.9997
20 decorin [Homo sapiens] gi|181519 8.77 2 77.09
444
99.99954
21 unnamed protein product [Homo sapiens] gi|158255712 5.39 2 76.91 99.99952
22 unnamed protein product [Homo sapiens] gi|189054552 5.92 3 74.51 99.99917
23 tumor necrosis factor gi|339992 4.9 3 63.86 99.99034
24 actin, beta-like 2 [Homo sapiens] gi|63055057 5.39 2 62.96 99.98811
25 heparan sulfate proteoglycan [Homo sapiens] gi|184427 6.05 2 60.56 99.97934
26 fibrillin gi|306746 4.81 1 59.89 99.97589
27 lumican gi|642534 6.16 2 57.45 99.95772
28 inter-alpha (globulin) inhibitor H4 isoform 1 precursor [Homo 
sapiens]
gi|31542984 6.51 1 55.35 99.93143
29 Chain B, Structural Properties Of The B25tyr-Nme-B26phe 
Insulin Mutant.
gi|61680182 6.9 2 55.08 99.92703
30 Keratin 77 [Homo sapiens] gi|113414871 5.63 2 54.06
444
99.90781
31 insulin-like growth factor binding protein 6 [Homo sapiens] gi|183894 8.15 1 50.85 99.80674
32 hypothetical protein [Homo sapiens] gi|57997569 5.89 2 49.91 99.76004
33 pro-alpha-1 collagen type 1 [Homo sapiens] gi|179631 5.15 3 48.75 99.68658
34 Chain B, Solution Structure Of The Monomeric [thr(B27)-
>pro,Pro(B28)- >thr] Insulin Mutant (Pt Insulin)
gi|159162548 6.9 2 45.58 99.34967
35 actin, gamma 2 propeptide [Homo sapiens] gi|4501889 5.31 2 41.92 98.48946
36 unnamed protein product [Homo sapiens] gi|16552261 5.01 2 41.92 98.48946
37 collagen, type XII, alpha 1 long isoform precursor [Homo 
sapiens]
gi|93141047 5.38 1 41.24 98.23342
38 Chain A, Structure Of A Novel Extracellular Ca2+-Binding 
Module In Bm-40(Slash)sparc(Slash)osteonec
gi|157833849 5.01 3 40.64 97.9717
39 Chain B, Nmr Structure Of Human Insulin Mutant Ile-A2-Ala, 
His-B10- Asp, Pro-B28-Lys, Lys-B29-Pro, 15 Structures
gi|159162579 5.44 1 34.24 91.14614
40 anti-colorectal carcinoma heavy chain [Homo sapiens] gi|425518 6.22 1 33.32 89.05708
41 hypothetical protein [Homo sapiens] gi|60219224 8.43 2 31.13 81.88106
42 CALU [Homo sapiens] gi|49456627 4.48 2 30.5 79.05246
43 KIF27B [Homo sapiens] gi|30025501 6.39 2 28.05
888
63.25104
44 keratin 10 [Homo sapiens] gi|623409 5.01 1 27.65 59.62309
45 unnamed protein product [Homo sapiens] gi|194388696 11.79 1 27.35 56.73537
46 ATF6 [Homo sapiens] gi|3953531 8.36 1 27.35 56.73537
47 complement component 1, s subcomponent precursor [Homo 
sapiens]
gi|4502495 4.86 1 26.02 41.23308
48 EGF-containing fibulin-like extracellular matrix protein 1 
precursor [Homo sapiens]
gi|9665262 4.95 1 25.79 38.03693
49 insulin-like growth factor binding protein 7 [Homo sapiens] gi|4504619 8.25 3 25.29 30.47629
50 cadherin-like 23 [Homo sapiens] gi|55958988 4.5 2 25.26 29.99437
51 Chain A, Crystal Structure Of Staurosporine Bound To Map 
Kap Kinase 2
gi|38492554 8.87 2 25.25 29.83298
52 ABT1-associated protein [Homo sapiens] gi|18093112 5.01 1 25.21
678
29.29423
53 hypothetical protein [Homo sapiens] gi|12052734 5.68 1 25.12 27.70089
54 immunoglobulin superfamily containing leucine-rich repeat 
variant [Homo sapiens]
gi|62898095 5 1 24.98 25.33225
55 fms-related tyrosine kinase 4 isoform 2 precursor [Homo 
sapiens]
gi|103472027 5.89 1 24.56 17.75054
56 putative [Homo sapiens] gi|553734 9.79 1 24.46 15.8347
57 RecName: Full=Protein FAM90A1 gi|158564039 9.66 3 24.31
444
12.96598
58 RecName: Full=Mucin-19; Short=MUC-19; Flags: Precursor gi|193806311 4.95 1 23.36 0
59 KIAA0611 protein [Homo sapiens] gi|3327036 8.36 2 23.01 0
60 trypsin inhibitor [Homo sapiens] gi|33985 6.58 2 22.72 0
61 hypothetical protein [Homo sapiens] gi|21739834 5.64 1 22.51 0
62 hypothetical protein LOC340533 [Homo sapiens] gi|56711286 6.03 1 22.26 0
63 prominin 1 isoform 2 [Homo sapiens] gi|224994189 6.97 1 22.01 0
64 Chain O, Crystal Structure Of Anthrax Edema Factor (Ef) In 
Complex With Calmodulin In The Presence Of 10 Millimolar 
Exogenously Added Calcium Chloride
gi|66360499 4.05 1 21.38 0
65 Chain B, Orientation In Solution Of Mmp-3 Catalytic Domain 
And N- Timp-1 From Residual Dipolar Coup
gi|34811011 8.27 1 21.07 0
66 hCG33036, isoform CRA_b [Homo sapiens] gi|119627063 6.07 2 19.9 0
67 dystonin isoform 1 [Homo sapiens] gi|34577047 5.52 3 19.85
444
0
68 hypothetical protein [Homo sapiens] gi|7018446 8.24 1 19.7 0
69 PRR7 protein [Homo sapiens] gi|18203805 8.91 1 19.61 0
70 R29893_1 [Homo sapiens] gi|2887499 9.95 1 19.51 0
71 KIAA0184 [Homo sapiens] gi|1136428 6.99 1 19.29 0
72 tRNA aspartic acid methyltransferase 1 variant 5 [Homo 
sapiens]
gi|167887558 9.3 1 19.25 0
73 alpha2-HS glycoprotein [Homo sapiens] gi|2521981 5.2 1 19.25 0
74 nebulin [Homo sapiens] gi|806562 9.1 1 18.07
444
0
75 testis-specific bromodomain protein [Homo sapiens] gi|46399198 9.05 1 19.14 0
76 immunoglobulin heavy chain variable region [Homo sapiens] gi|70798061 9.26 1 18.84 0
77 hypothetical protein - human gi|2135416 8.69 2 18.78 0
78 NUCB1 protein [Homo sapiens] gi|16041802 5.05 1 18.65 0
79 microtubule-associated protein 2 4R isoform; 4R-MAP2 
[Homo sapiens]
gi|913854 10.17 1 18.45 0
80 cadherin 15 preproprotein [Homo sapiens] gi|4826669 4.81 1 18.37 0
81 hCG27399, isoform CRA_c [Homo sapiens] gi|119607856 6.46 2 18.35 0
82 unnamed protein product [Homo sapiens] gi|158256468 5.89 1 18.16 0
83 sialic acid-binding Ig-like lectin 10 [Homo sapiens] gi|15217166 9.16 1 18.1 0
84 tetratricopeptide repeat domain 4 [Homo sapiens] gi|56204887 7.95 1 17.86 0
85 unnamed protein product [Homo sapiens] gi|21751193 6.21 1 17.85 0
86 IGFBP5 [Homo sapiens] gi|48145735 8.58 2 17.77 0
87 solute carrier organic anion transporter family, member 5A1 
isoform 2 [Homo sapiens]
gi|225637477 8.5 1 17.77 0
88 c-myc intron-binding protein 1 [Homo sapiens] gi|77997595 6.45 1 17.62 0
89 hCG1814189 [Homo sapiens] gi|119602137 5.76 1 17.62 0
90 hypothetical protein FLJ20294, isoform CRA_f [Homo 
sapiens]
gi|119588408 6.66 2 17.56 0
91 unnamed protein product [Homo sapiens] gi|35883 7.44 1 17.56 0
92 unnamed protein product [Homo sapiens] gi|194385514 6.44 2 17.52 0
93 Chain B, Human Complement Component C3 gi|78101268 5.55 1 17.47 0
94 NOL1/NOP2/Sun domain family, member 4 [Homo sapiens] gi|15680185 8.47 1 17.39 0
95 KiSS-1 metastasis-suppressor, isoform CRA_a [Homo 
sapiens]
gi|119611912 9.82 1 17.26 0
96 calcium-activated chloride channel protein 2 [Homo sapiens] gi|5726289 5.31 1 17.07 0
97 unnamed protein product [Homo sapiens] gi|14042878 4.78 2 16.7 0
98 ankyrin repeat and SOCS box-containing protein 1 [Homo 
sapiens]
gi|94721248 8.55 1 16.34 0
99 RecName: Full=Stromal interaction molecule 2; Flags: gi|17369338 6.3 1 16.27 0
Precursor
100 C2 [Homo sapiens] gi|15277207 6.44 1 16.02 0
